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The myeloproliferative disorders, polycythaemia vera (PV) and primary
thrombocythaemia (PT) are relatively indolent diseases but are complicated by
thrombosis and bone marrow fibrosis which cause significant morbidity and may
reduce life-expectancy especially in younger patients. Our understanding of the
pathogenesis of thrombosis and fibrosis in PV and PT and in primary myelofibrosis
(PMF) remains incomplete although platelet and vascular abnormalities have been
clearly implicated. The recent recognition of the procoagulant activities of cell
derived microparticles has led to their study in other prothrombotic disorders, where
they are observed to be elevated and to have a pathogenic role.
We have studied a cohort of patients with PV, PT and PMF and described their
clinical and laboratory features in comparison to other published observations. The
demographic, haematological and molecular characteristics of our cohort were
similar to other retrospective analyses, but the occurrence of thrombo-haemorrhagic
complications was lower. The presence of vascular abnormalities in these patients
was investigated using both established markers and an assay was devised to
measure platelet, endothelial, leucocytes and red cell microparticles in platelet poor
plasma using flow cytometry techniques. This assay was optimised for pre-
analytical variables, the most important of which was found to be sample
centrifugation. In keeping with previous studies, increased platelet activation was
observed in PV and PT patients compared to healthy controls using both established
markers and as evidenced by increased numbers of platelet microparticles. There
was no evidence of endothelial disturbance using the soluble endothelial marker E-
selectin but we did observe elevated endothelial microparticles in patients compared
to controls. Microparticles may therefore be useful as a marker of vascular
abnormalities in these disorders and in view of their prothrombotic properties may be
an additional pathogenic mechanism in the prothrombotic state and a potential
therapeutic target.
in
In relation to bone marrow fibrosis, plasma levels of platelet a-granule contents,
including the pro-fibrotic cytokine transforming growth factor P (TGFP), were
studied. We observed elevated levels of TGFp in patients compared to controls, with
the highest levels in patients with PMF and in those with PT or PV who had more
marked fibrosis. Further, levels of TGFp were strongly associated with another a-
granule protein beta-thromboglobulin, suggesting that platelet a-granules may be an
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Introduction and Literature review
i
1.1 Myeloproliferative disorders - Clinical Aspects
1.1.1 Epidemiology
The myeloproliferative disorders (MPD) include polycythaemia vera (PV), primary
thrombocythaemia (PT) and primary myelofibrosis (PMF) and are largely adult
diseases with an increasing incidence with age. The majority of cases are diagnosed
after the fifth decade. PV more commonly affects men in comparison to the female
predominance of PT. Depending on the population, annual incidences 0.2 to 28 per
100,000/year are reported for PV (McMullin et al, 2005) and 1-2.5/100,000/year for
PT (Jensen et al, 2000b;Mesa et al, 1999). The Leukaemia Research Fund registry,
which covers approximately 20% of the UK, reported a combined incidence of PV,
PT and PMF of 2.27 per 100,000 population per year between 1984 and 1993
(McNally et al, 1997). The incidence of both appears to be rising (Jensen et al,
2000b) but this is likely to be due to the identification of asymptomatic cases from
abnormal peripheral blood counts performed for other indications.
1.1.2 Pathophysiology and molecular aspects
Despite their phenotypic differences PV, PT and PMF share a number of common
clinical and pathological features. Chronic myeloid leukaemia (CML) was
previously included in this group of diseases but since the identification of its
molecular origin, specifically the BCR-ABL translocation, it is considered to be a
separate entity. Clinically they are all characterised by the overproliferation of
mature cells of one or more haematopoetic cell lines (erythrocytes in PV,
megakaryocytes and platelets in PT) and they can all be complicated by thrombosis,
haemorrhage, progression to marrow fibrosis and transformation to acute leukaemia.
The common clonal stem cell origin of these disorders was originally identified by
examination of X-linked polymorphic markers (Fialkow et al, 1981) and later by
patterns of X-chromosome inactivation (El Kassar et al, 1997). However, using this
technique, in up to 50% of PT patients a clonal population cannot be identified (El
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Kassar et al, 1997;Harrison et al, 1999;Shih et al, 2002), although this may be a
consequence of the limited sensitivity of the assay to detect low levels of clonal
haematopoiesis.
Cytokine and growth factor hypersensitivity is another shared feature. In vitro studies
in PV demonstrate erythroid colony formation in the absence of exogenous
erythropoietin (Epo) (Liu et al, 2003) and in PT, thrombopoietin (Tpo)
hypersensitivity is observed (Axelrad et al, 2000). In PV, this translates in vivo to
erythroid proliferation despite low Epo levels consequent on the suppression of renal
Epo synthesis by a negative feedback mechanism. In PT the picture is of
inappropriately high Tpo levels despite thrombocytosis. In the normal situation a
rise in the platelet count results in increased Tpo binding to its receptor (c-mpl) on
the platelet surface. This reduces the amount of free Tpo available to stimulate
megakaryocyte maturation and proliferation. In PT it is thought that abnormalities of
the receptor reduce its binding to Tpo, resulting in high circulating levels despite the
high platelet count (Schafer, 2006).
Clearly the shared stem cell origin of these disorders cannot explain their phenotypic
diversity. Recently a variety of mutated tyrosine kinases (or related molecules)
which result in abnormal signal transduction have been identified. The first
discovery was in CML where the chromosome translocation (t9:22) produces a
fusion kinase gene (BCR-ABL). This dysregulated tyrosine kinase is responsible for
myeloid overproliferation in CML and specific inhibitors of the molecule are now
the cornerstone of treatment (Deininger et al, 2000). Similarly a dysregulated
platelet derived growth factor receptor has been revealed in a proportion of patients
with idiopathic hypereosinophilic syndrome, a rarer MPD (Cools et al, 2003). These
findings prompted the suggestion that similar mechanisms may be at work in the
other MPD. Subsequently, a number of groups simultaneously published results
showing the presence of an acquired point mutation of the JAK2 gene (V617F) in a
proportion of PV, PT and PMF patients (Baxter et al, 2005;James et al,
2005;Kralovics et al, 2005;Levine et al, 2006).
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The JAK2 protein is a member of the Janus kinase family of tyrosine kinases that are
associated with haematopoetic cytokine and growth factor receptors. Its role in
intracellular signalling and the effect of the V617F mutation in MPD is
comprehensively reviewed by Khwaja (Khwaja, 2006). Following specific growth
factor receptor-ligand binding, the JAK molecules are activated leading to
phosphorylation of the cytoplasmic domains of the receptors. This promotes
downstream signalling in the STAT (signal transducers and activators of
transcription) pathway and the activation or suppression of genes involved in the
growth factor response. The V617F mutation affects the negative regulatory
pseudokinase domain (JFT2) of the protein. It is a gain of function mutation that
expresses a constitutively activated JAK2 tyrosine kinase. The mutated JAK2 can
therefore bind to the Epo or Tpo receptors and activate downstream signalling
pathways in the absence of growth factors. In vitro studies have shown that
expression of JAK2 V617F can induce Epo hypersensitivity in cultured cell lines
(James et al, 2005) and in murine bone marrow transplantation models produces a
PV like phenotype (Wernig et al, 2006). In JAK2 V617F positive PV patients,
erythroid progenitors heterozygous or homozygous for the mutation show increased
sensitivity to Epo compared to normal progenitors from the same patients (Dupont et
al, 2007).
The presence of the JAK2 V617F mutation has been demonstrated in over 80% of
patients with PV and 25-60% of PT and PMF patients (Baxter et al, 2005;James et
al, 2005;Jones et al, 2005;Kralovics et al, 2005;Levine et al, 2005). This important
discovery raises further questions: How does one mutation result in three
phenotypically distinct disorders? What is the molecular mechanism in the cases
negative for this mutation? These issues are currently the subject of investigation but
likely explanations include differences in mutant allele load and the presence of
alternative or additional mutations.
Homozygosity for the mutation is thought to occur by mitotic recombination and in
contrast to 25-30% homozygosity in PV patients, almost all (>97%) JAK2 V617F
positive PT patients are heterozygous for the mutation (Baxter et al, 2005;James et
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al, 2005;Kralovics et al, 2005;Levine et al, 2005). In a study of 962 patients with
PV or PT, the presence of homozygosity conferred phenotypic differences at
diagnosis with a higher haematocrit, higher leucocyte count and lower platelet count
(Vannucchi et al, 2007b). Splenomegaly was more frequent in homozygous patients.
In PT patients, homozygosity was independently associated with the occurrence of
cardiovascular events.
Other mutations affecting exon 12 of the JAK2 gene have been described in a
number of JAK2 V617F negative PV patients. These mutations did not appear to
confer a distinct phenotype, with clinical and bone marrow features similar to those
of JAK2 V617F positive patients. Gain of function mutations of the thrombopoietin
receptor gene (MPL) have also been identified in patients with MPD (Pardanani et
al, 2006;Pikman et al, 2006). The mutations (MPL W515L and MPL W515K) result
in the constitutive activation of the thrombopoietin receptor and JAK-STAT pathway
and consequently growth factor independence. In a cohort of 1182 patients, MPL
mutations were identified in around 5% and 1% of PMF and PT patients respectively
but were not found in PV (Pardanani et al, 2006). In keeping with this finding,
expression of the MPL mutation in a mouse model produces a clinical picture
characterised by marked thrombocytosis (Pikman et al, 2006) compared to the PV
phenotype induced by the JAK2 V617F mutation (Wernig et al, 2006). In some cases
the MPL and JAK2 V617F mutations were present concurrently, suggesting that they
may have complementary actions.
1.1.3 PV and PT - clinical and laboratory features and diagnosis
PV is characterised by an erythroid excess in the absence of a secondary cause. This
is usually reflected by a raised haematocrit and haemoglobin but these changes may
be masked in the presence of iron deficiency, which not uncommonly develops.
Direct measurement of red cell mass (RCM) may be used to exclude an apparent
erythrocytosis where the haemoglobin is elevated but RCM is normal. Diagnosis of
PV requires the exclusion of secondary causes of erythrocytosis driven by elevated
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Epo levels (McMullin et al, 2005). These include hypoxic conditions or abnormal
haemoglobins which cause a physiological Epo response or pathological conditions
of excess Epo production, such as renal tumours. Clonal cytogenetic abnormalities,
identified in 10-20% of patients or the JAK2 V671F mutation (or similar) can
confirm the primary nature of the erythrocytosis. Other myeloproliferative features
which support the diagnosis of PV include leucocytosis and/or thrombocytosis,
splenomegaly, typical bone marrow features of trilineage hyperplasia and evidence
of cytokine independence. Up to 60% of patients present with thrombotic or less
commonly haemorrhagic complications (Elliott & Tefferi, 2005). Patients may also
report pruritus, constitutional upset or symptoms of hyperviscosity including
headache and dizziness.
PT is characterised by a persistent thrombocytosis in the absence of a reactive cause
such as chronic inflammatory conditions or iron deficiency states. Positive features
supporting the diagnosis of PT include splenomegaly and clonal genetic
abnormalities including JAK2 V617F but this is present in only around 50% of cases.
PT may also be confused with other haematological conditions including
myelodysplastic disease, PV or pre-fibrotic hypercellular PMF. Some studies have
reported that PT patients with the JAK2 V617F mutation have features more like
those of PV compared to those without the mutation. At diagnosis they have higher
haemoglobin, neutrophil counts and increased bone marrow erythropoietic and
granulopoietic activity, as well as lower ferritin and Epo levels (Campbell et al,
2005;Wolanskyj et al, 2005). Like PV, up to 40% of patients present with thrombo-
haemorrhagic events (Elliott & Tefferi, 2005).
The diagnosis of these diseases has evolved as their pathogenesis has become better
understood. This has resulted in the development of different but overlapping
diagnostic criteria for PV including those of the Polycythaemia Vera Study Group
(PVSG), British Committee for Standards in haematology (BCSH) and the World
Flealth Organisation (WFIO) (McMullin et al, 2005;McMullin et al, 2007;Michiels et
al, 2006;Murphy et al, 1986;Tefferi et al, 2007) (Appendix 1). All PV criteria
require that a true erythrocytosis is established and that secondary causes are
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excluded. The early PVSG criteria also included presence of other myeloid features
including splenomegaly as support for the diagnosis of PV. These criteria were
retained in the BCSH 2005 guidelines with the addition of tests of clonality and
growth factor independence. The WHO criteria allow the use of elevated
haemoglobin values alone (in comparison to RCM or haematocrit) in defining
erythrocytosis and recognise clonality and growth factor independence but also
include typical bone marrow features as supporting evidence for PV. The
identification of the JAK2 V617F mutation in almost all PV patients has had the
greatest influence on diagnosis. Consequently, the BCSH and WHO diagnostic
criteria have been revised to include it as a positive criterion in combination with
evidence of erythrocytosis.
The diagnosis ofPT in patients with a persistent thrombocytosis above 600 xl09/L is
mainly one of exclusion of both reactive causes and other MPD (Michiels et al,
2006;Murphy et al, 1986;Tefferi & Vardiman, 2007). Identification of the JAK2
V617F mutation (or MPL mutations) confirm the primary nature of the
thrombocytosis but it is still necessary to exclude other haematological conditions by
careful assessment for erythrocytosis or bone marrow features of dysplasia or
myelofibrosis. As before and until further responsible mutations are identified, the
diagnosis of the 50-60% ofPT cases which are JAK2 V617F negative remains one of
exclusion.
Assessment of fibrosis is an important part of the histological assessment of the bone
marrow and a number of difficulties are recognised. Fibrosis reflects an increase in
the deposition of reticulin or collagen in the extracellular tissue and may be localised
or diffuse. In the normal bone marrow, no reticulin, individual fine fibres or small
focal networks may be present. Increased reticulin with diffuse fibre networks and
coarse fibres is frequently observed in abnormal marrow and may be reactive to
haematological or non-haematological malignant disease. Reticulin fibrosis is a
feature common to the MPD but is rarely marked in uncomplicated PT or PV, in
contrast to the fibrotic stage of PMF where the presence of coarse reticulin fibres and
collagen is diagnostic (Bain et al, 2001)
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The patchy nature of marrow fibrosis and differences in the processing of biopsies
may influence the quantification of fibrosis (Buesche et al, 2006). Further problems
are posed by differences in the histopathological diagnostic criteria used and a
variety of fibrosis grading systems have been employed in different regions at
different times (Thiele et al, 2005;Bauermeister, 1971). A European consensus
based on a number of published systems and the commonly used Bauermeister
criteria are shown in Table 1.1.
There are also differences between the diagnostic criteria for the myeloproliferative
disorders in the differentiation of PT from early pre-fibrotic MF. Using the PVSG
criteria, differentiation of PT from PMF is defined by the absence of collagen
fibrosis or affecting less than 1/3 of the biopsy with no splenomegaly or
leucoerythroblastic film features (Murphy et al, 1986). In contrast, the WHO criteria
place greater emphasis on the positive use of trephine histology to distinguish "true
PT" from the early stages of myelofibrosis. They define pre-fibrotic MF by the
presence of atypical megakaryocyte features (clustering, maturation defects or bare
nuclei) , in contrast to PT where the megakaryocytes are expected to be large and
mature (Tefferi & Vardiman, 2007). However in a recent study the trephines of 370
PT patients enrolled in the PT-1 trial were reviewed by haematopathology experts
who were unable to distinguish the two diagnoses according to the WHO
classification (Wilkins et al, 2008). This reflects the ongoing controversy as to
whether there is a spectrum of disease in PT patients from those without marrow
fibrosis through sub-clinical fibrosis to those who will ultimately develop clinical
MF; or alternatively that pre-fibrotic MF is a distinct entity commonly misdiagnosed
as PT which can be distinguished according to histological features at presentation
and which has a significantly higher likelihood of progression to clinical MF. The
interpretation of case-control and cohort studies that estimate the risk of progression
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1.1.4 PV and PT - Complications and Prognosis
Haemorrhagic or thrombotic events at presentation are reported in 30-55% of PT and
PV patients (Harrison et al, 2005;Jensen et al, 2000b;Marchioli et al,
2005;Passamonti et al, 2004;Wolanskyj et al, 2006) The natural history of PV and
PT is of death and disability from vascular and haematological complications but
with treatment, prognosis can be improved towards that of age matched controls.
Complications fall into two main categories: vascular, including haemorrhagic
episodes or arterial and venous thrombosis and haematological, including
progression to acute leukaemia (AL) or myelofibrosis (MF). Studies of PT and PV
populations published over the last 20 years give us some idea of the incidence of
these complications at presentation and follow-up, overall survival and the associated
risk factors. However the retrospective nature of many of these studies and
differences in diagnostic criteria, patient population, length of follow-up and
reporting methods mean that the results are not directly comparable and often appear
conflicting.
1.1.4.1 Thrombosis
Thrombosis is the most common complication in the MPD. At the time of
presentation thrombosis is reported in up to 55% of patients depending on the
demographics of the study cohort (Cortelazzo et al, 1990;Harrison et al,
2005;Marchioli et al, 2005;Tefferi et al, 2001 ;Wolanskyj et al, 2006). In 114 PT
patients who were over the age of 60 and/or had had a previous thrombosis, those
who did not receive cytoreductive therapy had an annual incidence of first
thrombosis of 24% (Cortelazzo et al, 1990). In contrast, in patients treated with
hydroxycarbamide the rate was 4%, comparable to that reported in other treated PT
groups (Harrison et al, 2005) and to the 5% annual incidence reported in treated PV
patients (Marchioli et al, 2005). In younger patient cohorts lower incidences of 0.8-
2.8% per year have been reported (Alvarez-Larran et al, 2007).
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At both presentation and follow-up the rates of arterial thrombosis are higher than
those of venous thrombosis. The most frequent arterial events are cerebrovascular,
followed by cardiac then peripheral thrombosis (Harrison et al, 2005;Jensen et al,
2000b;Marchioli et al, 2005). As in the general population, deep vein thrombosis is
commoner than pulmonary embolism or intra-abdominal thrombosis (Harrison et al,
2005;Marchioli et al, 2005) although the MPD are the single commonest causal
factor in intra-abdominal thromboses, present in around 30-50% of cases (Denninger
et al, 2000).
1.1.4.2 Haemorrhage
Haemorrhage is a less common complication in the MPD and is reported in around
6-12% of cases at presentation with an annual incidence during follow-up of 2-3%
(Harrison et al, 2005;Jensen et al, 2000b;Marchioli et al, 2005;Wolanskyj et al,
2006). In the study by Wolanskyj and colleagues, which had longer follow-up than
the others, the 10 year cumulative probability of haemorrhage was 15.1% and at 20
years 18.1%. Minor skin and mucous membrane bleeding is reported most
commonly but there can be major bleeding episodes, the majority of which are
severe gastrointestinal bleeding (Elliott & Tefferi, 2005;Harrison et al, 2005). The
risk of haemorrhagic episodes in PV patients has been associated with older age,
longer duration of disease and previous haemorrhage (Marchioli et al, 2005).
In PT patients, a platelet count of over 1000-1500 x 109/L at presentation is thought
to be associated with an increased risk of haemorrhage and has been attributed to the
finding of acquired von Willebrand disease in such patients (Budde et al, 1984), with
an inverse relationship between the platelet count and plasma levels of large von
Willebrand factor (VWF) multimers (Budde & van Genderen, 1997). It is proposed
that the increased platelet mass binds more large VWF multimers which are then
effectively removed from the circulation, producing a haemorrhagic tendency.
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1.1.4.3 Haematological transformation
Incidences of 5-24% for the development of MF in PT have been reported with the
incidence increasing with age and time from diagnosis (Cervantes et al,
2002;Murphy et al, 1986). Estimation of the incidence of transformation to MF and
AL is therefore likely to be influenced by the demographics of the study cohort and
the length of patient follow-up.
In studies with shorter follow-up of less than 10 years, AL and MF occurred in less
than 3% of patients (Alvarez-Larran et al, 2007;Harrison et al, 2005;Marchioli et al,
2005;Tefferi et al, 2001). Similarly in a retrospective study of 831 PV and PT
patients with a median follow-up of 9.6 years, the calculated 15 year cumulative risks
of AL or MF were 5% and 1.5% for PV and PT patients respectively (Passamonti et
al, 2004). However in a retrospective analysis of 322 PT patients with a median
follow-up of 13.6 years, cumulative probabilities of 1.4% and 3.8% at 10 years rising
to 8.1% and 19.9% at 20 years for AL and MF respectively, were reported
(Wolanskyj et al, 2006).
With regard to patient age, in 195 patients diagnosed with PT by PVSG criteria and
followed up for a median of 7.2 years (1.9-24) the actuarial probability of MF was
2.7% at 5 years, 8.3% at 10 years and 15.3% at 15 years (Cervantes et al, 2002). In
contrast, in 126 patients diagnosed with PT before age 40, using the same criteria, the
actuarial probability of freedom from MF at 10 years was calculated to be 97%
(Alvarez-Larran et al, 2007).
A number of studies have compared the diagnosis of PT by PVSG criteria or the
2001 WHO classification which places greater emphasis on bone marrow histology
and differentiation from MF (Thiele & Kvasnicka, 2003;Thiele et al, 2002;Florena et
al, 2004). These suggest that up to three-quarters of patients diagnosed with PT by
PVSG criteria would be diagnosed with early or pre-fibrotic MF by WHO criteria. In
two of these studies, they also examined sequential bone marrow biopsies performed
at follow-up examinations in some of the patients (Thiele et al, 2002;Thiele &
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Kvasnicka, 2003). These suggested that the development of reticulin fibrosis on
repeat marrow examination or overt MF was very uncommon in patients with "true
PT" diagnosed by WHO criteria but was much more frequent in patients with early
or pre-fibrotic MF. However these studies had a limited follow-up of 38±30 months
and 39±31 months respectively. A similar retrospective analysis of 322 patients
diagnosed with PT by the 2001 WHO criteria had a median follow-up of 13.6 years
and at least a decade in around three-quarters of the patients (Wolanskyj et al, 2006).
In contrast, they observed a cumulative risk of transformation to MF of 3.8% at 10
years, 19.9% at 20 years and 28.9% at 30 years in "true" PT, similar to the results
from earlier studies.
In PV, marrow reticulin is reported to be increased in 8-15% of patients at the time of
diagnosis (Spivak, 2002). Long term follow-up (12-25 years) of 204 patients
enrolled in the first PVSG trials showed the risk of MF to increase with time from
diagnosis with an overall risk of 50% at more than 15 years (Najean et al, 1994). In
this study, in patients treated with radiophosphorus MF was not observed before the
10th year but was reported in 20% of patients at 15 years, and 50% at 20 years. In
comparison, phlebotomy alone was associated with earlier progression to MF. More
recently the ECLAP study (European Collaboration on Low-dose Aspirin in PV),
which prospectively assessed the longer term outcomes of PV as determined by
current clinical practice, the rate of haematological transformation (to overt MF or
AL) was 1.3/100 persons/year (Marchioli et al, 2005). Longer disease duration
predicted the risk of MF with a relative risk (RR) of 5.74 (95% confidence interval
(CI) 1.15- 21.77) at 6 years and 15.24 (4.22-55.06) at 10 years.
In patients with post-PV/PT MF, the clinical features are similar to those of PMF.
There is infiltration of the marrow by fibrotic tissue resulting in pancytopenia and
leucoerythroblastic features in the peripheral blood film. Consequently patients
develop symptoms of anaemia, which is often transfusion dependent, are at increased
risk of infection and experience haemorrhagic complications of thrombocytopenia.
Splenomegaly, as a result of extramedullary haemopoiesis, contributes to the
pancytopenia and there may be local pain from stretching of the capsule and splenic
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infarct. Constitutional symptoms including fever, sweats and weight loss may also be
present. The International Working Group for myelofibrosis research and treatment
recently published proposed criteria for the diagnosis of post-PV and post-PT
myelofibrosis. These require documentation of a previous diagnosis of PV or PT by
the WHO rather than the PVSG criteria and bone marrow fibrosis of Grade 3-4
according to the Bauermeister classification (Bauermeister, 1971) in addition to other
clinical and laboratory features (Barosi et al, 2007). Treatment is mainly supportive
although judicial use of chemotherapy may be instituted for symptomatic
splenomegaly, constitutional symptoms or thrombocytosis. Splenectomy may also
be considered but is associated with significant peri- and post-operative morbidity
and mortality. A small number of young patients with high-risk disease may be
suitable for allogeneic stem cell transplantation (Cervantes, 2005).
1.1.4.4 Survival and risk stratification
In untreated PV and PT survival is reduced due to vascular complications (Chievitz
& Thiede, 1962). Most studies consider treated populations and in PT patients
survival has been reported to approach that of age-matched populations although the
relatively small patient numbers and short follow-up periods in some of these studies
limit their interpretation (Rozman et al, 1991;van Genderen et al, 1997). In a larger
study of 187 PT patients the findings were similar for older patients but for those
diagnosed before the age of 55 years the relative risk of death was four times greater
than for healthy age-matched controls (Bazzan et al, 1999). Two studies with longer
follow-up (median 9.3 years and 13.6 years) have suggested a median survival for PT
patients of 18-22 years (Passamonti et al, 2004;Wolanskyj et al, 2006). Survival was
similar to that of an age-matched population in the first 10 years but worsened
thereafter, RR 2.21 (95% CI 1.74-2.76) at 20 years and RR 3.37 (1.84 - 5.56) at 30
years (Wolanskyj et al, 2006). PV patients had reduced survival compared to either
PT patients or an age matched population, of 65% at 15 years compared to 73%
(p=0.01) (Passamonti et al, 2004).
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A variety of risk factors for thrombotic complications and overall survival have been
identified. Those most strongly and consistently associated with thrombotic risk are
older age (>60 years) and prior history of thrombosis (Gruppo Italiano,
1995;Landolfi et al, 2007;Marchioli et al, 2005;Passamonti et al, 2004;Wolanskyj et
al, 2006). More recently an elevated white cell count at diagnosis has been shown to
be independently associated with thrombosis in PT (Carobbio et al, 2007;Wolanskyj
et al, 2005) and PV (Landolfi et al, 2007), where it was also associated with
leukaemic transformation and reduced survival in a retrospective analysis (Gangat et
al, 2007).
The role of traditional cardiovascular risk factors is less clear but some studies have
found associations with tobacco use (Alvarez-Larran et al, 2007;Cortelazzo et al,
1990;Landolfi et al, 2007;Wolanskyj et al, 2006), diabetes mellitus (DM) (Landolfi
et al, 2007;Wolanskyj et al, 2006) and cardiac failure (Landolfi et al, 2007). There is
also limited data from small retrospective studies on the influence of concurrent
thrombophilias on thrombotic risk. In PT patients an increased incidence of anti-P2
glycoprotein I IgM antiphospholipid antibodies, reduced protein C and S levels and
an association between carriage of the Factor V Leiden mutation and incidence of
venous thrombosis have all been reported (Harrison et al, 2002;Jensen et al,
2002;Ruggeri et al, 2002).
Based on these risk factors, a number of models for risk stratification have been
proposed in an attempt to identify those patients at highest risk of thrombosis and so
to apply appropriate management strategies. At the most simplistic level, high risk
patients aged over 60 years and/or with a prior history of thrombosis and low risk
patients who meet neither of these criteria are easily identified. The identification of
an intermediate risk group of patients by inclusion of cardiovascular risk factors and
additional age criteria is less clear. Extreme thrombocytosis above 1000-1500 x
109/L is also considered to confer an increased thrombo-haemorrhagic risk, although
substantive evidence for this is lacking. Prospective data from the PT-1 trial which
includes such a group will be useful in determining its discriminative strength with
regard to their thrombotic risk and treatment needs. A stratification model which
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includes the presence of leucocytosis at diagnosis in addition to age and thrombotic
history has been shown to be predictive of survival using retrospective data (Gangat
et al, 2006). An example of a risk stratification model is outlined in Table 1.2.
In patients with PMF the median survival of 4 years from diagnosis is significantly
shorter than the 14 years for age and sex-matched controls. However low risk
patients can be identified (by the presence of normal haemoglobin and leucocyte
counts and the absence of peripheral blasts or constitutional symptoms) whose
median survival may be more than twice this (Cervantes, 2005). The major causes of
death are infection, haemorrhage, cardiac failure and leukaemic transformation
(Reilly, 1997). In patients developing overt post-PT or post-PV MF life expectancy
is likely to be similarly affected. The recent studies re-evaluating the diagnosis of PT
patients using the WHO criteria suggest that some of the shortened survival reported
in these patients may be accounted for by misclassified early or pre-fibrotic MF
(Thiele et al, 2002;Thiele & Kvasnicka, 2003).
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Low risk Intermediate risk High risk
Age (years) < 40 y <40 y 40-60 y > 60 y
and and and or
Platelet count xl 09/L <1000 <1000 <1000 >1000
and and and or
Prior thrombosis or haemorrhage NO NO NO YES
and and and or
Cardiovascular co-morbidities* NO NO NO YES
and and and
Inherited thrombophilia or NO YES** YES/NO _
cardiovascular risk factors
Table 1.2 Risk stratification for thrombosis
Example of risk stratification for thrombosis in patients with PV or PT adapted from
previously published models (Barbui et al, 2004;Harrison, 2005b;McMullin et al,
2005). *Cardiovascular co-morbidities include hypertension, diabetes and congestive
cardiac failure. **The inclusion of an intermediate risk group, based on the presence
of inherited thrombophilia or cardiovascular risk factors, in otherwise low risk
patients, is not agreed.
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1.1.5 Treatment
The goal of treatment in PV and PT is to reduce morbidity and mortality by reducing
the incidence of thrombo-haemorrhagic complications without increasing the risk of
fibrotic or leukaemic transformation. In both conditions antiplatelet agents are key in
the reduction of thrombotic risk. In PV, venesection is generally first line therapy to
normalise the haematocrit but cytoreductives may be required if venesection is not
tolerated or if control of thrombocytosis is required. Cytoreductives may also have
additional benefits in the reduction of thrombotic risk over and above their role in
normalisation of peripheral blood counts. In PT, normalisation of the platelet count
can be achieved using a number of different cytotoxic and non-cytotoxic agents.
In order to achieve a balance between the benefits of these therapies and concerns
regarding their potential leukaemogenic effects, individual patients are stratified
according to their thrombotic risk (Table 1.2). Thus, exposure to agents whose long
term risks are uncertain is avoided in low risk patients but is considered acceptable,
given the established benefits of such treatment, in patients at higher thrombotic risk.
Despite the lack of clear evidence for the contribution of traditional cardiovascular
risk factors to thrombotic risk, there is consensus of opinion that for individual
patients, cessation of smoking and the appropriate management of hypertension,
cholesterol and overweight is likely to be beneficial.
Aspirin
Aspirin has well established benefits in both the primary and secondary prevention of
cardiovascular disease in haematologically normal persons. Results from the
ECLAP study have supported the benefit of low-dose aspirin in PV (Landolfi et al,
2004). In this study, 518 PV patients with no clear indication or contra-indication for
antiplatelet therapy were randomised to either low-dose aspirin or placebo. Aspirin
use reduced the combined primary endpoint of non-fatal myocardial infarction,
stroke, major venous thromboembolism or death from a cardiovascular cause (RR
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0.40; 95%CI 0.18-0.91) although overall mortality and cardiovascular mortality were
not significantly reduced. There was no significant increase in major haemorrhage in
the aspirin group. Aspirin is therefore recommended for all PV patients in the
absence of a contraindication.
Despite the lack of similarly robust evidence for its benefit, aspirin is also widely
used in PT. A retrospective analysis of low dose aspirin use 68 PT patients, reported
a reduced incidence of thrombosis in patients treated with aspirin, alone or with
cytoreduction, compared to those receiving no treatment (van Genderen et al, 1997).
All patients were low risk for haemorrhage (platelet counts below 1000 x 109/L and
no history of haemorrhage) and there was an increase in the incidence of minor
bleeding episodes only. A number of factors provide some rationale for the use of
anti-platelet therapy in PT, including evidence of platelet activation (Jensen et al,
2000a;Musolino et al, 2000;Robertson et al, 2007;Villmow et al, 2002) and
increased platelet thromboxane A2 (Landolfi et al, 1992). Aspirin is also an effective
treatment to reverse the microcirculatory symptoms of PT such as erythromelalgia
(van Genderen et al, 1996) and is indicated in haematologically normal patients for
the prevention of cerebral ischaemia, the commonest vascular complication in PT
patients. It is generally avoided in patients with platelet counts of over 1000 xl09/L
due to the potential haemorrhagic risks associated with this level of thrombocytosis
(van Genderen et al, 1997).
Venesection
Phlebotomy to maintain the haematocrit within the normal range remains the
cornerstone of therapy in PV. The incidence of thrombosis was shown to increase
progressively for haematocrit above 0.44 (Pearson & Wetherley-Mein, 1978) and
cerebral blood flow improves by 73% with a haematocrit below 0.45 (Harrison,
2005b). On the basis of these studies a target haematocrit of less than 0.45 is
generally accepted. Results from the ECLAP study showed that the majority of
patients were tightly controlled with a haematocrit of between 0.44-0.47 throughout
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the study and that differences in haematocrit within the range of 0.40-0.55 were not
predictive of thrombosis (Di Nisio et al, 2007).
Cytoreduction
In patients with either PV or PT and who are at high risk of thrombosis (see Table
1.2), cytoreduction is indicated to maintain the platelet count below 400x109/L
(Barbui et al, 2004;Harrison, 2005b). However this target platelet count is based on
expert recommendation rather than a clear evidence base. In the ECLAP study of
PV patients, where this recommendation was used, platelet counts of up to 600 x
109/L were seen and compared to those below 400x109/L were not predictive for
thrombosis (Hazard ratio 0.96, 95% CI 0.66-1.38) (Di Nisio et al, 2007). In PT,
cytoreduction is not recommended in low risk patients but the question of benefit in
intermediate risk patients is currently being addressed by the intermediate arm of the
PT-1 study. Cytoreductive therapy may also be required in PV patients intolerant of
venesection at a level adequate to maintain a haematocrit in the target range
(McMullin et al, 2005). An isolated marked thrombocytosis (above 1000-
1500x 109/l) in otherwise low risk patients is generally considered to confer increased
risk of both thrombosis and haemorrhage and may therefore be an indication for
cytoreduction although evidence in support of this is lacking.
The choice of cytoreductive is dictated by efficacy, safety and tolerability and these
factors are partially dependent on the individual.
Hydroxycarbamide (formerly hydroxyurea)
In PT patients with a high risk of thrombosis, hydroxycarbamide is effective in
controlling platelet counts and reducing the incidence of thrombosis (Cortelazzo et
al, 1990;Harrison et al, 2005). In a comparison between hydroxycarbamide and no
cytoreduction in 114 high risk patients, thrombosis developed in 3.6% or treated
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patients compared to 24% of the untreated group at a median follow-up of 24 months
(Cortelazzo et al, 1990).
Whether the rate of leukaemic transformation seen in patients treated with
hydroxycarbamide is any higher than that of the underlying disease is a matter of
debate. There is no increased risk of leukaemia in young patients treated with
hydroxycarbamide for sickle cell disease however this population does not have an
underlying stem cell disorder (de Montalembert & Davies, 2001). The initial results
from the PT-1 study, with a median follow-up of 39 months, did not show an
increased risk of leukaemic transformation with hydroxycarbamide compared to
anagrelide, a non-cytotoxic drug (Harrison, 2005a); the long-term follow-up data will
be even more important in providing some answers to this issue. Hydroxycarbamide
is also associated with an increased risk of dermatological side effects including
mouth ulcers, leg ulcers and skin malignancies (Guillot et al, 2004).
At present hydroxycarbamide is considered to have the lowest leukaemic risk of the
cytotoxic agents and is generally the first line choice in high-risk patients over the
age of 40 years. In younger patients and pregnant women, non-cytotoxic agents such
as interferon and anagrelide may be preferred. Second line therapy is also indicated
in patients who are intolerant of hydroxycarbamide due to side effects or if the dose
required for adequate control of the platelet count results in unacceptable anaemia or
neutropenia. In this situation alternative or dual therapy with anagrelide may be
considered. In older patients, particularly where compliance is problematic,
alternative cytotoxics, including alkylating agents such as radiophosphorus or
busulphan, that may have more leukaemogenic potential may be appropriate (Barbui
et al, 2004;McMullin et al, 2005).
Anagrelide
Anagrelide selectively blocks megakaryocyte differentiation and proliferation and
thus reduces the platelet count. It is therefore an attractive option for cytoreduction
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as, from its pharmacological effects it would not be expected to increase the risk of
acute leukaemia. It has been widely used for some time in the United States and its
safety and efficacy was retrospectively analysed in 934 PT and 208 PV patients, of
whom 189 had not received any other cytoreductive therapy (Fruchtman et al, 2005).
Control of the platelet count to less than 600 xl09/L (or a reduction of more than
50% from baseline) was achieved in around two-thirds of PT patients. The rate of
leukaemic transformation was 2-3%, comparable to that reported in previous studies.
With regard to tolerability, 40% of patients reported drug related adverse events,
most commonly mild to moderate gastrointestinal symptoms, headache or dizziness,
oedema and cardiac symptoms such as palpitations.
This type of retrospective analysis is helpful but until recently there had been a lack
of randomised controlled trials of anagrelide with prolonged follow-up. In the high
risk arm of the PT-1 study 809 patients with PT and a high risk for thrombosis were
randomised to treatment with aspirin and either anagrelide or hydroxycarbamide
(Harrison et al, 2005). Control of the platelet count was similar but there were
statistically significant differences in the rates of vascular events between the groups.
The anagrelide group had more than double the rate of arterial thrombosis (Odds
Ratio (OR) 2.16; 95% CI 1.27-3.69) with significantly more transient ischaemic
attacks (OR 5.72; 2.08-15.73). In comparison the rate of venous thrombosis was
lower (OR 0.27; 0.06-0.71) especially for deep vein thrombosis.
That these discrepancies were seen despite comparable platelet counts, suggests that
hydroxycarbamide may have additional anti-thrombotic effects. For example the
white cell count was lower in patients receiving hydroxycarbamide and neutrophil
activation has been demonstrated in PT in association with increased markers of
coagulation activation (Falanga et al, 2000). Further analysis revealed a differential
effect of the JAK2 V617F mutation on the therapeutic response. Patients positive for
the mutation were more sensitive to the platelet lowering effect of hydroxycarbamide
and those on anagrelide experienced significantly more arterial thromboses compared
to those on hydroxycarbamide (15 v 9 events, p = 0.03) (Campbell et al, 2005).
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There was also more serious haemorrhage in the anagrelide group (Odds ratio (OR)
2.61; 95% CI 1.27-5.33), particularly gastrointestinal. This may be explained by the
anti-platelet aggregation effects of anagrelide in combination with aspirin.
Unexpectedly, the results suggested an increased rate of transformation to
myelofibrosis in the anagrelide group but the lack of baseline bone marrow
examinations means that the pre-existence of more pre-fibrotic changes in the
anagrelide group cannot be excluded. The side effect profile was consistent with the
results from retrospective studies and more patients on anagrelide withdrew from the
study due to these or because of serious adverse events.
Interferon alpha
A further non-cytotoxic option in both PV and PT, is interferon-alpha (IFN-a) which
controls counts in up to 90% of patients (Langer et al, 2005;Lengfelder et al, 1996).
In some patients, the JAK2 V617F allele load is also reduced (Langer et al,
2005;Samuelsson et al, 2006). Unfortunately its side effect profile means that its use
tends to be limited by tolerability and 25-30% of patients stop the treatment mainly
due to flu-like symptoms and depression (Langer et al, 2005;Lengfelder et al, 1996).
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1.2 Pathophysiology of thrombosis in myeloproliferative disorders
The elevated haematocrit and thrombocytosis are contributory factors to the
thrombotic risk in PV and PT but clinical evidence suggests that they are not wholly
responsible and a number of other abnormalities of the vascular system have been
identified.
1.2.1 Haematocrit and thrombocytosis
The effects of haematocrit and thrombocytosis on thrombotic risk have been
reviewed by Elliot and Tefferi (2005). Haematocrit is the major determinant of
whole blood viscosity in vitro but in vivo other factors are also involved. Higher
haematocrit levels significantly reduce cerebral blood flow due both to the increased
viscosity and to the negative regulatory effect of the higher arterial oxygen
concentrations consequent on the raised haematocrit. The axial migration of red cells
in normal flow conditions also means that the increased haematocrit narrows the
plasma/platelet zone and displaces it further towards the vessel wall. This has
multiple effects, increasing the shear forces to which the platelets are exposed and
increasing platelet-platelet and platelet-endothelial interactions.
The effect of the absolute platelet count on thrombotic tendency is unclear and no
significant correlation of degree of thrombocytosis and thrombosis has been
observed. In high risk PT patients, reducing the platelet count may reduce the
incidence of thrombosis but this may be due to more general myelosuppressive
treatment effects rather than the reduced platelet count itself. In keeping with this, in
the high risk arm of the PT-1 trial, significantly more arterial events were observed in
the anagrelide treated group compared to those on hydroxycarbamide despite
equivalent control of the platelet counts (Harrison et al, 2005).
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1.2.2 Platelet activation
Evidence of increased platelet activation has been widely observed in MPD patients
with increases in platelet expression of the activation markers P-selectin (P-
sel)(CD62) and thrombospondin, levels of soluble P-sel and platelet a-granule
contents and a greater proportion of platelet microparticles (Arellano-Rodrigo et al,
2006;Bellucci et al, 1993;Falanga et al, 2000;Falanga et al, 2005;Jensen et al,
2000a;Musolino et al, 2000;Robertson et al, 2007). P-sel levels have also been
variably correlated with thrombotic history (Arellano-Rodrigo et al, 2006;Falanga et
al, 2005;Jensen et al, 2000a;Musolino et al, 2000;Robertson et al, 2007;Villmow et
al, 2002). The cause of this platelet activation is unknown but leucocyte induced
activation, abnormalities of platelet receptors and increased platelet thromboxane A2
have been suggested. More recently, an association between the presence of the
JAK2 V617F mutation and markers of platelet activation has been reported
(Robertson et al, 2007).
Clinical observations also provide support for the role of platelet activation in the
thrombotic manifestations of MPD. Microvascular erythromelalgic symptoms are
highly sensitive to the effects of aspirin and markers of platelet activation were
observed to fall in line with symptom resolution following aspirin treatment (van
Genderen et al, 1996). Evidence from the ECLAP study in PV patients also showed
that aspirin was beneficial in reducing the risk of cardiovascular events (Landolfi et
al, 2004).
1.2.3 Leucocytes
Markers of leucocyte activation such as membrane CD lib and leucocyte alkaline
phosphatase (LAP) are elevated in MPD patients alongside increased plasma levels
of neutrophil enzymes (Falanga et al, 2000;Villmow et al, 2002). Increased platelet-
leucocyte interactions (PLA) are also observed, similar to other vascular conditions,
such as myocardial ischaemia and stroke, and correlate with markers of both
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leucocyte and platelet activation (Falanga et al, 2005;Jensen et al, 2001;Villmow et
al, 2002). Following the in vitro stimulation of whole blood with a neutrophil
agonist, an increase in neutrophil activation markers and PLA was observed, an
effect that was attenuated in PT patients who were treated with aspirin (Falanga et al,
2005). Leucocyte activation and degranulation releases enzymes including
myeloperoxidase and elastase and in vitro these cause endothelial cell detachment
and release of VWF and the anticoagulant protein thrombomodulin (TM). They may
also affect the balance of the coagulation system by the inactivation of anticoagulant
proteins (Esmon, 2005). In keeping with these observations, two recent large clinical
studies of PV and PT patients have shown that elevated leucocyte counts are
predictive for thrombosis (Landolfi et al, 2007;Gangat et al, 2007). An effect on
leucocytes by myelosuppressive therapy may also explain its beneficial effects over
and above those of non-myelosuppressive cytoreduction in reducing thrombotic risk.
1.2.4 Endothelial dysfunction and prothrombotic state
Evidence also exists for endothelial abnormalities in MPD but reports are
inconsistent. Soluble TM, VWF antigen and E-selectin have been studied as in vivo
markers of endothelial disturbance (Bellucci et al, 1993;Falanga et al, 2000;Landolfi
et al, 2007;Musolino et al, 2000;Robertson et al, 2007). Elevated serum levels were
observed in some studies and variably correlated with the thrombotic history but in
others were no different from controls. Impaired flow mediated vasodilatation, a
feature of many vascular conditions, was also observed in PV patients compared to
controls matched for cardiovascular disease. Interestingly, this effect was not
correlated with either the haematocrit or platelet count (Neunteufl et al, 2001).
Evidence for an underlying state of increased thrombin activity in MPD patients
comes from the observation of increased levels of prothrombin fragments, fibrin
degradation products and thrombin-antithrombin complexes (Bellucci et al,
1993;Falanga et al, 2000;Robertson et al, 2007). However, similar to measures of
endothelial dysfunction, these findings are not consistently observed. Rather than
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implying a primary role for endothelial dysfunction or increased thrombin activation
it may be that these observations simply reflect the influence of other prothrombotic
factors on the vasculature including age and co-morbidities.
1.2.5 Molecular mechanisms
Studies of the effects of clonality on thrombotic risk using X chromosome
inactivation patterns suggest that a proportion of PT patients have polyclonal disease
and may have a reduced thrombotic risk (Harrison et al, 1999;Shih et al, 2002).
However in the latter of these studies, patients with monoclonal disease were
significantly older, a recognised risk factor for thrombosis. In a more recent
publication no association of clonality with thrombosis or with markers of platelet or
coagulation activation were observed but patients with the JAK2 V617F mutation
had increased levels of P-sel (Robertson et al, 2007). In PT patients this mutation is
associated with higher leucocyte counts (Campbell et al, 2005;Carobbio et al,
2007;Kittur et al, 2007;Wolanskyj et al, 2005) and in PV a gene dosage effect on
leucocyte count and activation is observed (Vannucchi et al, 2007a). Since P-sel
levels and leucocyte count have been correlated with thrombosis, we might predict
an association between JAK2 V167F mutation status and thrombosis. However
such a correlation has been observed in only two retrospective studies of over 100
patients and only with venous (not arterial) thrombosis (Campbell et al, 2005;Kittur
et al, 2007) whilst other similarly sized studies have not reported such an association
(Carobbio et al, 2007;Wolanskyj et al, 2005).
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1.3 Pathophysiology of myelofibrosis
Marrow studies in PMF demonstrate a marked increase in neovascularisation of the
stromal tissue together with an increased deposition of extracellular matrix (ECM)
components - collagens, fibronectin, laminin and vitronectin. This is a cytokine-
mediated reactive phenomenon and in particular, growth factors including
transforming growth factor P (TGFP) and platelet derived growth factor (PDGF)
have been implicated. Bone marrow and platelets are a major source of these factors
(Fava et al, 1990). Imbalances in the levels of tissue metalloproteinases, which break
down the ECM and their inhibitors, are also observed. It is likely that similar
mechanisms are involved in the development of fibrosis in PV and PT. The recently
identified JAK2 tyrosine kinase and MPL mutations seen in a proportion of PMF, PT
and PV may also have a causative role in the development of fibrosis.
1.3.1 Platelets, megakaryocytes and cytokines
Several observations suggest a key role for megakaryocytes and platelets in the
pathogenesis of marrow fibrosis. Megakaryocyte hyperplasia is a prominent feature
in PMF and the presence of dysplastic forms may be an important distinguishing
feature from PT (Tefferi & Vardiman, 2007). In addition, the marrow stromal
reaction is often noted to be maximal in areas of megakaryocyte clustering. CD34
positive peripheral blood stem cells isolated from patients with PMF and cultured
with Tpo generate greater numbers of megakaryocytes than normal CD34 positive
cells and show reduced rates of apoptosis (Ciurea et al, 2007). Marrow fibrosis is
also a prominent feature of both acute megakaryoblastic leukaemia and transient
myeloproliferative disorder (TMD) which is characterised by an increase in
circulating megakaryoblasts (Hattori et al, 2001).
TGFp and PDGF are the cytokines most strongly implicated in the pathogenesis of
myelofibrosis. Megakaryocytes are a major site for their synthesis and both are
stored in platelet a-granules (Fava et al, 1990). The functions of PDGF and TGFp
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are reviewed by Miyazono (1989) and Reilly (1992). PDGF stimulates the growth
and cell division of fibroblasts. TGFp has a number of actions; it increases the
expression of genes coding for collagen, fibronectin and other stromal elements; it
has strong angiogenic properties; and it shifts the balance of tissue
metalloproteinases and their inhibitors towards increasing the ECM.
The roles of TGFp and PDGF are partly inferred from studies of other
haematological disorders where fibrosis is a prominent feature. TMD, an acute
leukaemia-like disorder seen in children with Down syndrome, is characterised by
organ fibrosis and circulating megakaryoblasts. The blasts and liver tissue from
TMD patients with hepatic fibrosis showed increased expression of the PDGF genes
and TGFp gene expression was increased in blast cells from both TMD and acute
megakaryocytic leukaemia (Hattori et al, 2001). Similarly in PMF bone marrow,
increased expression of the genes for PDGF and its receptor was observed in
advanced PMF compared to the pre-fibrotic state (Bock et al, 2005). In hairy cell
leukaemia, where fibrosis is a prominent feature, TGFp was present at higher
concentrations in the bone marrow, serum and plasma of 13 patients compared to
healthy controls (Shehata et al, 2004). In this study, ex-vivo experiments also
demonstrated that TGFp enhanced the production and deposition of reticulin and
collagen fibres by bone marrow fibroblasts. Elevated serum levels of TGFp have
also been observed in PMF patients compared to controls (Rameshwar et al, 1998).
The role of TGFp is also supported by the results of in vitro experiments. Studies
have used a mouse model of MF where Tpo is over-expressed by infection with a
Tpo encoding retrovirus (Tpohlgh mice). This results in the development of a
myeloproliferative syndrome with severe marrow and splenic fibrosis in wild type
mice but in contrast no reticulin deposition was seen in TGF-P null mice (Chagraoui
et al, 2002). Similarly in a rat model, supra-pharmacological doses of recombinant
human megakaryocyte growth and development factor induced predominantly
reticulin fibrosis in the bone marrow associated with an increase in bone marrow and
plasma TGFp levels (Yanagida et al, 1997). As TGFp levels normalised, reversal of
the fibrotic changes in the bone marrow was observed.
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Although a role for TGFp and PDGF in fibrosis has been established, the
mechanisms of their increased production and release are less clearly defined.
Decreased platelet PDGF activity but increased megakaryocyte PDGF mRNA
expression (Katoh et al, 1988;Katoh et al, 1990;Lev et al, 2002) and increased
plasma and urinary PDGF concentrations (Gersuk et al, 1989;Lev et al, 2002) have
been reported in patients with MPD. Consistent with this, intraplatelet levels of P-
thromboglobulin (BTG) and platelet factor 4 (PF4), which are also stored in platelet
a-granules, are reported to be decreased in MPD (Katoh et al, 1988), while plasma
and urine levels are elevated (Sacchi et al, 1986). This would support a mechanism
whereby defects of a-granule storage or release could result in elevated levels of
PDGF and TGFp in the plasma and/or bone marrow.
One potential confounding factor in these studies is that poor technique may cause in
vitro platelet activation and release of a-granule contents. BTG and PF4 are present
in platelets in similar amounts however in vivo there is an increased ratio of BTG to
PF4. Rapid clearance of PF4 through binding to endothelial cells compared to a
slower renal clearance of BTG is thought to account for this difference (Dawes et al,
1978). It has been proposed that these properties can be exploited to detect
artefactual in vitro platelet activation when there is a comparable elevation of both
BTG and PF4, in contrast to a normal sample with low levels of both or in vivo
platelet a-granule release with elevated BTG to PF4 ratio (Kaplan & Owen. 1981).
Electron microscopy studies of megakaryocytes in TPOhlgh mice, have shown
extensive emperipoiesis of neutrophils, associated with intracytoplasmic rupture of
a-granules (Schmitt et al, 2000). Increased megakaryocyte P-sel expression was
also observed suggesting this may mediate sequestration of neutrophils via the P-
selectin glycoprotein ligand (PSGL), leading to a-granule rupture and growth factor
release. Similar findings were observed in bone marrow trephines from 12 patients
with PMF.
Intracellular signalling involving NFkB (nuclear factor kappa beta) has also been
implicated in the abnormal release of TGFp. Spontaneous NFkB activation is
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reported in monocytes in PMF and results in increased interleukin-1 (IL-1) and
consequently TGF(3 production by an autocrine mechanism (Rameshwar et al, 2000).
NFkB activation is also reported in megakaryocytes and circulating CD34 positive
cells in PMF (Komura et al, 2005). In TPOhlgh mouse models of MF, increased
plasma levels of IL-1 a are observed (Wagner-Ballon et al, 2006) and treatment with
the NFkB inhibitor bortezomib was shown to reduce NFkB activation and plasma IL-
la. Bone marrow and spleen fibrosis and myeloproliferation was also reduced via a
reduction in marrow TGF(3 (Wagner-Ballon et al, 2007).
1.3.2 Molecular mechanisms
The fibrotic effects of the JAK2 V617F mutation, detected in around 50% of PMF,
can be deduced from mouse models transplanted with BM expressing either the wild
type or mutated JAK2 protein. Expression of JAK2 V617F but not the wild type
resulted in clinico-pathological features similar to PV in humans including
erythrocytosis, leucocytosis, megakaryocyte hyperplasia and bone marrow reticulin
fibrosis (Wernig et al, 2006). Megakaryocyte hyperplasia and dysplasia was seen
even in the absence of thrombocytosis, suggesting that quantitative or qualitative
megakaryocyte changes may be more important in the pathogenesis of fibrosis than
the thrombocytosis per se. Strain specific differences were seen in the mice, in
particular in levels of reticulin fibrosis, suggesting the influence of other undefined
factors.
Several groups have now shown that compared to PMF, more patients with post-PV
MF are homozygous for the JAK2 V617F mutation (Passamonti et al, 2006;Popat et
al, 2006;Tefferi et al, 2005). Gene dosage of JAK2 V617F was also measured in
megakaryocytes from 68 patients with JAK2 V617F positive PT, PV, PMF and pre-
fibrotic MF (Hussein et al, 2007). Significantly lower levels of mutated JAK2 alleles
were found in the megakaryocytes from patients with PT or prefibrotic MF compared
to patients with PV or PMF with manifest fibrosis. The difference between pre¬
fibrotic and fibrotic MF might suggest a causative role for gene dosage in fibrotic
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progression but sequential follow-up showed no direct correlation between
development of homozygosity for JAK2 V617F and the progression of fibrosis.
The gain-of-function mutations of the Tpo receptor MPL reported in a small number
of patients with JAK2 V617F negative PMF have also been studied in murine
models. Similar to the JAK2 V617F mutation, expression of MPL W515L but not
wild-type resulted in a myeloproliferative disorder characterized by marked
thrombocytosis, splenomegaly due to extramedullary haematopoiesis and increased
reticulin fibrosis (Pikman et al, 2006). Both the JAK2 V617F and MPL mutations
cause deregulated MPL signalling which is mimicked by the Tpohlgh mouse models
in which fibrosis is a prominent feature. However the discrepancy between the
frequent presence of these mutations in PMF, PV and PT, but a significant degree of
fibrosis in only a proportion, implies that other factors must also be involved.
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1.4 Microparticles, vascular disease and thrombosis
Microparticles are submicron plasma particles which are formed from platelets,
endothelial cells, leucocytes and erythrocytes, by the exocytic budding of cell
membranes. During their formation, the symmetry of the plasma membrane lipid
bilayer is altered, resulting in the exposure of a phospholipid rich surface.
Microparticles also bear antigens expressed on the surface of the cells from which
they originate. It is this phospholipid rich surface and the expression of functional
molecules such as tissue factor or selectins that mediate the biological actions of
microparticles in the initiation and propagation of thrombus and in cellular
interactions. Elevated levels of microparticles are found in a number of conditions
associated with vascular dysfunction, thrombosis and inflammation.
1.4.1 Biological aspects of microparticles
1.4.1.1 Formation ofmicroparticles
Microparticles are constitutively released from the surface of cells but their
formation can be up-regulated by cell activation or apoptosis. Other small vesicles
which are also released from cells include exosomes, pre-formed intracellularly and
released by fusion with the cell membrane, and apoptotic bodies which are formed
late in the process of cell death. Membrane microparticles differ from these vesicles
in both their mechanism of formation and their functional properties. After cell
activation or apoptosis is triggered, there is a rise in cytosolic calcium concentration,
leading to kinase activation and phosphatase inhibition which induce cytoskeletal
changes. Consequently there is alteration of the normal lipid bilayer of the cell
membrane, with "flip-flopping" of the internal negatively charged phospholipids to
the external surface. Membrane blebbing and microparticle formation then results
(VanWijk et al, 2003). Microparticle membrane composition therefore reflects the
membranous elements of the cell of origin. Their surfaces are rich in negatively
charged phospholipids, chiefly phosphatidylserine (PPS), and they bear surface
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antigens of their parent cell including functional molecules such as tissue factor (TF)
or selectins.
A number of cell activation and apoptosis triggers which induce microparticle
formation have been identified including chemical stimuli such as cytokines,
thrombin and endotoxin, or physical stimuli such as shear stress or hypoxia
(VanWijk et al, 2003). In platelet microparticle (PMP) formation it has been shown
that platelet glycoprotein (GP) receptors and adhesion molecules can also be
involved. For example, the GPIb receptor mediates adhesion to VWF and, under
hydrodynamic flow, stretching of the platelet membrane occurs followed by
separation of areas of tethered membrane and the production of microparticles
(Reininger et al, 2006). Platelet P-sel levels correlate with PMP levels in mice and in
vitro, P-sel immunoglobulin can induce microparticle formation in human blood;
this effect is abolished by blocking antibodies to the counter-receptor PSGL
(Hrachovinova et al, 2003).
It is likely that the nature of the trigger influences both the number of the
microparticles released and their physical and functional properties. For example, in
vitro, endothelial cells can be induced to express different profiles of surface
antigens, such as adhesion molecules or tissue factor, by different stimuli. Many of
these same stimuli can also induce microparticle release. It might therefore be
expected that the induced endothelial cell changes will be reflected in the
composition and antigenic profile of the microparticles which will in turn determine
their pathophysiological effects. This was demonstrated by culturing endothelial
cells from brain, kidney and coronary arteries and exposing them to apoptotic or
activating stimuli (Jimenez et al, 2003b). The endothelial microparticles (EMP)
released following apoptotic stimuli had higher levels of surface Annexin V binding
to PPS and of constitutive endothelial cell markers such as CD31 (Platelet
Endothelial Cell Adhesion Molecule, PECAM). In contrast, EMP induced by
activation with tumour necrosis factor a (TNFa) expressed higher levels of inducible
antigens, such as E-selectin (E-sel, CD62E), which were also increased on the parent
endothelial cells. Additionally, microvascular endothelial cells released significantly
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more microparticles overall compared to the macrovascular coronary artery
endothelium. The formation of phenotypically heterogeneous microparticles is
represented in Figure la.
1.4.1.2 Microparticles - coagulation activity
Microparticles are likely to support coagulation and thrombus formation in a number
of different ways. Under certain conditions they can also exhibit anticoagulant
properties dependent on their origin and the stimulus to release. Accordingly,
microparticles may contribute to the complex regulation of the balance between an
anti- or prothrombotic vasculature. A schematic summary of the postulated role of
microparticles in the development of localised thrombus is shown in Figure lc.
In addition to coagulation factors and calcium ions, cell membrane phospholipids are
necessary for the optimal activity of the coagulation system. Negatively charged
phospholipids, mainly PPS, have a catalytic role promoting the formation of the
intrinsic tenase and the prothrombinase enzyme complexes on the membrane surface.
This phospholipid surface has traditionally been thought to be provided by activated
platelets (previously known as platelet factor 3) but microparticles can also support
this process with their PPS rich surfaces. Microparticles expressing TF can also be
identified in some circumstances, thus providing a suitable environment both to
initiate and to propagate coagulation (Figure lb).
Microparticles have been shown to support coagulation by both FVII/TF dependent
and independent pathways. Using a thrombin generation assay to study the
procoagulant potential of microparticles, Pereira and colleagues reported that platelet
free plasma from patients with antiphospholipid syndrome had an increased
endogenous thrombin potential compared to healthy controls. This effect was
dependent on the presence of PMP and correlated with microparticle numbers
(Pereira et al, 2006). Combes and colleagues found that TNF stimulation of cultured
human umbilical vein endothelial cells (HUVEC) resulted in an increase in the
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release of EMP expressing surface TF (Combes et al, 1999). The addition of
increasing concentrations of these EMP to a coagulation assay shortened the plasma
clotting time compared to EMP from unstimulated HUVEC. The effect was not seen
in FVII deficient plasma, showing the procoagulant activity of the EMP to be
FVII/TF dependent in this situation. In contrast, EMP induced in vitro by cisplatin
treatment were found to be highly procoagulant and thrombin generation was not
reduced by blocking antibodies to TF or FVII (Lechner et al, 2007). Similarly
microparticles have been identified in healthy volunteers which supported low grade
thrombin generation, independent of TF (Berckmans et al, 2001).
Microparticles can also contribute to the development of platelet and fibrin rich
thrombus at sites of vascular injury, through the recruitment of cells and
concentration of tissue factor (Figure lc). In mouse models fluorescently labelled
microparticles were observed to accumulate in areas of developing thrombus
(Hrachovinova et al, 2003). Activated endothelium at sites of vascular injury and
activated platelets within developing thrombus both express P-sel which may bind to
monocyte microparticles expressing TF via the P-sel receptor PSGL-1. In mice
lacking P-sel/PSGL-1 or in the presence of blocking antibodies, platelet thrombi with
minimal tissue factor and fibrin are formed (Falati et al, 2003). Similarly PMP from
activated platelets can mediate leukocyte-leukocyte interactions in vitro via binding
of P-sel to PSGL (Forlow et al, 2000). Such interactions could lead to increased
numbers of leucocytes and leucocyte microparticles (LMP) on surfaces expressing P-
sel thus promoting the concentration of TF and localised thrombin generation within
developing thrombus.
1.4.1.3 Microparticles - effects on endothelium
Endothelial dysfunction is a common feature of many vascular disorders including
atherosclerosis, diabetes, antiphospholipid syndrome, thrombotic thrombocytopenic
purpura and sickle cell disease, where it is likely to have an important pathogenic
role. Elevated levels of microparticles have been reported in all of these disorders
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(see later). Correlation between EMP levels and other serum markers of endothelial
dysfunction including TM and endothelial adhesion molecules has also been reported
(Koga et al, 2005;Nomura et al, 2005;0gura et al, 2004). Soluble intercellular
adhesion molecule (sICAM), which has been found to be related to endothelial
dysfunction and coronary artery disease (CAD), was measured concurrently with
EMP in patients with DM (Koga et al, 2005). Levels of both EMP and sICAM were
elevated compared to non-diabetic controls and were greater in DM patients with
CAD than those without CAD. EMP were also assessed in patients following stem
cell transplantation and rose in parallel with levels of vascular cell adhesion
molecule-1 (VCAM-1) and E-sel (Nomura et al, 2005).
Comparison of microparticle levels with in vivo measures of vascular dysfunction
shows similar results. In patients with end-stage renal failure (ESRF) a strong
correlation between EMP levels and reduced flow mediated brachial artery dilation
and increased indices of arterial stiffening was observed (Amabile et al, 2005). In
vitro, microparticles from patients with ESRF, but not healthy controls or
microparticle supernatant, caused impaired endothelial dependent vasorelaxation in
rat aorta and reduced nitric oxide release. These effects correlated strongly with
EMP levels and could be induced by purified EMP alone. Circulating EMP may
therefore contribute to the vascular changes seen in ESRF through inhibition of the
endothelial nitric oxide pathway. Similarly, an inverse correlation was found
between EMP numbers and endothelium dependent vasodilatation of the coronary
arteries in diabetic patients undergoing angiography, where EMP numbers correlated
with the presence of coronary artery lesions (Koga et al, 2005).
These observations suggest that EMP may not only provide an indication of the local
or general state of the endothelium induced by activating or injurious external stimuli


















Figure 1a: Formation of microparticles.
GPIb - glycoprotein lb, ICAM - intercellular adhesion molelule, ICAMR - ICAM receptor, Psel - P-selectin,
PSGL - P-selectin glycoprotein ligand, TF - tissue factor, vWF - von Willebrand Factor.
Figure 1b: Functions of microparticles in cellular interactions and coagulation.
AA - Arachidonic acid
Figure 1c: Postulated role of microparticles in the development of thrombus.
1.4.1.4 Microparticles - cellular interactions
Microparticles bear antigens of their cell of origin and can transfer these surface
molecules to other cell types. In doing so they may alter the biological activity of the
recipient cells. Additionally, the binding of microparticle surface antigens to their
specific counter-receptor may induce intracellular signalling pathways. Some of the
known cellular interactions ofmicroparticles are illustrated in Figure lb.
EMP induced by in vitro stimulation of HUVEC with TNFa showed heterogeneous
expression of a number of adhesive receptors including PECAM-1, ICAM-1,
VCAM-1, E-sel and avp3 integrin. After incubation with these EMP, cultured
monocytic cells also expressed these endothelial antigens at the cell surface (Sabatier
et al, 2002b). The results suggested that this phenomenon was likely to involve
receptor binding rather than membrane fusion. In addition, the co-incubated
monocytes had increased levels of TF mRNA and increased TF dependent
procoagulant activity. This effect was significantly inhibited by the addition of
blocking antibodies to ICAM-1 and its counter-receptor suggesting it to be at least
partly dependent on specific EMP and monocyte adhesion molecule interactions.
A key feature in atherosclerosis is monocyte adhesion to endothelial cells followed
by subendothelial migration. Cytokines such as IL-ip and TNF-a can affect this
process by inducing the synthesis or up-regulation of leucocyte-endothelial adhesion
molecules. The in vitro stimulation of both monocytes and endothelial cells by high
shear stress induced PMP, resulted in significantly increased production of IL-8, IL-
ip and TNF-a and increased the expression of adhesion molecules on both cell types
(Nomura et al, 2001;Barry et al, 1998). PMP have also been shown in vitro, to
increase platelet aggregation and to induce endothelial cell expression of cyclo-
oxygenase-2 and production of prostaglandin E (Barry et al, 1997) These effects
could be replicated by arachidonic acid isolated from the PMP lipids (Barry et al,
1998;Barry et al, 1997) which suggests that microparticles may also be able to
modulate cell functions by the direct delivery of active substances.
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Microparticles may also provide a novel mechanism of cross-talk between the
cellular elements of the inflammatory and coagulation systems. Microparticles
induced by in vivo stimulation of healthy volunteers with a chemotactic peptide were
able to induce IL-6 release and TF expression by endothelial cells in vitro. This was
associated with a TF dependent increase in the procoagulant activity of the
endothelial cells, an effect which appeared to be mediated by LMP (Mesri & Altieri,
1999). Similarly, the addition of neutrophils, cell free supernatant or purified
microparticles, but not microparticle free supernatant to cultured endothelial cells
induced the release of IL-6 and IL-8 (Mesri & Altieri, 1998). Thus leucocytes
activated by inflammatory cytokines may release microparticles which can promote
procoagulant endothelial changes.
1.4.2 Definition and in vivo measurement ofmicroparticles
The definition of microparticles and the methods used in their measurement vary
between research groups and these factors are likely to have an important influence
on the observed results. A forum addressing this methodological variation suggested
that most laboratories defined microparticles by size (less than 1 jam) and expression
of cell lineage-specific antigens. Isolation and measurement techniques are more
variable but most commonly microparticles are measured in platelet poor plasma or
microparticle suspensions by either flow cytometry or activity assays (Biro et al,
2004;Dignat-George et al, 2004;Hugel et al, 2004;Jimenez et al, 2004;Jy et al,
2004;Nomura, 2004;Shet et al, 2004) .
Despite the variation in absolute numbers, studies which have assessed the relative
proportions of microparticle subtypes in plasma show fairly consistent results. In
general PMP are found to be the most abundant with LMP, EMP and erythrocyte
(RMP) microparticles accounting for the remainder (Daniel et al, 2006;Berckmans et
al, 2001) although this profile may be altered in some disease states.
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1.4.3 Microparticles in vascular disorders
Microparticles have been studied in many conditions which share common
pathophysiological features with evidence of platelet and coagulation activation and
vascular dysfunction, including cardiovascular disease and DM, venous thrombosis,
thrombotic microangiopathies, antiphospholipid syndrome. A limited amount of
information is also available regarding the role of microparticles in primary
haematological diseases complicated by thrombosis. A summary of the results of
these studies is given in Tables 1.3 and 1.4.
1.4.3.1 Cardiovascular disease and venous thrombosis
Endothelial dysfunction, vascular inflammation and a prothrombotic state arise in
patients with CAD, the vascular complications of diabetes, hypertension,
cerebrovascular disease and venous thrombosis (VTE). As might be expected from
the pathophysiologic processes involved, elevated microparticles have been reported
in all of these diseases.
In 25 patients with deep vein thrombosis or pulmonary embolism, EMP levels were
markedly elevated in patients with VTE compared to controls (Chirinos et al, 2005).
PMP were not elevated despite higher levels of platelet expression of the activation
marker P-sel. Increased leucocyte expression of the activation marker CDllb and
EMP-monocyte conjugates in the VTE patients was also seen.
Overall microparticles are elevated in diabetic patients but studies have found
differences in the microparticle profile in relation to disease type and the presence of
complications. In type I DM the procoagulant potential of microparticles, as
measured by a prothrombinase assay, was elevated and correlated with degree of
glycaemic control (Sabatier et al, 2002a). In contrast, although total numbers of
microparticles were elevated in type II DM there was no associated increase in their
procoagulant potential. Levels of PMP and monocyte microparticles have been
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shown to correlate with the extent of diabetic retinopathy which is associated with
microvascular damage (Ogata et al, 2006).
In a prospective observational study of 217 diabetic patients referred for investigative
angiography, elevated EMP levels were predictive for the presence of coronary
artery lesions, OR 3.5 (1.8-6.9). Further, it was a more significant independent risk
factor than length of diabetic disease, lipid levels or the presence of hypertension
(Koga et al, 2005). Interestingly, elevated EMP levels were predictive in identifying
a subpopulation of diabetic patients without typical anginal symptoms who had
angiographic evidence of CAD.
Procoagulant microparticles and in particular EMP are elevated in patients with acute
coronary syndromes compared to either patients with stable anginal symptoms or
normal controls (Bernal-Mizrachi et al, 2003;Mallat et al, 2000). This likely reflects
the degree of acute vascular injury and inflammation at the time of measurement. In
addition LMP are abundant in atherosclerotic plaques and elevated circulating
CDlla positive LMP were reported to be predictive for subclinical atherosclerotic
lesions (Chironi et al, 2006).
Circulating EMP are also elevated in acute ischaemic stroke (CVA) (Simak et al,
2006). It was observed that while PPS positive EMP were elevated in all acute CVA
compared to controls, endoglin positive EMP were elevated only in the moderate-
severe group. Endoglin expression is associated with endothelial apoptosis and is
upregulated on cultured endothelial cells under hypoxic conditions. These findings
may therefore reflect more extensive endothelial injury in the more clinically severe
group. Notably, the patient samples were collected at an average of 37 hours
following hospital admission suggesting an ongoing procoagulant state.
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DISEASE STUDY TMP PMP EMP LMP RMP
VTE Chirinos et al, 2005 (nst) t
Type I DM Sabatier et al, 2002 t t t
Type II DM Sabatier et al, 2002 t = =
DM retinopathy Ogata et al, 2006 T t
DM + CAD Bernal-Mizrachi et al, 2004 t
ACS Bernal-Mizrachi et al, 2003 f t
Mallat et al, 2000 t = t =
Acute CVA Simak et al, 2006 (nst) t =
CRF Amabile et al, 2005 t t t t
Amabile et al, 2006 t t
Hypertension Preston et al, 2003 t t
Table 1.3 Microparticles in cardiovascular disorders
Summary of results of published studies of plasma microparticle levels in patients
with cardiovascular disorders compared to healthy controls.
DISEASE STUDY TMP PMP EMP LMP RMP
Acute TTP Jimenez et al, 2003 t
SCD Shet et al, 2003 t = = t t
PNH Hugel et al, 1999 t =
Simak et al, 2004 17= t =
MPD Villmow et al, 2002 t
Table 1.4 Microparticles in prothrombotic haematological disorders
Summary of results of published studies of plasma microparticle levels in
prothrombotic haematological disorders compared to healthy controls.
Abbreviations: total (TMP), platelet (PMP), endothelial (EMP), leucocyte (LMP) and
erythrocyte (RMP) microparticles. Venous thromboembolism (VTE), diabetes mellitus
(DM), coronary artery disease (CAD), acute coronary syndrome (ACS), cerebrovascular
accident (CVA), chronic renal failure (CRF), thrombotic thrombocytopenic purpura (TTP),
sickle cell disease (SCD), paroxysmal nocturnal haemoglobinuria (PNH), myeloproliferative
disorders (MPD).T- statistically significant increase; (nst) - non-significant increase; = - no
difference; -l - statistically significant reduction.
43
Patients with chronic renal failure (CRF) are also at increased risk of accelerated
cardiovascular disease and have evidence of endothelial dysfunction. In keeping
with this, elevated levels of EMP have been found in CRF (Amabile et al,
2005;Faure et al, 2006), however no difference was identified in EMP levels
between those with or without a history of vascular disease. Assessment of in vivo
measures of endothelial dysfunction in ESRF shows a strong correlation with levels
of EMP (Amabile et al, 2005). The study of microparticles may also provide insight
into the causes of endothelial dysfunction; culture of HUVEC with uraemic toxins
induced EMP formation supporting a direct effect of uraemia on endothelial function
(Faure et al, 2006). Hypertension is another important factor in renal disease and the
associated shear stress is trigger for microparticle formation. In severe hypertension,
in the absence of CRF, both EMP and PMP are elevated and correlate with systolic
pressure (Preston et al, 2003).
1.4.3.2 Thrombotic thrombocytopenic purpura
Microvascular endothelial injury, triggering the formation of platelet rich thrombi is
thought to be of primary importance in the pathogenesis of thrombotic
thrombocytopenic purpura (TTP) and related disorders. When plasma from patients
with acute TTP was incubated with cultured brain and renal microvascular
endothelial cell lines and a 5-6 fold increase in EMP generation compared to control
plasma was observed (Jimenez et al, 2001). There was also a proportional increase in
the procoagulant activity of the EMP as measured by the Russell Viper Venom Time.
The phenotype of the EMP generated by TTP plasma was similar to that of EMP
induced by culture with activating rather than apoptotic stimuli (Jimenez et al,
2003b), with an increased ratio of CD62E+ to CD31+ EMP. In addition, more than
60% of the CD62E+ EMP co-expressed VWF (Jimenez et al, 2003a) in the form of
ultra large VWF multimers. These EMP strongly induced stable platelet aggregation,
in the presence of ristocetin, by a VWF-dependent mechanism.
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In relation to the clinical findings, elevated numbers of EMP in the plasma of
patients with acute TTP compared to normal controls or those in remission were
observed. The EMP phenotype in the patients also reflected that found in vitro, with
an increased ratio of CD62E+ to CD31+ EMP. The level of co-expression of VWF
on the CD62E+ EMP was five times that of the normal controls. These studies
suggest a pathophysiological role for microvascular EMP in TTP through the
expression of ultra large VWF and the induction and stabilisation of platelet
aggregates.
1.4.3.3 Primary haematological diseases
The vaso-occlusive episodes of sickle cell disease were previously thought to be
secondary to vessel occlusion by sickled erythrocytes. More recent evidence suggests
that other factors are important, in particular, microvascular endothelial activation
and endothelial-erythrocyte adhesion. In keeping with the prothrombotic clinical
phenotype, in vivo markers of coagulation and fibrinolysis are elevated including
prothrombin fragments (PF1+2), thrombin-antithrombin complexes (TAT) and D-
dimer (Switzer et al, 2006).
Erythrocyte microparticle levels are significantly increased in sickle cell patients
compared to controls and account for the majority of circulating microparticles.
However, endothelial and monocyte microparticles are also increased compared to
healthy controls both in the steady state and greater still in vaso-occlusive crises,
supporting the theory of endothelial activation (Shet et al, 2003). A proportion of
these endothelial and monocyte microparticles express TF and shorten the plasma
clotting time, an effect partially inhibited by anti-TF antibodies. The total levels of
microparticles and the TF positive subset also correlated with D-dimer, TAT and PT
1+2 measurements.
Elevated levels of microparticles have also been reported in paroxysmal nocturnal
haemoglobinuria (PNH), another prothrombotic disorder (Simak et al, 2004;Hugel et
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al, 1999). In one study PMP appeared to account for the majority and RMP were
infrequent but they did not measure LMP or EMP. The procoagulant potential of the
microparticles was confirmed using a prothrombinase assay (Hugel et al, 1999). In
contrast, Simak found that EMP were elevated in the PNH patients as a whole, but
that individual patients had increased numbers ofPMP (Simak et al, 2004). However
they also observed that the majority of microparticles in both patients and normal
controls were RMP in contrast to most other studies where PMP predominate,
suggesting that methodological differences may have influenced the results.
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1.5 Hypothesis, aims and objectives
With current treatment, the life expectancy for patients with PV and PT is
significantly improved from that of the natural history of the disease. However,
thrombotic and fibrotic complications continue to contribute significant morbidity to
patients with these conditions and may reduce survival, in particular for younger
patients. Our understanding of the pathophysiology of these complications is
incomplete but in both there is evidence for platelet abnormalities and, in thrombosis,
other vascular disturbances. Phenotypic differences dependent on the presence of the
recently recognised JAK2 V617F tyrosine kinase mutation in a proportion of patients
have been described but whether this mutation has any direct role in the
complications of these disorders is unclear.
The pathogenesis of thrombosis in these disorders is likely to be multifactorial and in
addition to platelet activation, there is evidence for leucocyte activation, endothelial
disturbance and a procoagulant state. Similar abnormalities are associated with
elevated microparticles from platelets, leucocytes, erythrocytes and endothelial cells
in other prothrombotic disorders. To date, only one published study has measured
PMP in MPD and they reported an increased proportion of PMP which correlated
with markers of platelet activation. In conjunction with the recognised procoagulant
properties of microparticles, these observations suggest that investigation of
microparticles in myeloproliferative disorders may extend our understanding of the
pathogenesis of thrombosis in these diseases.
Platelets and megakaryocytes have been shown to have a central role in bone marrow
fibrosis through the effects of pro-fibrotic cytokines in particular TGFp and PDGF.
However the mechanisms by which elevated levels of these cytokines are present
remain elusive. Possible mechanisms include specific release possibly as a result of
aberrant intracellular signalling or non-specific "leak" consequent on defects in the
packaging or storage of the cytokines in intracellular a-granules. Measurement of
circulating levels of these profibrotic cytokines along with other factors contained
within the platelet a-granules, may provide additional evidence for the latter theory.
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Aims and Objectives
■ To identify and describe the local MPD population
o Description of the clinical and laboratory features of the local MPD
population and relation to findings from larger studies
o Description of the management of the local MPD population in
comparison to existing guidelines
o Assessment of clinical and laboratory parameters in relation to the JAK2
V617F mutation
o Assessment of the effect of the JAK2 V617F mutation on patient
diagnosis
■ To set up a flow cytometry assay for the detection of plasma microparticles
o Review of currently published methods ofmicroparticle isolation
o Optimisation and standardisation of preanalytical variables in sample
collection and processing
o To identify platelet, endothelial, leucocyte and red cell microparticles by
size and surface antigen expression
o To devise a suitable method ofmicroparticle quantitation
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■ To investigate microparticles and established markers of vascular function in
patients with myeloproliferative disorders
o Measurement of platelet, endothelial, leucocyte and red cell
microparticles in patients with MPD compared to controls
o Relation of microparticle levels to clinical features, haematological and
molecular parameters
o Measurement of established markers of platelet and endothelial function
and coagulation activation in patients with MPD compared to controls
o Relation of markers to clinical features, haematological and molecular
parameters and comparison with findings from previous studies
o Assessment of the correlation of microparticle numbers with established
vascular markers in MPD patients and controls
■ To investigate circulating levels of profibrotic cytokines in comparison to other
platelet a-granules proteins in patients with myeloproliferative disorders
o Measurement of TGFp and PDGF in MPD patients compared to controls
o Correlation of TGFp and PDGF levels with the platelet a-granule
proteins BTG and PF4
o Correlation of levels of a-granule proteins with clinical, haematological
and molecular parameters




Clinical and laboratory characteristics
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2.1 Introduction
PV and PT are relatively rare diseases and until recently our insight into their
pathogenesis has been limited and studies of the incidence of complications and the
effect of therapeutic interventions have been small and retrospective. However in the
last 5 years, the publication of a number of large clinical trials and observational
studies and the identification of a JAK2 tyrosine kinase mutation in a proportion of
these patients, have significantly advanced our understanding in this field. These
studies and the clinical and laboratory features of PV and PT are discussed fully in
Chapter 1 but are summarised here for reference to our own observations in the
current study.
Around 30-50% of patients with PV or PT present with a thrombotic, or less
commonly, a haemorrhagic episode or experience these as a complication during
follow-up. In PT patients, arterial microvascular symptoms such as CVA and
erythromelalgia predominate whereas in PV, venous thrombosis and large vessel
arterial disease are commoner. The factors most strongly and consistently associated
with thrombotic risk are older age (>60 years), prior history of thrombosis and more
recently, elevated white cell count at diagnosis (Carobbio et al, 2007;Gruppo
Italiano, 1995;Landolfi et al, 2007;Marchioli et al, 2005;Passamonti et al,
2004;Wolanskyj et al, 2006). The older age of most PV and PT patients means that
traditional cardiovascular risk factors are commonly present but their role in
thrombotic risk is less clear. In a smaller proportion of patients, haematological
progression to acute leukaemia or myelofibrosis occurs with increasing time from
diagnosis.
The diagnosis of these diseases has evolved as their pathogenesis has become better
understood. In particular the identification of the JAK2 V617F tyrosine kinase
mutation has significantly simplified the diagnosis ofPV in the majority of cases and
has prompted review of the diagnosis in "PV" patients negative for the mutation. In
PT patients with the mutation, a phenotype with more similarities to PV is described,
with higher haematocrit and leucocyte counts, signs of iron deficiency and lower
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platelet counts. Some studies have suggested that it may also be associated with an
increased risk of venous thrombosis.
The aim of therapy in PV and PT is to reduce the risk of vascular complications
without increasing the risk of leukaemic transformation. Risk stratification is
therefore used to help guide management decisions (Table 1.2). Concerns about the
potential leukaemogenic risk of the standard cytoreductive hydroxycarbamide mean
that observation or non-cytotoxic alternatives may be preferred in those at low
thrombotic risk or younger patients. A recent study of aspirin in PV patients has
confirmed its predicted benefits in reducing thrombotic risk and this benefit has been
extrapolated to PT patients.
We have identified the PV and PT population in Edinburgh and in this chapter we
describe the demographics, clinical and laboratory features at diagnosis and the
complications experienced by those who participated in the main study. The
frequency of the JAK2 V617F mutation in this population has been established and
compared to previously published results and we have examined its relation to
clinical and laboratory parameters. We have also reviewed the diagnosis of PV
patients negative for the JAK2 V617F mutation.
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2.2 Materials and Methods
2.2.1 Patient identification and recruitment
Patients with a working diagnosis of PT or PV, based on either the PVSG or BCSH
criteria (Appendix 1), were identified from the haematology out-patient services at
the Royal Infirmary of Edinburgh (RIE) and the Western General Hospital (WGH)
Edinburgh. Letters of invitation, patient information sheets and consent forms were
sent to patients one week prior to their clinic appointments (Appendix 2). Patients
who wished to participate returned their completed consent form by post or at their
clinic visit and thereafter a study visit was arranged to coincide with their next
clinical appointment.
2.2.2 Data collection
Clinical history and haematological parameters at diagnosis, molecular data and
follow-up information was obtained by review of the patient case records.
Cardiovascular disease (CVD) was defined as a history of ischaemic heart disease
(IHD) (including angina, acute coronary syndrome or myocardial infarction),
cerebrovascular disease (transient ischaemic attack (TIA) or stroke) or peripheral
vascular disease (PVD). Cardiovascular risk factors (CVRF) included diabetes
mellitus, hypertension, hypercholesterolemia, smoking and cardiac failure. Vascular
events included cardiovascular thrombosis, TIA or stroke, deep vein thrombosis
(DVT) or pulmonary embolism (PE) or microvascular symptoms including vascular
headache and erythromelalgia. Vascular events at presentation included those which
occurred up to one year prior to the diagnosis ofMPD.
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2.2.3 Ethics
Ethical approval for the study was obtained from the Lothian Local Research Ethics
Committee.
2.2.4 Statistical analysis
For normally distributed data the mean and standard error of the mean (SEM) are
presented and comparisons between groups were made using the student's t-test. For
non-normally distributed data, the median and interquartile range (IQR) is presented
and the non-parametric Mann-Whitney U test was used for between group
comparisons. Associations between qualitative variables were investigated with the
Fisher's exact test for 2 x 2 tables. A value of P<0.05 (2-tailed) was considered




2.3.1 Edinburgh MPD patient population and study cohort
At the start of the study period 185 patients with a diagnosis of PV (50) or PT (135)
documented in their case records were identified over two hospital sites. Just under
half of these (42%) participated in the study. Table 2.1 shows the breakdown of the
numbers invited to take part, those who consented and those who finally participated
in the study.
We compared the basic demographics of the participating (study cohort) and non-
participating patients. Of all the patients identified, 72.9% had PT compared to 76%
of those who participated in the study. The study cohort were younger than those
who did not participate with a mean age (standard error (SEM)) of 64.7 (1.7) v 71.5
(1.5) years (p=0.003). This was mainly due to differences in the PT group, 64.3 (2.0)
v 73.7 (1.7) years (p<0.001), whereas the mean age of the PV patients in the study
cohort was similar to those not participating, 66.0 (3.3) v 66.3 (2.8) years (p=0.945).
In the overall local MPD population there was no significant difference in age
between the PT and PV patients, 69.6 (1.3) v 66.2 (2.1) years respectively (p=0.172).
2.3.2 Study cohort - Clinical characteristics
Age and time from diagnosis
The study cohort consisted of 78 patients, 59 PT and 19 PV. The age, sex and follow-
up period for the patients is detailed in Table 2.2. There was no significant difference
in these parameters between the PV and PT patients. In the patients recruited from
the RIE the median time from diagnosis was 71.3 (IQR 34.8-129.6) months
compared to 30.8 (20.7-43.8) months for the WGH patients (p<0.001).
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All (n) PT(n) PV (n)
R1IE
Total 101 74 27
Invited to participate 73 51 22
Consented 48 37 11
Withdrew/DNA 5 1 4
In study 43 36 7
WGH
Total 84 61 23
Invited to participate 58 42 16
Consented 37 24 13
Withdrew/DNA 2 1 1
In study 35 23 12
Table 2.1 Local MPD patient population and study cohort
Breakdown of the numbers of PV and PT patients identified at the Royal Infirmary
of Edinburgh (RIE) and the Western General Hospital Edinburgh (WGH) and those
participating in the current study. Around two-thirds of those invited to participate
gave their consent however some withdrew thereafter or did not attend (DNA).
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Vascular co-morbidities and cardiovascular risk factors
Data on the presence of pre-existing CVD (diagnosed prior to the diagnosis of PT or
PV) and CVRF (identified at any time before or after the diagnosis of PT or PV) was
available from the case records for 76 patients (Table 2.2). There was no
documented history of CVD or CVRF in 40 patients (51.9%). In 21 patients there
was a documented history of CVRF but no CVD and five of these patients had more
than one risk factor. The commonest CVRF in this group was hypertension in 18
patients. In total, three patients had DM and one patient had cardiac failure.
Smoking at the time of study entry was reported by only five patients. A documented
history of CVD prior to the diagnosis ofMPD was present in 15 patients (19%), five
of whom had multiple vascular co-morbidities. A similar proportion of PV and PT
patients had CVRF but more PT patients had had cardiovascular or venous events
prior to diagnosis, although this was not statistically significant.
To establish the prevalence of undiagnosed hypertension we performed a small audit
of consecutive patients at the MPD clinic. A single blood pressure (BP) reading was
taken in 32 patients; 20 PT, 10 PV and 2 PMF. The mean age of these patients was
similar to the study cohort at 65.5 and 64.7 years respectively (p=0.76). A
documented history of hypertension was present in 34.4% of the audit group
compared to 36.8% of the study cohort. Twenty-one of the 32 audit patients had no
history of hypertension; 13 had a normal BP (below 140/90), six had borderline
systolic hypertension (systolic BP 140-150) and only two had a BP of over 150/90.
In the 11 patients with a documented history of hypertension, four had a normal BP,
three had borderline readings and four had a BP over 150/90.
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Entire cohort PT PV PT v PV
n = 78 n = 59 n = 19 p value
Age at study entry (mean, SEM) 64.7(1.7) 64.3 (2.0) 66.0 (3.3) 0.663
Age at diagnosis (mean, SEM) 59.5 (1.7) 58.5 (2.1) 62.4 (3.2) 0.319
Male sex, n (%) 32(41.0)
25 (42.3) 7(36.8) 1.000
Presentation data n = 76 n = 57 n = 9
Cardiovascular risk factors, n (%)
Any 33 (43) 25 (43.8) 8(42.1) 1.000
Diabetes mellitus 3 (3.9) 3 (5.3) 0 0.569
Elypertension 27 (35.1) 21 (36.8) 7 (36.8) 1.000
Hyperlipidaemia 5 (6.6) 7 (12.3) 0 0.182
Smoking 5 (6.6) 5 (8.8) 1 (5.3) 1.000
Congestive cardiac failure 1 (1.3) 1 (1.8) 0 1.000
Pre-existing cardiovascular or
venous disease, n (%)
Any 17 (22.4) 16(28.1) 3 (15.8) 0.372
Ischaemic heart disease 9(11.8) 8 (14.0) 2 (10.5) 1.000
Cerebrovascular disease 8(10.5) 7(12.3) 1 (5.3) 0.671
Peripheral vascular disease 4(5.3) 5 (8.8) 0 0.320
Venous thrombosis 4(5.3) 3 (5.3) 1 (5.3) 1.000
Thrombosis at presentation, n (%)
Any 22 (28.9) 16(28.1) 6(31.6) 0.777
Arterial 15 (19.7) 12(21.0) 3 (15.8) 1.000
Venous 7 (9.2) 4 (7.0) 3 (15.8) 0.351
Haemorrhage at presentation, n (%) 6 (7.9) 3 (5.3) 3 (15.8) 0.151
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Entire cohort PT PV PT v PV
00IIe n = 59 n = 19 p value











Any 7(9.1) 6(10.3) 1 (5.3) 0.674
Arterial 6 (7.8) 6(10.3) 0 0.327







4(5.2) 4 (6.9) 0 0.567
Table 2.2 Clinical characteristics of patient cohort
Clinical characteristics of PV and PT patients at the time of diagnosis and at study
entry. P values for comparison ofPV and PT groups are shown.
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Clinical presentation
Data on clinical presentation was available for 76 patients. An incidental finding of
raised haematocrit or thrombocytosis was the commonest presentation occurring in
61.5% of patients. The remainder of patients had a history of haemorrhagic or
thrombotic events at or within the 12 months prior to presentation (Table 2.2).
A history of arterial events was the commonest symptomatic presentation occurring
in 14 patients (19.7%). These included four TIA, two CVA, four peripheral arterial
thrombosis and four patients with microvascular symptoms (erythromelalgia or
headache). There was no prior history of CVD or CVRF in seven of these patients,
five had CVRF only and two patients had a history of PVD or IF1D. Haemorrhagic
symptoms were the least common presentation and included two epistaxis, two
minor gastrointestinal bleeding episodes, one intra-articular knee bleed and one
rectus sheath haematoma.
Complications arising after the diagnosis of PT or PV
Thrombotic complications were recorded in seven patients (9%) following diagnosis;
six arterial (four TIAs and two peripheral thromboses) and two VTE. No
haemorrhagic complications were observed (Table 2.2).
In four patients originally diagnosed with PT, progression to clinical MF was
recorded after 12, 27, 54 and 84 months follow-up. Leucoerythroblastic film features
were present in all four patients and two had documented splenomegaly at the time
of diagnosis of post-PT MF. All had bone marrow trephines confirming Grade 3-4
fibrosis. The diagnostic bone marrow trephine reports were available for three of the
patients; all reported an increase in reticulin and two reported megakaryocyte atypia
at initial presentation. One patient died within 6 months of the diagnosis of post-PT
MF; the others survive with subsequent follow-up of 10, 83 and 120 months. No
leukaemic transformations were observed.
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Risk stratification and management
None of the patients in the study cohort were assessed to be low risk for thrombosis
(for risk stratification see Table 1.2). Seven patients (two PV and five PT) were
considered at intermediate risk and the remaining 71 patients were in the high risk
category. In the PV group 18/19 were undergoing or had previously had venesection
and 15 patients were receiving hydroxycarbamide. In the PT group 53/59 were
currently treated with hydroxycarbamide and of these, three were receiving
combined therapy with anagrelide. Two patients were receiving single therapy with
anagrelide or interferon respectively. No cytoreductive therapy was given in three
PT patients aged between 40 and 59 years with no history of or risk factors for
thrombosis (intermediate risk). One further patient under 40 years, who had
presented with a retinal vein thrombosis in association with thrombocytosis, and who
was considering pregnancy, was being observed while hydroxycarbamide was
withheld. Other treatment given prior to study entry included anagrelide in one
patient, interferon in two patients, radiophosphorus in four patients and busulphan in
one patient.
15 PV and 48 PT patients (78.9% and 81.4% respectively) were on aspirin at the time
of study entry and three PT patients were on an alternative antiplatelet drug.
Warfarin was used in three PV patients for VTE (in two cases recurrent) and in five
PT patients, two with recurrent VTE, one with a previous arterial thrombosis, one
with atrial fibrillation and one with a mechanical heart valve. Combination therapy
with warfarin and aspirin was used in only two of these patients. 15 patients were
prescribed statin therapy.
2.3.3 Haematological and molecular parameters
The values for the haematological parameters in the PT and PV patients at diagnosis
and at study entry are shown in Table 2.3. 17 patients with PT (29.3%) had a platelet
count greater than 1000 x 109/L at diagnosis.
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JAK2 V617F
The JAK2 V617F mutation was present in 17/19 PV patients (89.7%) and 24/54 PT
patients (44.4%). A comparison of the haematological parameters at diagnosis in the
PT patients according to JAK2 mutation status is shown in Table 2.4. Haemoglobin
and haematocrit values were significantly higher at diagnosis in patients with the
JAK2 V617F mutation compared to wild type. The mean platelet count was higher
in patients with wild type JAK2 but this was not statistically significant.
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Mean (SEM) 139.9 (2.1) 185.8 (2.9) <0.001
Haematocrit
Mean (SEM) 0.41 (0.01) 0.56(0.01) <0.001
Leucocyte count (xlOy/L)
Median (IQR) 9.1 (8.0, 10.5) 10.0(8.6, 13.0) 0.118
Platelets (xl09/L)
Median (IQR) 788(620, 1102) 447 (319, 660) <0.001








Mean (SEM) 133.5 (3.7) 139.6(2.1) 0.167
Haematocrit
Mean (SEM) 0.38 (0.009) 0.42 (0.009) 0.002
Leucocyte count x 109/L
Median (IQR) 5.6 (3.7-11.5) 8.4 (3.4-18.1) 0.018
Platelets x 109/L
Median (IQR) 405 (350,486) 351 (285,456) 0.078
Table 2.3 Haematological parameters in patient cohort
Haematological parameters at the time of diagnosis and study entry in PT and PV
patients. Values for the mean and SEM or the median and IQR are shown. P values







Mean (SEM) 132.9 (2.7) 149.7(2.5) <0.001
Haematocrit
Mean (SEM) 0.38 (0.02) 0.45 (0.01) <0.001
Mean cell volume (fl)
Mean (SEM) 87.9(1.0) 88.0(1.7) 0.974
Leucocyte count (x 10y/L)
Median (IQR) 9.3 (8.5, 10.6) 8.5 (7.4, 10.2) 0.213
Platelets (x 10y/L)
Median (IQR) 792 (619, 1222) 769 (618, 946) 0.357
Table 2.4 Haematological parameters in PT patients according to JAK2
mutation
Haematological parameters at the time of diagnosis in PT patients according to the
presence of the JAK2 V617F mutation. Values for the mean and SEM and the
median and IQR are shown. P values for statistically significant differences are
shown in bold.
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2.3.4 Association of clinical and laboratory variables with thrombosis
There was no difference in the overall incidence of thrombosis between the PT and
PV groups (p=1.0, Fisher's exact test). Arterial thrombosis (at or after presentation)
was commoner in PT patients and venous thrombosis was commoner in PV patients
but these differences were not statistically significant (Table 2.1).
There was no significant difference in age at study entry between patients who had or
had not experienced a thrombosis (mean age (SEM) 62.5 (2.9) v 66.4 (2.0) years
respectively, p=0.275) and age over 60 years was not associated with a history of
thrombosis (p=0.312). However patients who had presented with a thrombotic event
were younger at diagnosis (53.8 (3.1) v 62.4 (2.0) years (p=0.026). Patients who had
experienced a complicating thrombosis had a median follow-up of 193.5 months
compared to 37.8 months for those without (p<0.001).
A history of CVD was recorded in 16/77 patients at the time of diagnosis of their
MPD. There was no association of a history of CVD with arterial, venous or any
thrombosis at presentation; a thrombotic event at presentation was recorded in 3/16
patients with a history of CVD v 18/61 without (p=0.534). CVRF were recorded in
an additional 21 patients and a history of either CVD or CVRF combined was not
associated with thrombosis at presentation, with events in 9/37 patients with CVD or
CVRF v 12/40 patients without (p=0.617).
Thrombosis arising after the diagnosis of PV or PT (complicating thrombosis)
occurred in seven out of 34 patients with a previous history of either thrombosis or
CVD (at or prior to MPD diagnosis) but none of 43 patients with no such history
(p=0.002). Five out of the six patients with a complicating arterial thrombosis had a
previous history of CVD (p<0.001). The other patient had hypertension and
hypercholesterolemia and had originally presented with symptoms of
erythromelalgia.
Six patients presented with a VTE, one of whom had a past history ofVTE and had a
subsequent VTE. One further patient had a VTE following diagnosis and had a
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history of previous arterial thrombosis and erythromelalgia. No association between
VTE and a previous history of such was detected (p=0.365).
There was no difference in the haematocrit or platelet count at diagnosis between
patients with or without thrombosis at presentation (haematocrit, mean (SEM) 0.45
(0.02) v 0.45 (0.01), p=0.94; platelets, median (IQR) 662 (510, 1052) v 681 (574,
987) x 109/L, p=0.579) but the leucocyte count was higher in those with thrombosis
(median (IQR) 10.4 (8.4, 13.9) v 8.9 (8.1, 10.3) x 109/L, p=0.023). Patients with a
leucocyte count above the median value of 9.1 x 109 /L were more likely to have a
recorded thrombotic event at or following diagnosis, 16/36 v 7/37 (p=0.024). This
appeared to be mainly due to thrombosis at presentation, 14/36 v 6/37 (p=0.038)
rather than as a complicating event (3/36 v 2/37). In the PT patients the presence of
the JAK2 mutation was not associated with any thrombosis, with events in 6/23
JAK2 V617F positive patients v 12/30 wild type patients (p=0.384) or with venous
thrombosis alone (p=0.620).
2.3.5 Diagnosis of PV and the use of JAK2 V617F mutation status
Molecular status, with regard to JAK2, was known for all 19 PV patients in the study
cohort and was negative in two of these. A further five patients outwith the study
who had a working diagnosis of PV were shown to be negative for the JAK2 V617F
mutation. We therefore reassessed the original diagnoses in those patients negative
for the mutation using the PVSG criteria, BCSH guidelines (2005) and the WPIO
criteria (2001 and 2008) (Appendix 1). Diagnostic data for each of the patients is
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In only one patient (G) by one set of criteria (WHO 2001) was a positive diagnosis of
PV reached. A summary of the diagnostic outcome of the use of each of the criteria
is shown in Table 2.7. All seven patients met the definition of an absolute
erythrocytosis based on the haemoglobin values used in the WHO criteria, however
patients A and B did not meet this criteria based on either haematocrit or measured
RCM. No patient had complete investigations for alternative causes of
erythrocytosis although arterial oxygen measurements and abdominal ultrasound
scans excluded hypoxic lung disease or renal disease. Only two patients were
investigated for evidence of erythroid independence.
Patient C had typical bone marrow features to support a diagnosis of PV. Patient D
had a leucocyte count of 12.2 x 109/L supporting a diagnosis of PV by PVSG or
WHO criteria, but as a smoker did not meet the higher cut-off in the BCSH criteria.
Patient E had borderline splenomegaly on ultrasound scan, in support of a diagnosis
of PV. However in these three patients there was insufficient data to confirm or
exclude a diagnosis of PV at least by the WHO criteria and in most cases by the
PVSG or BCSH criteria
Patient F had a reduced serum Epo and borderline splenomegaly. Investigations for
alternative mutations affecting JAK2 exon 12 and for the von Hippel Lindau and
erythropoietin receptor gene mutations that cause congenital erythrocytosis, were
negative. The diagnosis therefore lies between PV and idiopathic erythrocytosis.
Patient G had bone marrow hypercellularity with increased erythroid and
megakaryocyte activity and a peripheral thrombocytosis but a normal Epo level. He
did not meet the BCSH criteria for PV but did achieve this diagnosis by the WHO
2001 criteria.
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C Not PV Not PV Insufficient Insufficient
D Insufficient Not PV Insufficient Insufficient
E Not PV Insufficient Borderline Insufficient
F Not PV Borderline Borderline Insufficient
G Insufficient Not PV PV Insufficient
Table 2.7 Differential diagnostic outcomes for JAK2 V617F negative
polycythaemia
The diagnosis of patients labelled as PV but negative for the JAK2 V617F mutation
was reviewed using the criteria of the PVSG, BCSH, WHO. This table details the
outcome for each patient according to each set of criteria. In many cases there was
insufficient data to confirm or refute a diagnosis ofPV.
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2.4 Discussion
Clinical and laboratory features
Almost half of the PV and PT patients that we identified participated in the study.
Their make-up reflected the characteristics of the local patient population with more
PT than PV patients. This is in contrast to the findings of the Leukaemia Research
Fund UK registry (McNally et al, 1997) which recorded a higher incidence of PV.
As our data indicate prevalence they may be affected by different life expectancies in
the groups. The patients in the study cohort were younger than the overall local PV
and PT population largely due to the PT study patients being younger than their
counterparts who did not participate. More of these older patients may have been
considered unable to give informed consent due to dementing co-morbidities or may
have declined to participate due to perceived difficulties in attending the clinic
appointments. The mean age of the total patient group (68.7 years) and the study
cohort (64.7 years) was similar to that reported in the literature (Gangat et al,
2006;Gangat et al, 2007;Harrison et al, 2005;Marchioli et al, 2005). There were
more women than men in the study group (3:2), with similar ratios in the PV and PT
subgroups. This sex distribution contrasts with the equal ratios or predominance of
men reported in PV (Gangat et al, 2007;Marchioli et al, 2005;McMullin et al, 2005).
At entry to the study, patients had been followed-up from diagnosis for a median of
almost 4 years and a maximum of over 26 years. Follow-up was shorter for patients
from the WGH site because management of this patient group had commenced there
only three years previously.
An asymptomatic presentation was recorded in over 60% of the patients, in keeping
with the trend towards increasing numbers of patients diagnosed following the
incidental finding of haematological abnormalities on blood counts performed for
unrelated reasons (Jensen et al, 2000b). Thrombo-haemorrhagic symptoms at
presentation were recorded in just over a third of patients, at the lower end of the
range reported in the literature (Elliott & Tefferi, 2005;Harrison et al, 2005;Jensen et
al, 2000b;Marchioli et al, 2005;Passamonti et al, 2004;Wolanskyj et al, 2006).
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Consistent with the findings in these other retrospective studies, these episodes were
mainly thrombotic with twice as many arterial thromboses (including microvascular
symptoms) compared to venous (18.7 v 9.3%) and the commonest symptoms were
cerebrovascular in origin.
Around half of the patients had no documented history of CVD or CVRF prior to
diagnosis with PV or PT. CVD was recorded in 20% of patients and in a quarter of
these there was more than one diagnosis. IHD and cerebrovascular disease were the
commonest diagnoses, each in 10% of patients, similar to the 16% prevalence of
CAD in a casenote review of 180 of PV and PT patients (Ganti et al, 2003). Only
4/78 patients had a diagnosis ofPVD, similar to the ECLAP patients (Marchioli et al,
2005) but much lower than the 35% recorded in the high risk arm of the PT-1 trial
(Harrison et al, 2005).
In a further 25% of the patients, the presence of one or more CVRF was recorded.
This was most commonly hypertension, present in 35% of the study cohort, similar
to the findings in the high risk arm of the PT-1 trial (23%) and the ECLAP study
(39%) of PV patients (Harrison et al, 2005;Marchioli et al, 2005). We attempted
evaluate whether undiagnosed hypertension might be a significant issue. In 21
patients, age-matched to our study cohort, who were attending the MPD clinic and
who did not have a diagnosis of hypertension, the majority (62%) were
normotensive. A further 29% had borderline systolic hypertension and only 2/21
were clearly hypertensive. Although all would require further assessment with repeat
BP measurement, this suggests that undiagnosed hypertension is not widespread but
may be significant for individual patients. Less than 10% of the patients reported
smoking at the time of diagnosis. This seems low compared to the 25% rate reported
in the general Scottish population (Corbett J et al, 2007) and other study populations
(Gangat et al, 2007;Harrison et al, 2005;Marchioli et al, 2005) which may suggest
either under reporting or under recording.
Analysis for the JAK2 V617F mutation was performed in 73 patients in the study
cohort. Of these, 90% of the PV patients and 44.4% of PT patients were positive for
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the mutation, in keeping with the published literature (Baxter et al, 2005;James et al,
2005;Jones et al, 2005;Kralovics et al, 2005;Levine et al, 2005). With regard to
phenotypic variation in PT patients, those positive for the JAK2 V617F mutation had
significantly higher haemoglobin and haematocrit values at diagnosis (p<0.001),
consistent with previous reports (Campbell et al, 2005;Wolanskyj et al, 2005), but
there was no difference in the values for mean cell volume. Higher leucocyte and
lower platelet counts were also noted but these differences were not statistically
significant.
Thrombo-haemorrhagic and haematological complications
Despite the relatively small patient numbers, the prolonged length of time from
diagnosis provides a total of 419 patient years of follow-up. During this period only
seven thrombotic events occurred in six patients, an incidence of 1.67 per 100 patient
years, similar to although lower than, other treated patient populations (Harrison et
al, 2005;Jensen et al, 2000b;Marchioli et al, 2005;Passamonti et al, 2004;Wolanskyj
et al, 2006). As with the nature of events at presentation, the majority of these were
arterial.
Unlike previous studies, we did not detect an association between older age and a
history of thrombosis (Gruppo Italiano, 1995;Landolfi et al, 2007;Marchioli et al,
2005;Passamonti et al, 2004;Wolanskyj et al, 2006). In fact patients experiencing a
thrombotic event at presentation were on average younger at the time. This may be
explained by the earlier presentation of symptomatic patients. As would be expected
with a cumulative risk, patients who had had a complicating thrombosis had a longer
median follow-up from diagnosis; at 16 years this was over five times greater than
those in whom no thrombotic events had occurred.
Previous thrombosis is another established risk factor for subsequent thrombosis.
We distinguished a previous history of CVD, where the diagnosis was made prior to
that of the MPD, from vascular thromboses occurring either at presentation (or
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within the previous 12 months) or following diagnosis. No association was seen
between thrombosis at presentation and previous thrombosis, CVD or CVRF. There
was however a significant association between thrombosis arising after the diagnosis
of PV or PT and a prior history of thrombosis or CVD combined. Complicating
arterial thromboses were associated with a previous diagnosis of CVD (p<0.001) but
not CVRF alone. We did not detect an association of any clinical variables with
complicating VTE but this may well be as a result of the small numbers in the
current study as VTE following diagnosis was an infrequent occurrence, recorded in
only two patients.
With regard to haematological and molecular parameters only the leucocyte count at
the time of diagnosis was associated with a history of thrombosis at presentation, as
has previously been reported (Carobbio et al, 2007;Landolfi et al, 2007;Wolanskyj et
al, 2005). This effect was not apparent for complicating thrombosis which may
either reflect the small numbers of events, or that the effect is lost with normalisation
of the leucocyte count by cytoreduction. Contrary to some previous reports we found
no association between JAK2 mutation status and risk of venous thrombosis
(Campbell et al, 2005;Kittur et al, 2007) although again this was an infrequent event.
Progression to post-PT MF was recorded in four patients on the basis of clinical and
histological evidence. Review of the diagnostic trephine reports in three of these
patients revealed the presence of atypical megakaryocytic features. According to the
WHO criteria for PT, this might suggest a diagnosis of pre-fibrotic MF, which has
been associated with an increased risk of progression to clinical MF (Tefferi &
Vardiman, 2007;Thiele et al, 2002;Thiele & Kvasnicka, 2003). All three reports also
described an increased degree of reticulin fibrosis at diagnosis which may be another
predisposing factor. These findings support concerns about the interpretation of the
results from the high risk PT-1 trial where a significantly increased risk of
progression to MF was seen in the anagrelide arm but diagnostic trephines were not
available (Harrison et al, 2005). However, we did not review the diagnostic
trephines for all our patients and therefore do not know the prevalence of such
findings in the cohort as a whole.
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Management
The majority of PV patients were receiving venesection and cytoreductive therapy
with hydroxycarbamide. At the point of entry to the study, the mean haematocrit
was 0.42 and 75% of patients were below the target of 0.45 (McMullin et al, 2005).
Cytoreduction for thrombocytosis is also recommended and the median platelet
count in the PV patients was 405 x 109/L with 75% less than 450xl09/L. These
results may suggest less aggressive management compared to the current guidelines
however in a recent study of PV patients receiving standard current management, no
effect of platelet count or haematocrit level on thrombotic risk was observed (Di
Nisio et al, 2007).
In the PT group, only four patients were not receiving cytoreductive therapy, three of
whom were aged 40-60 years but had no other risk factors for thrombosis. The vast
majority (52/55) of PT patients on cytoreductives were receiving hydroxycarbamide;
two required dual therapy with anagrelide to achieve adequate control of the platelet
count without unacceptable side effects including cytopenias and mouth ulcers. In
patients on cytoreduction, at the single time point of entry to the study over 80% of
the PT patients had a platelet count below 500 xl09/L but only 50% had a platelet
count below the widely accepted target of 400x109/L ((Barbui et al, 2004;Harrison,
2005b).
Although the leukaemic risk of hydroxycarbamide is likely to be low, until adequate
long term follow-up data are available, the current guidelines continue to recommend
that non-cytotoxic agents should be considered in high risk patients under the age of
40 years (Barbui et al, 2004;McMullin et al, 2005). Four PT patients in the study
were under 40 years and all had indications for cytoreduction. However, only one of
these patients received a non-cytotoxic agent in the form of anagrelide; the other
three received hydroxycarbamide, one after being intolerant of interferon.
Radiophosphorus and alkylating agents are currently recommended only as second
line therapy in patients over the age of 60 years due to concerns regarding their
leukaemogenicity (Barbui et al, 2004;McMullin et al, 2005). Radiophosphorus or
74
busulphan had previously been used in five patients; two of these patients were
below the age of 60 when they were treated in the mid-1980s. None had
experienced haematological transformation at the time of the study.
In keeping with the current guidelines, the majority of PT and PV patients were
managed with aspirin or another antiplatelet agent (Barbui et al, 2004;McMullin et
al, 2005). Overall over 90% of patients were on either antiplatelet or anticoagulant
therapy and no haemorrhagic complications were recorded following diagnosis.
Although the exact contribution of CVRF to thrombotic risk is unclear, control of
these in individual patients is generally practised. As previously discussed it is likely
that a minority of patients had undiagnosed hypertension. In addition, in seven of
eleven non-study patients with known hypertension this was not controlled to
recommended levels. Tobacco use and hyperlipidaemia appeared to be infrequent
but again may have been underdiagnosed. These findings suggest that more pro¬
active assessment and management ofCVRF may be indicated in our MPD patients.
JAK2 V617F in the diagnosis of PV
We reviewed the diagnosis of seven PV patients who were JAK2 V617F negative. A
number of issues were highlighted by comparison of the diagnoses based on each of
the PVSG, BCSH and WHO guidelines. Notably, despite borderline RCM results in
two patients, both would meet the definition for an absolute erythrocytosis using the
WHO criteria based on the haemoglobin values alone. In contrast all of the patients
with haematocrit values above the cut-off in the BCSH criteria also had an elevated
measured RCM. The use of elevated haemoglobin values alone to assess absolute
erythrocytosis has not been validated (McMullin et al, 2005) and our results suggest
that it may result in the inclusion of patients who do not have an elevated measured
RCM.
There are also difficulties in the inclusion or exclusion and interpretation of some of
features in support of a diagnosis of PV. In one case with a reduced serum Epo, the
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diagnosis lies between idiopathic erythrocytosis and PV. The differentiation depends
on whether the ultrasound measured spleen size of 13.5cm is judged to be
"splenomegaly", highlighting the recognised difficulties of interpreting this
parameter (McMullin et al, 2005). The exclusion of histological data from the
BCSH and PVSG guidelines meant that two patients who are likely to have a
myeloproliferative disorder based on their bone marrow histology, did not meet these
criteria for PV.
The other three cases had borderline results in support a diagnosis of
myeloproliferative disorder and probably have had insufficient investigation to
confirm or refute the diagnosis of PV. This is especially true for the 2008 WHO
criteria where in JAK2 wild type patients, two out of three of consistent bone marrow
histology, reduced Epo levels and endogenous erythroid colony (EEC) growth must
be present. Most UK haematology departments do not have access to EEC tests
which are expensive and require technical expertise, making the use of these
guidelines difficult. However in these cases measurement of the serum Epo level
may indeed be of value in directing further investigation as it would be expected to
be reduced in PV and to remain so even following venesection (McMullin et al,
2005;Tefferi & Vardiman, 2007).
In a clinical context, this diagnostic review of JAK2 V617F negative PV patients
emphasises the importance of pursuing further investigation, both for features in
support of PV or to determine an alternative explanation, in patients with a
confirmed erythrocytosis who are negative for the mutation.
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Summary
The demographics of our study cohort, in particular the PT patient group, were
similar to but slightly younger than the local MPD population. The group had a
relatively low incidence of thrombo-haemorrhagic events both at presentation and
follow-up, with more arterial than venous events, in keeping with the findings of
other recently published studies. There were no statistically significant differences in
thrombo-haemorrhagic events between the PV and PT groups but this is likely to be
affected by the relatively low numbers of patients and events. Consistent with
previous reports we identified associations between thrombosis and leucocyte count
at diagnosis and prior thrombotic history but in contrast found no associations with
age or JAK2 mutation status. Management of the patient group as a whole was
generally in keeping with the current guidelines although control of haematocrit and
platelet counts was less aggressive than current recommendations and under






Differences in the definition of microparticles and the methods used to isolate and
measure them are likely to have an important influence on the results reported from
individual studies. A forum addressing these issues reported that most groups define
microparticles as plasma particles of less than 1 pm in diameter, bearing surface
antigens of their cell of origin (Jy et al, 2004;Biro et al, 2004;Dignat-George et al,
2004;Hugel et al, 2004;Nomura, 2004;Shet et al, 2004;Jimenez et al, 2004). Some
groups also used the additional criterion of Annexin V binding as evidence of the
PPS rich surface of microparticles. While the use of such a consensus definition is
helpful there remains significant variation between studies in the absolute numbers of
microparticles reported for both patients and controls. This is likely to be due, in
part, to the second issue of methodological differences.
Isolation techniques vary widely from centre to centre and microparticles may be
measured in platelet poor plasma (PPP), microparticle suspensions or less commonly
whole blood (Biro et al, 2004;Dignat-George et al, 2004;Hugel et al, 2004;Jimenez
et al, 2004;Jy et al, 2004;Nomura, 2004;Shet et al, 2004). PPP is obtained by serial
centrifugation of citrated whole blood and may also be filtered to remove particles of
greater than 1pm. Alternatively, microparticles can be isolated from the PPP by
ultracentrifugation, washing and resuspension of the microparticle pellet. The latter
method is likely to avoid any platelet contamination but there are concerns that
microparticles may be created in vitro by the ultracentrifugation steps. There has
been no direct comparison of these methods and even within them there is wide
variation in the centrifugation protocols used.
Measurement of microparticles is most commonly performed by flow cytometry but
increasingly solid phase capture assays which exploit the functional properties of
microparticles are used and results may be expressed as percentages, absolute
concentrations or activity units. A summary of the published methods of
measurement of in vivo levels of plasma microparticles and the reported ranges is
shown in Table 4.4, Chapter 4.
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Flow cytometry
Flow cytometry techniques allow both the quantitation of microparticles and
identification of subtypes. Microparticles are isolated in PPP or microparticle
suspensions and then labelled with fluorescently conjugated monoclonal antibodies.
Annexin V binding can be used to confirm the phospholipid properties of the
microparticles. Monoclonal antibodies (mAb) to specific surface antigens expressed
on the cells of origin are used to identify the subtype of microparticle, for example
anti-CD42 (GPIb) for identification of PMP or anti-glycophorin A for RMP. Two or
three colour flow cytometry can be used to identify which microparticle subtypes
express particular antigens, for example TF expression on monocyte microparticles.
A variety of cell specific mAb are used in the identification of microparticles and the
specificity chosen is likely to influence the results (Table 3.1). For example CD42a
and CD62P (P-sel) are both platelet specific antigens but CD42a is present on all
platelets while CD62P is found only on activated platelets.
Flow cytometry also permits the direct analysis of microparticle size by assessment
of their forward light scatter. The identification of events of a specified size is most
accurately done by comparison with using calibration beads of known diameter.
Although a criteria of <lpm has been suggested for microparticle definition, in
practice there is variation in the size criteria used from 0.8pm to 1.5pm
Alternatively, some groups have identified microparticles as those particles of a size
less than the platelet population in normal subjects (Villmow et al, 2002). However,
this is a less standardized method as it is likely to be subject to biological variation.
Further, as platelets are reported to be 2-3 pm in diameter, the populations of PMP
and small platelets may form a continuum in terms of size.
Absolute quantitation of microparticles by flow cytometry can be achieved using
commercially produced counting beads of known concentration, which are added to




Solid phase capture assays isolate and immobilise microparticles in platelet free
plasma using Annexin V binding antibodies which have a high affinity to the
phospholipid surfaces and/or antibodies to specific cell surface antigens. This
method of quantitation exploits the functional properties of the microparticle
phospholipids by using an assay of prothrombinase activity and expresses quantity in
PPS equivalents. As this technique cannot directly assess the size of the
microparticles the sample can be filtered to remove particles of greater than 1pm
before analysis. These assays describe activity and not absolute microparticle
numbers which may not be directly equivalent.
Enzyme linked immunoassays (ELISA)
In attempt to develop easier methods for microparticle detection, commercial ELISA
assays have also been investigated. These use combinations of antibodies to platelet
antigens to allow PMP capture and detection in PPP and good correlation with
measurement by standard flow cytometry methods in samples of in vitro induced
PMP has been demonstrated (Osumi et al, 2001). More recently there has been
publication of a clinical study where in vivo levels of microparticles were measured
using this method (Inoue et al, 2006) and this may prove to be a useful method of
detection.
We have designed a flow cytometry assay for the measurement of microparticles in
PPP with identification of endothelial, platelet, red cell and leucocyte microparticles
by size and antigen expression. The assay is based on previously published methods
but we have aimed to optimise and standardise the sample preparation techniques.
We have also devised a suitable method to allow the absolute quantitation of


























CD42b GPlb 5, 6, 22, 23
CD42 GPlblX 7
Platelet
CD41 GPIIbllla 8, 10, 11, 16, 18
CD61 GPIIIa 9, 19, 22, 24
CD62P P-selectin - activation 20,23
Monocyte CD14





Erythrocyte CD235 Glycophorin A 8,9 22
Table 3.1 Specificities of monoclonal antibodies used in microparticle
identification
References (1) Jimenez et al 2001,(2) Jimenez et al 2003, (3) Gonzalez-Quintero et al 2003,
(4) Gonzalez-Quintero et al 2004, (5) Chirinos et al 2005, (6) Mallat et al 2000, (7) Bernal-
Mizrachi et al 2003, (8) Amabile et al 2005, (9) VanWijk et al 2002, (10) Shet et al 2003,
(11) Faure et al 2006, (12) Koga et al 2005, (13) Simak et al 2004, (14) Simak et al 2006,
(15) Combes et al 1999, (16) Sabatier et al 2002, (17) Dignat-George et al 2004, (18)
Bretelle et al 2003, (19) Pereira et al 2006, (20) Nomura et al 2005, (21) Ogata et al 2006,
(22) Hugel et al 1999, (23) Villmow et al 2002, (24) Harlow et al 2002
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3.2 Identification ofmicroparticles
3.2.1 Antibody selection and titration
Directly conjugated fluorescent mAb were used for microparticle identification and
the choice of specificity was based on the published literature and local laboratory
experience. EMP and PMP were identified using phycoerythrin (PE) labelled CD31
(PECAM) and fluorescein isothiocyanate (FITC) labelled CD42 (GPIblX) (both
AbD serotec). RMP were identified using FITC labelled CD235a (Glycophorin A)
(BD Biosciences) and LMP were identified using FITC labelled CD45 (AbD
serotec). Samples were also stained with the appropriate negative isotype controls;
Mouse IgGl PE, Mouse IgGl FITC and Mouse IgG2a FITC (all AbD serotec).
According to published methods, 25 pi of PPP were incubated with 2pl of each mAb
or isotype control for 1 hour at room temperature in the dark. Phosphate buffered
saline (PBS) was then added to a total volume of 1ml prior to analysis.
All mAb were titrated to determine saturating concentrations. PPP and platelet rich
plasma (PRP) samples were used for the titration of CD31 and CD42 antibodies and
a dilution of 1 in 4 in PBS was found to be optimal. Due to low numbers of
microparticles positive for CD45 and glycophorin A, mAb to these antigens were
titrated using lysed whole blood and an optimal antibody dilution of 1:4 was
determined. An example titration is shown in Figure 3.1. In practice when using the
CD45 antibody on PPP samples a consistent right shift in the "negative" peak was
noted in the specific mAb labelled samples as compared to the negative isotype
control. To investigate whether this may be due to true events or to antibody excess
we performed a number of samples with a further dilution of antibody to 1:8. This
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Figure 3.1 Example antibody titration.
Example of antibody titration using the CD31 PE antibody. Fluorescence histograms
for the isotype control, neat antibody and serial dilutions are shown. Values for peak
channel fluorescence (PCF) are shown for each dilution. With serial dilution of the
antibody the PCF reduces towards that of the isotype control. At an antibody




Calibrated lpm beads (Duke Scientific Corporation) were diluted 1:100 with PBS
and 0.5% bovine serum albumin. The flow cytometer instrument settings were set to
those used for microparticle collection (Appendix 3). The data was acquired on a
contour plot and the bead population was used to identify a region with forward




Figure 3.2 Size calibration beads
Contour plot illustration the use of size calibration beads to set the 1 pm gate by
forward scatter (FSC-H), for determination ofmicroparticles by size
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3.2.3 Flow cytometer sample collection
All flow cytometric experiments were carried out using a Fluorescence Activated
Cell Scanner (FACScan) benchtop flow cytometer using FACS Flow™ optimised
sheath fluid (Becton Dickinson Immunocytometry Systems). The flow cytometer
was regularly calibrated using calibrite beads (BD biosciences). Flow cytometer
settings were optimised to measure events of less than 1 pm and to minimise non¬
specific electronic noise (Appendix 3). Samples were collected for two minutes on
medium flow and all events were collected.
3.2.4 Flow cytometry analysis
Analysis was performed using both the Macintosh driven Cell Quest software for the
preliminary work and FCS express software (DeNovo Software) for the majority of
the analysis.
3.2.4.1 Determination of microparticles by size
Based on the forward scatter of the calibrated size beads it was possible identify
events less than 1pm in size. We also considered other described methods of size
analysis including "less than platelets". However we were unable to clearly
distinguish the platelet and microparticle populations by forward and side scatter as
these formed a continuous population. Furthermore, by analysis of samples of PRP
using a contour plot we could identify a region of highest density of events which
had a size consistent with platelets: the lower forward scatter limit of this region was
less than 1pm in size. (Figure 3.3).
For the remainder of the analysis, a gate of less than 1pm was set using the calibrated
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Figure 3.3 Comparative analysis of platelet rich plasma and platelet poor
plasma
Forward and side scatter profiles of platelet rich plasma and platelet poor plasma
samples (PRP, PPP). The residual PPP platelet count in this sample was 3 x 109/L.
The size region of <lpm is superimposed onto the plots. The dot plots of (a) PRP
and (b) PPP show that platelets and microparticles (<lpm) did not form two distinct
populations. The contour plots show the areas of highest density of events and their
size distribution in the (c) PRP and (d) PPP samples. The lower size limit of the area
of events in the PRP lies below 1 pm.
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3.2.4.2 Determination ofmicroparticle subtype by antibody specificity
Fluorescence gates were set by forward gating of samples stained with specific mAb
on histograms plots using negative isotype control samples for comparison to
exclude non-specific background staining (Figures 3.4, 3.5, 3.6)
For EMP and PMP the CD31 PE positive gate was set by using the double labelled
CD31 PE / CD42 FITC sample in comparison to the CD42 FITC / IgGl PE isotype
control sample. The CD42 FITC positive gate was set using the CD31 PE / CD42
FITC sample in comparison to the CD31 PE/ IgGl FITC isotype control sample
(Figure 3.4).
EMP were defined as CD42 negative, CD31 positive events less than 1pm. To
correct for non-specific staining, the number of CD42 negative, PE positive events in
the isotype control sample could then be subtracted from this (Figure 3.4g).
PMP were defined as CD31 and CD42 double positive events less than 1pm. The
number of non-specifically labelled events in the isotype control samples was <1%
of the CD31/42 positive events therefore a correction was not performed.
LMP were defined as CD45 positive events less thanlpm. The positive gate was set
using the CD45 FITC labelled sample in comparison to the IgG2a FITC isotype
control (Figure 3.5). To correct for non-specific staining, the number of FITC
positive events in the isotype control sample was subtracted from the CD45 positive
events.
RMP were defined as Glycophorin A positive events less than 1pm. The positive
gate was set using the Glycophorin A FITC labelled sample in comparison to the
IgGl FITC isotype control (Figure 3.6). To correct for non-specific staining, the
number of FITC positive events in the isotype control sample was subtracted from








Sample Gates applied Number of events
PPPCD31 PE / CD42 FITC <lpxn, PE +ve, FITC +ve 10174
PPP CD31 PE/ IgGl FITC isotype <lpm, PE+ve, FITC +ve 4
PPP IgGIPE isotype / CD42 FITC <lpm, PE+ve, FITC +ve 6
PMP corrected = 10164
Figure 3.4f
Sample Gates applied Number of events
PPPCD31 PE/CD42 FITC <lpm, PE +ve, FITC -ve, 380
PPP IgGIPE isotype / CD42 FITC <lpm, PE+ve, FITC -ve 39
EMP corrected = 341
Figure 3.4g
Figure 3.4 Analysis of platelet and endothelial cell microparticles
Analysis of platelet and endothelial cell microparticles. (a) Histogram showing FITC
staining of CD42a labelled sample (green line) and IgGl isotype control sample
(black line) and setting of FITC positive gate, (b) Histogram showing PE staining of
CD31 labelled sample (red line) and IgGl isotype control sample (black line) and
setting of PE positive gate, (c and d) Dot plots of FITC positive (green) and negative
(black) events in the FITC IgGl isotype control sample (c) and PE positive (red) in
the PE IgGl isotype control sample (d); less than 1% of the isotype control events
are positive. CD42 FITC /CD31 PE double positive events (PMP - yellow) and
CD31 PE positive / CD42 FITC negative events (EMP - blue) are shown in (e). PMP
numbers are calculated by subtraction of FITC/PE double positive events in the
isotype control samples from the CD42 FITC/ CD31 PE labelled sample (f). EMP
numbers are calculated by subtraction of FITC negative /PE positive events in the
isotype control sample from the CD42 FITC/ CD31 PE labelled sample (g).
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Figure 3.5a
Figure 3.5b Figure 3.5c
Sample Gates applied Number of events
PPP Glycophorin a FITC <lpm, FITC +ve 3428
PPP IgGl FITC isotype <lpm, FITC +ve 68
RMP corrected = 3360
Figure 3.5d
Figure 3.5 Analysis of red cell microparticles
Analysis of red cell microparticles. (a) Histogram showing FITC staining of
Glycophorin A labelled sample (green line) and IgGl isotype control labelled sample
(black line) and setting of FITC positive gate, (b and c) Dot plots of FITC positive
(green) and negative (black) events in the IgGl isotype control labelled sample (b)
and in the Glycophorin A FITC labelled sample (c); less than 1% of the isotype
control events are positive. RMP numbers are calculated by subtraction of FITC
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Sample Gates applied Number of events
PPP CD45 FITC <lpm, FITC +ve 265
PPP IgG2 FITC isotype <1 pm, FITC +ve 19
LM P corrected = 246
Figure 3.6d
Figure 3.6 Analysis of leucocyte microparticles
Analysis of leucocyte microparticles. (a) Histogram showing FITC staining ofCD45
labelled sample (pale blue line) and IgG2 isotype control labelled sample (black line)
and setting of FITC positive gate, (b and c) Dot plots of FITC positive (blue) and
negative (black) events in the IgG2 isotype control labelled sample (b) and in the
CD45 FITC labelled sample (c); less than 1% of the isotype control events are
positive. LMP numbers are calculated by subtraction of FITC positive events in the
isotype control sample from the CD45 FITC labelled sample (d).
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3.3 Quantitation ofMicroparticles
Quantitation of events in flow cytometry is often expressed as a percentage of a
population of cells. However this method is not suitable for quantitation of
microparticles due to the cell poor nature of PPP. In order to allow comparison
between samples from subjects collected at different times, a method of absolute
quantitation is required. This can be achieved using commercial counting beads of
known quantitation which can be "spiked" into the flow cytometry sample.
However, many of these beads are significantly larger than the microparticle size
which poses difficulties in analysis using instrument settings optimised for events of
less than 1pm. Further, the beads are identified using a fluorescence trigger and this
appeared to skew the microparticle populations collected in double labelled samples.
We therefore devised a method whereby a sample of counting beads at a known
concentration was collected for a defined time period, allowing determination of the
volume sampled in that time. This was performed prior to each microparticle
collection session and all samples were collected for the same time period. We were
then able to calculate the absolute microparticle concentration in the plasma sample.
Quantitation method
Trucount counting beads were used (BD biosciences) for which the exact
concentration is provided for each individual vial but is approximately 1000 beads
per pi. The beads are 4pm in size and are double fluorescence labelled (FITC and
PE). Using the recommended reverse pipetting technique, 50pl of beads were
diluted in 950pl of PBS (Cellwash, BD biosciences). Optimal flow cytometer
instrument settings were determined according to the advice given with the beads
(Appendix 3). After vortexing, the diluted bead sample was collected for a defined
time period and the number of events within the predefined bead region was recorded
(Figure 3.7). This was performed three times and the mean bead count was
calculated.
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The following calculation was then applied to determine the microparticle (MP)
concentration in the plasma sample where 25 pi of plasma was diluted to a final
volume of lOOOpl with PBS (Cellwash, BD biosciences).
Final Trucount concentration (beads/pl) =
Volume sampled in X seconds (pi)
Final sample MP concentration (MP/pl) =
Original plasma MP concentration (MP/pl) =
Stated bead concentration (beads/pl) x 50pl
lOOOpl
Mean bead count (in X seconds)
Final Trucount concentration (beads/pl)
MP count (in X seconds)
Volume sampled (pi)
Final sample MP/pl x lOOOpl
25pl
To assess the variation in the recorded bead event count for a single preparation of
Trucount beads, 12 preparations were collected in triplicate at both the start and end
of a flow cytometry session. The coefficient of variation (CV) for the bead event
count for a single preparation was 2.88% (standard deviation (sd) 1.51). During this
period a problem was identified with the flow cytometer that was reducing the flow
rates. After resolution of this problem, the subsequent four collections had a CV of
1.68% (sd 0.45).
A new Trucount preparation was made for each flow cytometry session and for
comparison the Trucount preparation from the previous session was also analysed.
The difference between pairs of samples made on the same day or run on the same
day was expressed as a percentage of the mean bead count for the pair. There was
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greater variation between bead counts for Trucount preparations made on the same
day and run on different days (mean difference (sd) 12.9% (13.0), n=9) than for
preparations made on different occasions and run on the same day (3.6% (3.54),
n=12). This suggests that variation in the flow rate on different days had a greater
influence on the bead count than variation in the preparation. This is likely to reflect
the fault in the flow cytometer that was reducing the flow rates over this time period.
3.4 Preanalytical variables
3.4.1 Centrifugation protocols
Whole blood was collected from eight healthy subjects into citrate vacutainers
(Becton Dickinson) at room temperature and PPP was prepared at room temperature
according to four different protocols (P1-P4) adapted from those reported in the
literature (Table 3.2). In protocols P1-P3, PRP was obtained in the first step. PPP
was then obtained by a second centrifugation step and the removal of the middle
portion of the supernatant. In protocol 4, PPP was prepared in a single step.
EMP and PMP were measured as described and microparticles per microlitre (/pi) of
plasma were calculated. Results were analysed using the paired t-test and expressed
as the mean and SEM. The residual platelet count of the PPP was measured using a
Sysmex analyser (1:5 dilution, capillary mode).
PMP numbers decreased with length of time of centrifugation and were lowest using
Protocol 3 (P3 v PI, P2, P4, p=0.02, 0.03, 0.008 respectively). EMP numbers showed
a similar trend but this was not statistically significant (Table 3.3, Figure 3.7).
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Protocol Step 1 Step 2
PI 160g x 10 mins 1500g x 6 mins
P2 160g x 10 mins 1500g x 10 mins
P3 160g x 10 mins 1500g x 15 mins
P4 1500gx 15 mins -
Table 3.2 Summary of centrifugation protocols
Summary of centrifugation protocols showing centrifugal force applied (g) and length of
centrifugation (minutes)
Protocol PMP per p.1 vPl v P2 v P3 v P4
PI 1829 (268) - 0.080 0.024 0.153
P2 1532 (219) - - 0.031 0.716
P3 1007 (143) - - - 0.008
P4 1454 (143) - - - -
Protocol EMP per p.1 v PI v P2 v P3 v P4
PI 463 (119) - 0.145 0.079 0.153
P2 403 (93) - - 0.221 0.343
P3 374 (86) - - - 0.824
P4 366 (65) - - - -
Table 3.3 PMP and EMP values by centrifugation protocol
Mean (SEM) PMP/pl and EMP/pl for each centrifugation protocol (n=8 for all). P values for
comparison of protocols are given with statistically significant results in bold
Protocol PPP platelet
count (mean)
Range vPl v P2 v P3 v P4
PI 9.6 0-20 - 0.348 0.076 0.367
P2 7.9 0-14 - - 0.061 0.719
P3 3.9 0-10 - - - 0.003
P4 7.3 5-10 - - - -
Table 3.4 Residual platelet count in PPP by centrifugation protocol
Mean and range of residual platelet count in PPP for each centrifugation protocol (n=8 for
all). P values for comparison of protocols are given with statistically significant results in
bold
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Figure 3.7a
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PI P2 P3 P4
Figure 3.7b
Figure 3.7 PMP and EMP per microlitre by centrifugation protocol
Results for (a) PMP and (b) EMP per microlitre are shown for each centrifugation
protocol P1-P4. Each coloured line represents the samples from one subject. PMP
numbers were significantly lower for protocol 3 compared to the other protocols.
EMP numbers showed a similar trend but this was not statistically significant.
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PPP platelet count x 10A9/L
Figure 3.8 Association of residual platelet count with PMP and EMP
Association of PPP residual platelet count with PMP and EMP results. There was a
significant strong correlation between residual platelet count and measured PMP
(Pearson correlation).
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The mean PPP platelet count also decreased according to the centrifugation protocol
used and was lowest for P3 (Table 3.4). The differences only reached statistical
significance for P3 v P4. For protocols 1 and 2, maximum platelet counts of greater
than ten were obtained. The PPP platelet count correlated with PMP (r=0.707,
p<0.001, Pearson correlation) but not EMP numbers (r= -0.325, p=0.432), (Figure
3.8)
There was also a trend towards Protocol 3 giving the highest percentage of events of
less than 1 pm compared to all events however the ranges were wide and this was not
statistically significant.
3.4.2 Temperature and media
Whole blood was collected from seven healthy volunteers into citrate and CTAD
(citrate, theophylline, adenosine and dipyridamole) vacutainers (Becton Dickinson)
and PPP was prepared at 4°C and room temperature, using centrifugation protocol 3
(Table 3.2).
EMP and PMP were measured and microparticles per microlitre of plasma were
calculated. Duplicate samples from each subject were compared i.e. citrate 4°C v
CTAD 4°C; citrate 20°C v CTAD 20°C; citrate 4°C v citrate 20°C; CTAD 4°C v
CTAD 20°C. Results were analysed using the paired t-test.
Overall there was no significant difference in mean EMP or PMP numbers according
to collection media or temperature although differences were seen in some individual




































Table 3.5 PMP and EMP values by collection media and temperature
Comparison of PMP and EMP according to collection media (citrate or CTAD) and
processing temperature (4°C v 20°C). Values for the mean and sd are given, P values




Figure 3.9 Comparison of PMP and EMP according to sample media
Comparison of (a) PMP and (b) EMP according to sample preparation in citrate or
CTAD. Each subject is shown in a different line colour and there are two sets of





Figure 3.10 Comparison of PMP and EMP according to sample temperature
Comparison of (a) PMP and (b) EMP according to sample preparation at 4°C and
20°C. Each subject is shown in a different line colour and there are two sets of





20 ml citrated whole blood collected via 12g needle
Centrifuge within 1 hour
Sample preparation
Centrifuge at 160g for 10 mins
I
Remove Platelet Rich Plasma
(PRP) supernatant. Retain 100pl
for analysis.
I
Centrifuge at 1500g for 15 mins
I
Remove middle portion of
supernatant - Platelet Poor
Plasma (PPP)
Flow Cytometry Assay - (250pl)
Residual Platelet Count (RPC) - (1 OOpil)
Freeze remainder at -70°C for soluble
plasma markers (x 2 aliquots)
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Labelling for Flow Cytometry Assay
Isotype controls
25yi.l PPP 2j.il of 1:4 mAb - IgGl PE
IgGl FITC
IgG2 FITC
IgGl PE + CD42 FITC
IgGl FITC + CD31 PE
Specific antibodies
25gil PPP 2pi of 1:4 mAb- CD31 PE + CD42 FITC
Glycophorin A FITC
CD45 FITC
Incubate for 30 minutes at room temperature in the dark
Add PBS to a total volume of 1ml
Analyse within 4 hours
Flow Cytometer Set Up
Clean thoroughly prior to use as per manufacturer's protocol
Run through distilled water on high flow until flow rate <1000 events/ sec
Trucount beads
50pl of high concentration Trucount beads in 950pl of PBS
Set Trucount instrument settings (fluorescent trigger FL = 180)
Acquire for 120 seconds on medium flow x 3
Samples
Set on microparticle instrument settings (Forward scatter trigger =10)
Vortex immediately prior to analysis
Acquire samples for 120 seconds on medium flow rate (no gate applied)
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3.6 Discussion
At the time of initial design of our microparticle assay, the main information on
assay methods was from the forum reported in the Journal of Thrombosis and
Haemostasis and the papers published by these groups, in particular the Miami group
(Jy et al, 2004). Subsequently there has been growing interest in the measurement of
microparticles and more extensive data has been presented and published on the
effects of preanalytical variables, method of analysis and storage conditions.
Preanalytical variables - sample collection
Our results suggest that overall there was no significant difference in microparticle
numbers depending on the temperature used in preparation or whether CTAD or
citrate medium was used. This result may be surprising as we might have expected
any in vitro platelet activation and consequent PMP formation to be reduced by
processing the samples at a lower temperature. However, our results are in keeping
with other presented data (Shah et al, 2007) which found no temperature effect and
no difference between acid-citrate-dextrose and citrate media. The use of steps to
reduce in vitro platelet activation including good and consistent venepuncture
technique and the rapid processing of samples may have helped to minimise the
effects of the processing conditions. Recently the effect of high fat meals increasing
the total numbers of circulating microparticles has been reported (Tushuizen et al,
2006) and it is possible that other such physiological variables, for example, exercise
may influence microparticle numbers in healthy individuals.
Preanalytical variables - centrifugation and platelet contamination
We measured EMP and PMP and residual platelet count in samples prepared using
four different centrifugation protocols. With increasing length of centrifugation in
protocols 1-3, the number of PMP was reduced in tandem with the residual platelet
count. The fall in the number of PMP with increasing centrifugation may reflect
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either or both of two possibilities: removal of microparticles with longer
centrifugation or reduced platelet contamination with longer centrifugation.
The American laboratory standard for production of PPP is centrifugation at 1500g
for at least 15 minutes to produce plasma with a platelet count of less than 10 x 109/1.
Protocol 3, which included such a step, consistently produced PPP with a platelet
count of less than or equal to 10. Further, protocol 3 had the highest ratio of events
less than lpm versus greater than lpm. However the average proportion of events
that were <lpm in size was still only 40%. This suggests that although our PPP had
low residual platelet count, this platelet presence may still be numerically significant
in comparison to the microparticle numbers.
The results for EMP showed a similar but non-significant trend to reduced numbers
with longer centrifugation, in keeping with the theory that microparticles may be lost
with increasing centrifugation. It would be useful to examine the effect of increasing
centrifugation on RMP and LMP numbers.
Comparing the results for PRP and PPP, the numbers of events of less than 1 pm
could be up to 10 times higher in the PRP than PPP. This may be in part due to the
inclusion of the smaller end of the platelet population within the 1pm gate (Figure
3.3c). However, even when a smaller size gate was set, a higher number of events
were present in this region in the PRP, again in keeping with the theory that
microparticles may be lost during the centrifugation.
Not all studies have employed an initial gentle centrifugation step to produce PRP
prior to isolation of PPP. The proposed reasoning behind the use of this step is to
avoid the creation of microparticles by more rigorous centrifugation but as it
produces PRP prior to the 2nd centrifugation step it seems unlikely that it would
reduce any artefactual creation of PMP. We addressed this by comparing protocol 3
to 4 and found that PMP numbers were indeed higher when this initial step was not
used but the residual PPP platelet count was also higher.
Our results are supported by similar data presented recently which show that those
protocols using PPP which have the most rigorous centrifugation steps produce lower
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microparticle numbers and less platelet contamination than those using more gentle
centrifugation (Weltermann et al, 2007). Therefore, when flow cytometry is used for
microparticle detection, the choice of centrifugation process may result in the
underestimation any of the microparticle subtypes or overestimation of the number of
PMP due to platelet contamination.
The presence of residual platelets may also be a significant factor in methods which
exploit the phospholipid properties of microparticles, such as prothrombinase capture
or functional coagulation assays. In particular, in samples frozen for future analysis,
the greater the platelet contamination the more phosphatidylserine exposure occurs
on the platelet surface during the freeze-thaw process. It was demonstrated that
compared to fresh samples, levels of Annexin V binding were increased in freeze-
thawed samples and the increase was greatest in those with the most platelet
contamination (Weltermann et al, 2007). It was suggested that for samples being
frozen prior to analysis for Annexin V binding, prothrombinase capture or thrombin
generation, a double-spin centrifugation protocol may be more suitable to reduce
platelet contamination.
Quantitation ofmicroparticles
The results for our devised method for absolute counting of microparticles confirm
low intra-assay variation in the bead count and low variation in the flow rate over a
single flow cytometry session. They also confirm the reliability of the bead
preparation technique with low variability between preparations. They suggest
however that there can be significant variation in the rate of flow of the flow
cytometer over a time period. In view, of this we elected to run a Trucount bead
preparation pre and post each session to determine the volume sampled and allow
comparison of microparticle samples run on different days. A similar method has
been validated and employed by other groups (pers comm, M. Shah)
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Analysis of microparticles - antigen detection
Our choice of antibodies was based on those used in published clinical studies. It
may have been useful to have had in vitro models of microparticle production for
each of the cell types to confirm their detection of the respective microparticle
species. We used PPP and PRP or lysed whole blood samples to perform the
titrations for each of the antibodies. The use of whole blood may have led to an
antibody excess as numbers of antigenic sites might be expected to be lower in PPP.
We chose CD31 (PECAM), a shared platelet and endothelial antigen, to identify
EMP as it is constitutively exposed on resting endothelial cells in comparison to
antigens which in in vitro studies are only expressed on a subset of EMP following
specific stimuli (Abid Hussein et al, 2003). CD31 and CD42 double staining has
been employed in numerous in vivo studies to identify EMP (CD31+, CD42-) and
PMP (CD31+, CD42+) (Table 3.1). In practice we identified some difficulties with
the use of a shared endothelial and platelet antigen, to identify EMP in a situation
where EMP were significantly rarer events than PMP. The IgGl PE isotype control
for the CD31 frequently showed significant, person specific, background staining.
Correction of PMP and EMP numbers by subtraction of excess positive events in the
isotype control may therefore have resulted in an absolute underestimation of both
EMP and PMP. The significant difference in absolute EMP and PMP meant that in
relative terms this had a much greater effect on EMP numbers and often produced
negative values. In future, we would consider the use of more specific endothelial
antigens, such as CD 144, bearing in mind that these may only identify subsets of
EMP released from activated endothelial cells (Abid Hussein et al, 2003).
In an attempt to address the problem of excess isotype staining we reanalysed the
data using the values obtained for EMP before subtraction of the isotype control
numbers. This resulted in an upward shift of all the EMP results in absolute terms
but as it was applied to all the samples, relative differences were retained. This
process also removed the negative values which are not biologically plausible and
allowed more valid statistical comparisons to be made.
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The glycophorin A antibody adequately stained red cells in whole blood and detected
events less than 1pm. Similarly the CD45 antibody detected leucocytes in whole
blood, however very few CD45 positive events of less than 1 pm were detected in
PPP. During analysis of the study samples, a consistent shift in the "negative" peak
for the specific antibody was noted. We considered whether this may be due to true
events especially as the mean fluorescence intensity of microparticle events is likely
to be low due their size. However it is more likely that this was due to antibody
excess as we performed a number of samples with a further 1:2 dilution of antibody
which resulted in a loss of this phenomenon.
Another reason that we considered for the lack of CD45+ events in PPP was the
sample preparation. It was proposed to us that the initial gentle centrifugation may
not adequately separate leucocyte MP (pers comm, Amsterdam group), however this
theory would suggest that they are a different size from other microparticles. In order
to investigate this we prepared duplicate samples for a number of study subjects in
which the initial centrifugation step was omitted. There was no significant difference
in the results although the numbers were small.
We only used antibodies against cell specific antigens and therefore we did not
assess the phospholipid properties of the microparticles. Annexin V binding is not
universally employed as a criterion for microparticles (Jy et al, 2004) and some
studies have suggested that it is not exhibited by all microparticles (as defined by
size and antigen specificity) (Shet et al, 2003). However, as Annexin V binding
would be expected over all microparticle subtypes, its use would have allowed us to
assess the total number of microparticles. With the current method we were unable
to do this satisfactorily due to difficulties distinguishing true events which were not
stained with specific antibody, from electronic noise and debris at the lower limits of
detection of the flow cytometer.
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Analysis of microparticles - size discrimination
We analysed microparticle size using commercial size calibrated beads of lpm. A
cut off of 1pm is generally accepted but some groups use 0.5pm-l .5pm and others
use comparison with the platelet population (see Table 4.4, Chapter 4). In our assays
the events collected formed a continuous population of less than and greater than
lpm. In this case it would seem that an upper limit of 1pm is a somewhat arbitrary
cut-off however the absence of clear separation of the populations made this the most
consistent choice of method. It does however raise the question of what biological
differences exist between the larger microparticles and smaller platelets in this
crossover region.
Another "size issue" is whether the presence of exosomes can be excluded from the
microparticle population as defined by size and antigen expression. This distinction
may be important as exosomes differ from microparticles in their formation and
constitution and are therefore likely to have different functional properties (Thery et
al, 2002). Exosomes are generally considered to be 50-100 nm in size and standard
flow cytometers are unable to resolve events of this size, however the presence of
exosomes might affect functional assays dependent on their specific properties.
Currently our understanding of the biology of exosomes remains limited and as more
becomes known it will be important to consider their influence on our study of
microparticles.
Summary
We have designed a flow cytometry assay for the detection and quantitation of
plasma microparticles (platelet, endothelial, red cell and leucocyte) according to their
antigenic phenotype and size. We found that the pre-analytical variable with the
most significant influence on the assay results was the centrifugation technique used
for the preparation of the platelet poor plasma. The effect of this and the resultant
degree of platelet contamination was most important for the measurement of platelet
microparticles in our assay, particularly because we did not identify a clear size
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distinction between the microparticle and platelet populations. Further, the effect of
even a small degree of platelet contamination such as was present in our samples
may be significant if measuring the functional properties of microparticles in a
coagulation assay using stored frozen samples. In the future, further optimisation of
the assay by investigating the use of double-spun samples, alternative specific
endothelial antibodies and double staining for Annexin V would be valuable.
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Chapter 4
Microparticles in Myeloproliferative Disorders
112
4.1 Introduction
Microparticles have diverse functions in coagulation and cellular interactions and
numbers are elevated in a variety of conditions where vascular dysfunction and
inflammation are important pathophysiological mechanisms. Quantitation of
microparticles and identification of their cell of origin can therefore provide
information about the state of the vasculature and disease mechanisms. In the MPD
evidence exists for platelet, endothelial, leucocyte and coagulation abnormalities.
However the pathogenesis of the prothrombotic state in MPD is not comprehensively
established and normalisation of the abnormal peripheral blood counts does not
abolish the thrombotic risk associated with these disorders. A more detailed review
of the literature on microparticles and vascular abnormalities in MPD is provided in
Chapter 1. The investigation of microparticles in MPD has been very limited to date
and further study may enhance our understanding of the vascular abnormalities in
MPD and may suggest potential pathogenic mechanisms to direct future
investigation.
We have therefore measured platelet, endothelial, leucocyte, and red cell
microparticles in patients with PV and PT compared to control subjects and have
examined their associations with clinical and haematological parameters.
113
4.2 Materials and methods
4.2.1 Subjects
Recruitment of 19 PV and 59 PT patients and clinical data collection was carried out
as detailed in Chapter 2. One patient was excluded from analysis due to
pancytopenia as a result of transformation to myelofibrosis and in one patient no
samples could be obtained. 30 healthy volunteers aged over 40 years and not on
regular medications were recruited by advertisement across the hospital sites.
4.2.2 Sample collection and processing
Subjects attended on a single occasion and 15ml of blood was obtained by
venepuncture with a 14G needle into citrate vacutainers (Becton Dickinson).
Samples were processed within one hour and PPP was prepared. Measurement and
analysis of microparticles was performed according to the protocol described in
Chapter 3. Microparticle analysis failed in one patient. Microparticles results are
reported as microparticles per microlitre of plasma (/pi).
4.2.3 Statistical analysis
Normally distributed data is reported as mean values and SEM. Between group
comparisons were made by the student's t-test. Microparticle values and some
haematological parameters were not normally distributed and values are therefore
reported as median and IQR. Distribution of haematological parameters and
microparticles is shown in Figures 4.1 and 4.2. Between group comparisons were
made using the non-parametric Mann Whitney U tests. No correction was made for
multiple comparisons. Associations between variables were analysed used
Spearman's rank correlation. Multivariant analyses were by multiple regression
analysis of data log transformed to a normal distribution. P values of <0.05 were
considered to be statistically significant. All calculations and analyses were






























Figure 4.1 Distribution of haematological parameters
Box plots illustrating the normal distribution of haemoglobin and haematocrit values
and the skewed distribution of leucocyte and platelet count values for the whole
study cohort. * denotes outlier values
Figure 4.2 Distribution of PMP, EMP, LMP and RMP values
Box plots illustrating the skewed distribution of PMP, EMP, LMP and RMP, for the




The demographic characteristics and haematological parameters of the study subjects
are summarised in Table 4.1. MPD patients were significantly older than controls
and had higher platelet counts. A comparison of the PV and PT patients is shown in
Tables 2.2 and 2.3, Chapter 2; PT subjects were slightly older than PV subjects (66.0
v 64.3 years, p=0.663) and PV patients had a higher haematocrit (0.42 v 0.38,
p=0.002) and leucocyte count (8.4 v 5.6 x 109/L, p= 0.018).
4.3.2 Microparticle results by diagnosis
Microparticle results are summarised in Tables 4.2a and 4.2b and Figure 4.3. PMP
were significantly elevated in patients compared to controls. EMP were also
significantly higher in patients than controls, by either method ofEMP analysis (with
or without subtraction of isotype control values, as discussed in Chapter 3). LMP
were higher in patients than controls (p=0.061) but this difference only reached
statistical significance for the PT patients (p=0.048). There was no difference in
RMP between patients and controls. There was no significant difference between the















137.4 (2.2) 135.1 (1.9) 0.431
Haematocrit
Mean (SEM)
0.41 (0.005) 0.40 (0.006) 0.096
Leucocyte count x 10y/L
Median (IQR)
5.9 (5.0-7.0) 6.3 (4.9-8.6) 0.142
Platelets x 10y/L
Median (IQR)
237 (206-269) 397 (304-464) <0.001
Table 4.1 Demographic and haematological parameters
Demographics and haematological parameters at study entry for patients and control






















































































Table 4.2 PMP, EMP, LMP and RMP quantitation
Results for quantitation of PMP, EMP with (EMP sub) and without subtraction of
isotype control values, LMP and RMP in (a) patients compared to control subjects
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4.3.3 Microparticles, gender and age
For the cohort as a whole, there were no significant differences in microparticle
subgroups according to gender. The MPD patients were significantly older as a
group than the control subjects by 15.2 years (95% CI 11.3-19.1 years) (Table 4.1).
No significant correlations of microparticles with age, for either the control subjects
or the patients, were detected by Spearman's rank testing (Figure 4.4). However, as
the control group were all under 60 years, we divided the MPD group into those
patients above (n=50) and below 60 years (n=27). The mean age (SEM) in the
younger MPD group was 47.7 (1.7) years, similar to the control group 49.4 (1.0)
years, (p=0.397). We then compared microparticle levels between the three groups
(Figure 4.5).
PMP remained significantly higher in the younger MPD patients compared to
controls, 6217/pl (4138, 8731) v 2069/pl (1122, 2980) respectively, (p<0.001). PMP
were even higher in the older MPD group at 9873/pl (5150, 18916), (p=0.024)
compared to the younger group. EMP remained elevated in the younger MPD
patients compared to controls, 222/pl (135, 441) v 66/p.l (43, 112) respectively,
(p<0.001), but were not significantly different from the older MPD patients at 230/pl
(120, 412), (p=0.898). There were no significant differences in RMP or LMP
according to age group.
4.3.4 Microparticles and haematological parameters
There was no significant difference in haemoglobin or haematocrit between MPD
patients as a whole compared to controls but haematocrit was higher in the PV
patients compared to PT patients (p=0.02) (Table 2.3). The platelet count was higher
in patients than controls (p<0.001) but was not significantly different between PV
and PT patients (Table 4.1 and Table 2.3).
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There were moderate but significant correlations between the peripheral platelet
count and PMP (r =0.61, p<0.001) and with EMP (r =0.497, p<0.001) (Figure 4.6).
As the peripheral platelet count was significantly higher in patients than controls, we
also compared the ratios of PMP and EMP to peripheral whole blood platelet count.
The PMP and EMP to platelet ratios were significantly higher in patients compared
to controls; PMP to platelet ratio, 21.7 (13.2, 35.5) v 7.7 (5.2, 13.0) respectively and
EMP to platelet ratio 0.55 (0.36, 0.96) v 0.25 (0.19, 0.40) respectively, (p<0.001 for
both). The ratios were similar in PT and PV patients. There was a weak correlation
between leucocyte count and LMP, r=0.225. There was no correlation between



















• • • •
• •
0 0







0> ./!» * »•
































• 0*-1 ' 0
0 0














































• n.x • #
/0 • 0 • •
o-• a %s <ft ti




















Figure 4.4 Relationship of PMP, EMP, LMP, and RMP to age in (a) control
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4.3.5 Effect of residual platelet count
We also measured the residual platelet counts in the PPP. The median PPP platelet
count was higher in patients than controls, 3 x 109/1 (range 0, 23) v 1 x 109/1 (0, 4),
(p<0.001). There was no difference in PPP platelet counts between PV and PT
patients (p=0.91). Comparison of the PMP to residual PPP platelet count ratios
showed a higher ratio in the MPD patients compared to controls (p=0.004).
There were seven patient samples with a PPP platelet count of greater than or equal
to 10 x 109/1. After exclusion of these samples, there was still a significant difference
in PMP between patients and controls, 7249/j.il (4447, 12825) v 2069/pl (1122,
2980), (p<0.001). Comparing only samples with PPP platelet counts of less than or
equal to 2 x 109/1, the median PMP for the MPD patients was lowered at 5150/pl
(3526, 8471) but remained twice that of the control group (p<0.001).
4.3.6 Microparticles and JAK2 V617F
JAK2 V617F status was known for 51/56 PT patients of whom 22/51 were positive
for the mutation. There were no significant differences in microparticle numbers
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4.3.7 Microparticles, cardiovascular disease and thrombosis
The presence of CVRF or a history of CVD, VTE or microvascular symptoms were
present in over half of the patient cohort and are discussed in detail in Chapter 2. We
compared microparticle levels in the three groups detailed below in Table 4.3 and
shown in Figure 4.8. PMP and EMP were higher in each of the three groups
compared to controls, including PV and PT patients with no history of CVRF, CVD
or thrombosis (all p<0.001). LMP were higher in patients with no history of CVRF,
CVD or thrombosis 82/pl (45, 137) and in patients with CVRF only 76/ju.l (44, 128)
than in controls 48/pl (31, 70), (p=0.033 and p=0.058 respectively). There was no
difference for patients with a history of thrombosis or CVD compared to controls
(p=0.45). RMP were not significantly different from controls in any of the patient
groups. There were no significant differences in any of the microparticle subtypes
between any of the patient groups (all p>=0.1).
N
All patients 75
No thrombosis, CVRF or CVD 27
CVRF only 15
Thrombosis or CVD (+/- CVRF) 33
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4.3.8 Microparticles and treatment
Drug therapy was known for 75 patients of whom 66 were treated with
hydroxycarbamide. PMP were significantly higher in the patients treated with
hycdroxycarbamide compared to not 9019 (5350, 14931) v 4368 (2417, 6037) /pi,
(p=0.0017). There was no significant difference in peripheral platelet count between
the two groups (p=0.85) but the treated group were significantly older with a mean
age (SEM) of 67.1 (1.7) compared to 47.9 (3.8) years, (p=0.001). There were no
significant differences in EMP, RMP or LMP (all p>0.2).
PMP were higher in patients on antiplatelet therapy compared to not, 8556/pl (5112,
14789) v 5391/pl (3723, 7974) but this was not statistically significant (p=0.095).
There was no difference in microparticle levels for the 15/59 patients on statin
therapy (all p>0.5).
4.3.9 Multivariant analysis
On multivariant analysis of the group as a whole, the presence of disease, platelet
count and age were all significant independent predictors of PMP (p<0.001, p<0.001
and p=0.011 respectively). Disease was the strongest predictor for EMP (p<0.001)
but platelet count was also of borderline significance (p=0.050). Within the patient
group, platelet count was the strongest predictor of PMP (p<0.001) but age was also
significant (p=0.012).
There were 11 patients below the age of 60 years with no history of vascular events
or CVRF. Comparison of this group to the age matched control subjects revealed
that both PMP and EMP were significantly elevated at 6566/pl (4368, 12439) v
2069/pl (1122, 2980) and 325/pl (122, 488) v 66/pl (43, 112) respectively both
p<0.001). The platelet count was greater in the patients compared to controls, 445 x
109/L (362, 662) v 239 x 109/L (213, 271), (p<0.001) but on multivariate analysis the
presence of disease was the only significant predictor ofPMP and EMP.
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4.4 Discussion
We have observed significantly elevated levels of PMP and EMP in patients with
MPD compared to healthy controls. LMP levels were also higher but this was
statistically significant in PT patients only and we found no difference in RMP from
controls. The presence ofMPD was an independent predictor of PMP and EMP; age
and platelet count were also independent predictors for PMP. We found no
correlation between microparticle levels and thrombotic history. These results are
consistent with previous observations of platelet activation and endothelial
disturbance in MPD and of elevation of microparticles in prothrombotic disorders
where they may have a pathological role.
Microparticle levels in normal subjects
We observed similar proportions of microparticle subtypes in our healthy control
subjects compared to previously published clinical studies with PMP accounting for
the majority (70-80%) and lower numbers of RMP, EMP and LMP. The absolute
PMP and EMP numbers in our healthy control subjects were intermediate compared
to previously reported values (Table 4.4). There are a number of possible
methodological differences which may account for this variation in absolute numbers
including the mAb specificities used, the size criterion applied, quantitation method
and sample preparation. In general, lower PMP and EMP values were reported from
studies using either ultracentrifugation methods or which prepared PPP at higher
centrifugation speeds compared to ours. In contrast, studies using slower or shorter
centrifugation protocols reported higher EMP values. This difference could be
confounded by their use of a larger size limit of 1.5pm but we found that changing
the size limit had a minimal effect on EMP numbers. With regard to PMP, one study
using slower, shorter centrifugation for PPP preparation, reported higher PMP
numbers but in the study by Preston and colleagues, which used a protocol similar
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Platelet and endothelial microparticles
We observed around four-fold higher levels of PMP and EMP in MPD patients
compared to controls, with similar levels in PT and PV patients. As microparticles
are released following activating or injurious stimuli, these observations would be
consistent with a number of reports of platelet activation and endothelial
abnormalities in MPD including one study which measured PMP (Arellano-Rodrigo
et al, 2006;Bellucci et al, 1993;Falanga et al, 2000;Jensen et al, 2000a;Musolino et
al, 2002;Robertson et al, 2007;Villmow et al, 2002). However we also considered
the effect of confounding factors in our study group including methodological
factors. The patient group was significantly older than the control group, had a
higher peripheral platelet count and approximately half of the patients had known
cardiovascular comorbidities.
PMP were significantly higher in the older MPD patients (>60 years) compared to
the younger group (<60 years) consistent with an effect of age on PMP. However
both PMP and EMP remained significantly higher in the younger MPD group
compared to the control subjects (age matched) excluding the possibility that
difference between patients and controls was an effect of age alone.
We also considered the additional effect of cardiovascular co-morbidities in the
patient group such as hypertension and IHD which are associated with increased
microparticles (Bernal-Mizrachi et al, 2003;Mallat et al, 2000;Preston et al, 2003).
We found no difference amongst the MPD patients dependent on a history of such
co-morbidities. Further, an elevation in PMP and EMP compared to the age-matched
healthy controls, was still present in younger MPD patients with no history of
thrombosis, cardiovascular disease or risk factors (n=l 1). These results imply that the
presence of PV or PT per se results in increased PMP and EMP independent of
advancing age and cardiovascular co-morbidities. An increase of PMP with age has
not been previously described and it would be useful to perform a comparison of
microparticles in healthy older and younger people. That PMP were even higher in
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older MPD patients may be consistent with the association of increased age with
thrombotic risk.
PV and PT patients had similar platelet counts but these were significantly higher
than in the control subjects. It may therefore be postulated that the increase in
circulating PMP could be accounted for by similar levels of production but from a
greater number of platelets. Consistent with this theory, PMP were significantly
correlated with peripheral platelet count however the ratio of PMP to whole blood
platelet count was significantly higher in patients than controls. Although overall
platelet mass is therefore likely to be a contributing factor, these results would
suggest a qualitative difference in the release of PMP from platelets in MPD patients
perhaps due to increased platelet activation. Concomitant measurement of
microparticle P-sel levels may have provided additional useful information in this
respect.
Another explanation might be sampling differences. We treated the control and
patients samples in exactly the same ways in order to minimise any such differences.
However it was noted that despite identical sample handling, the measured residual
platelet count in the PPP samples was significantly higher in patients than controls.
As we observed a continuum between PMP (<lpm) and small platelets (>lpm),
greater numbers of small platelets included in the PMP gate might explain the
difference in PMP between patients and controls. To investigate this further we
analysed the PMP to PPP platelet count ratios and these were higher in patients than
controls. Further, when PPP samples with residual platelet counts of over 10 or even
2 x 109/1 were excluded from the analysis the median PMP levels remained higher in
patients than controls although the median values were lowered. This suggests that
differences in PPP quality do not fully account for the differences in PMP. However,
even using the widely accepted size criterion of <lp.m, residual platelets in the PPP
sample may influence PMP results and this may be even more significant in studies
using slower centrifugation protocols.
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EMP levels were also correlated with platelet count. A number of possible
explanations for this might be considered. A higher platelet count particularly with
platelet activation may promote more platelet-endothelial cell interactions with
resultant endothelial cell activation or damage and microparticle release (Burger &
Wagner, 2003). Similarly PMP have themselves been reported to induce endothelial
cell changes in vitro (Barry et al, 1997;Barry et al, 1998) and the correlation of PMP
with platelet count may therefore be a confounding factor. Methodological issues
may also be important; we measured EMP by CD31 (PECAM) positivity which is an
adhesion molecule constitutively expressed by both endothelial cells and platelets.
In addition we used CD42 negativity to differentiate EMP from PMP. It is possible
that use of this shared marker in a situation where PMP comprised the vast majority
of events detected may have artefactually influenced EMP detection. Against this, in
one patient (excluded from the analysis) who had developed clinical myelofibrosis
with severe thrombocytopenia, EMP numbers were significantly higher than PMP.
In future the use of an exclusive endothelial antigen such as CD 144 may clarify this.
Although the effect of these potential confounding factors should be borne in mind,
multivariate analysis of our data supported the evidence that disease was
independently associated with both PMP and EMP, and additional independent
associations of age and platelet count on PMP.
Leucocyte microparticles
In view of more recent work reporting increased leucocyte activation and PLA in
MPD and the association of leucocyte count with thrombosis, we also investigated
LMP in MPD patients (Carobbio et al, 2007;Falanga et al, 2000;Falanga et al,
2005;Jensen et al, 2001;Landolfi et al, 2007). In the control patients LMP were
observed at similar levels to EMP. We found that LMP were elevated in MPD
patients compared to controls with similar levels in the PV and PT patients.
However the difference from controls was only significant in PT patients, probably
due to the combined effects of a relatively small difference and smaller numbers of
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PV patients. There was no correlation between LMP and age but a weak correlation
with leucocyte count was observed. LMP were highest in patients with no history of
cardiovascular disease, risk factors or thrombosis although this did not reach
statistical significance compared to patients with such a history. We considered that
this difference might be explained by higher leucocyte counts in low risk patients not
treated with hydroxycarbamide. Both the leucocyte count and LMP were higher in
the non-hydroxycarbamide treated group but these differences were not statistically
significant.
Leucocyte and in particular monocyte microparticles are recognised to be an
important source of TF and their recruitment to areas of vascular damage or
aggregates of activated platelets may contribute to localised thrombin generation
(Falati et al, 2003;Shet et al, 2003). Further investigation of these findings in a
larger patient cohort would be useful to clarify whether a significant difference
exists. It would also be of interest to measure LMP in high risk patients at
presentation and serially following commencement of hydroxycarbamide therapy.
We measured LMP using the pan-leucocyte antigen CD45 in order to detect both
monocyte and neutrophil microparticles but specific antibodies for each and double
staining for TF may be more informative.
Red cell microparticles
We observed no difference in RMP between patients and controls or according to
clinical or haematological parameters. In contrast a study, published only in abstract
form, reported higher levels of all microparticle subtypes including RMP in MPD
compared to controls with PMP accounting for the majority (Fontana et al, 2006).
They also observed higher levels of RMP in patients with a history of thrombosis
compared to without and levels were associated with increased red cell distribution
width and length of disease. We did not collect data on red cell distribution width
but did not identify a positive correlation of RMP with length of disease. A number
of our patients and controls had RMP results significantly outwith the interquartile
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range. In one case this was associated with sample haemolysis but this did not
appear to affect any of the other samples and the reason for these outlying results is
unclear.
Other factors influencing microparticle numbers
We observed no positive correlation between any microparticle subgroup and either
thrombotic history or the presence of cardiovascular disease or risk factors - one or
more of which were present in around two-thirds of the MPD patients. Blood
pressure has previously been correlated with increased PMP and EMP but the
difference from controls was statistically significant in severe hypertension only and
not in mild disease (Preston et al, 2003). Similar to the current observations, patients
with CRF have elevated microparticle levels compared to controls but no difference
was observed between patients according to history of previous vascular events
(Faure et al, 2006). It may be that additional increments in circulating microparticles
above those associated with steady state disease only occur in the acute setting. This
would be supported by the finding of higher microparticle numbers in acute coronary
syndrome compared to stable angina (Bernal-Mizrachi et al, 2003;Mallat et al,
2000). In addition, the lack of a detectable correlation ofmicroparticle numbers with
previous thrombosis may not be surprising given the variable correlation reported for
other markers of platelet and endothelial activation in MPD. Clearly, the small
numbers in this study and others may be insufficient to detect relatively small
differences.
We did not detect any difference in microparticle numbers, of any subtype, in PT
patients in relation to JAK2 V617F mutation status. No clear predictive value of
JAK2 V617F in thrombotic risk has been established although some studies have
shown an association with venous thrombosis (Campbell et al, 2005;Kittur et al,
2007). Further, the differences in haematological parameters at diagnosis associated
with JAK2 V617F, such as increased leucocyte count and elevated haematocrit, are
generally attenuated by treatment effects. Thus in treated patients we might not
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expect to see a differential effect of JAK2 V617F on parameters of vascular
activation. However, two recent studies have reported an association between JAK2
V617F and increased markers of platelet activation (Arellano-Rodrigo et al,
2006;Robertson et al, 2007). In contrast we did not find an association with PMP,
which are also likely to reflect platelet activation. Differences in study design and the
small numbers involved may account for this discrepancy with as neither did we
detect such differences in other platelet activation markers (see Chapter 5).
Microparticle binding to other cellular elements is a further factor which may affect
the measurement of microparticles by reducing the numbers circulating in cell free
samples. Platelet binding to activated leucocytes is now well established in MPD
and in other vascular disorders (Falanga et al, 2005;Jensen et al, 2001). It is therefore
possible that PSGL-1 positive leucocyte microparticles may also bind activated
platelets or endothelium, as are observed in MPD, thus reducing the circulating
numbers. Similarly, leucocyte positivity for platelet antigens may in fact be partly
due to PMP binding and this has been shown by electron microscopy in patients on
cardio-pulmonary bypass (Chung et al, 2007). In acute DVT, where a marked
increase in EMP was seen there was also noted to be increased leucocyte activation
and EMP-monocyte conjugates (Chirinos et al, 2005).
Summary
We have observed elevated PMP, EMP and LMP in patients with MPD even in the
absence of co-morbid cardiovascular disease. These findings support the existing
evidence for platelet, endothelial and leucocyte abnormalities in MPD.
Microparticles may therefore be a useful marker for in vascular disturbance in MPD.
In light of the known prothrombotic effects of microparticles the results reported
may be a newly recognised mechanism contributing to thrombotic risk in these
diseases. PMP can increase platelet aggregation and both PMP and EMP may
induce endothelial dysfunction and increased expression of endothelial molecules.
All microparticles may promote thrombin generation by providing a suitable
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phospholipid surface and microparticle TF may also contribute to coagulation
activity. Current treatment of MPD reduces but does not remove the associated
prothrombotic risk and it is of note that markers of platelet, endothelial and
coagulation activation remain elevated in treated patients. The current observation of
elevated microparticles in MPD patients despite standard treatment may suggest an






The pathogenesis of thrombosis in MPD is has not been comprehensively elucidated
but previous studies have identified platelet activation, endothelial dysfunction and
coagulation activation as potential contributing factors (Arellano-Rodrigo et al,
2006;Falanga et al, 2000;Musolino et al, 2000;Robertson et al, 2007). Correlation of
these parameters with patient characteristics, in particular thrombotic history, has
however been inconsistent. In other prothrombotic disorders correlation between
levels of platelet and endothelial microparticles and more established markers of
platelet, endothelial and coagulation activation have been reported (Koga et al,
2005;Nomura et al, 2005;0gata et al, 2006;Shet et al, 2003).
The selectins are cell adhesion molecules which mediate leukocyte, platelet and
endothelial interactions via binding with specific carbohydrate ligands. Their
biology is comprehensively reviewed by Polgar (P-selectin) and Roldan (E-selectin)
(Polgar et al, 2005;Roldan et al, 2003). P-sel is contained in the membrane of
platelet a-granules and in the Weibel-Palade bodies of endothelial cells. On platelet
activation, the a-granules fuse with the cell membrane and release their contents and
P-sel is translocated to the platelet surface. Its major receptor is PSGL expressed
mainly by leucocytes. P-sel - PGSL interactions have a key role in leucocyte rolling
on endothelium and dimeric or oligomeric forms of P-sel may induce cross-linking
of leucocyte PSGL and subsequent signal transduction. PSGL is also expressed by
platelets to a lesser extent and, along with the VWF receptor GPIba, another
counter-receptor for P-sel, can mediate platelet rolling on activated endothelium.
Soluble P-sel can also be detected in plasma and is elevated in prothrombotic
disorders and cardiovascular diseases (Polgar et al, 2005). There appear to be a
number of mechanisms for the production of sP-sel including secretion of an
alternatively spliced molecule lacking the transmembrane domain and cleavage of
surface P-sel from activated platelets (Ishiwata et al, 1994;Michelson et al, 1996).
E-sel is expressed specifically on the surface of stimulated endothelial cells unlike
other soluble endothelial adhesion molecules such as VCAM and ICAM-1 which can
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be expressed on a variety of cells including leucocytes. Its counter receptors are
PSGL and endothelial selectin ligand 1 (ESL-1) and thus, like P-sel, it is involved in
leucocyte rolling on endothelium. Soluble E-sel is most likely generated by
enzymatic cleavage from its membrane insertion, consequent on cytokine stimulation
of endothelial cells. From in vitro studies of cytokine activated HUVEC, sE-sel
correlates with endothelial surface expression of E-sel. It is therefore postulated that
in vivo, sE-sel levels reflect the presence of either systemically or locally
activated/damaged endothelium. Elevated levels of sE-sel are reported in some
clinical studies of patients with cardiovascular risk factors and overt disease but there
is a lack of consensus, with other studies reporting no differences from controls.
Whether sE-sel has any active pathogenic role in these disorders is unclear (Roldan
et al, 2003).
The degree of activation of the coagulation system can be measured in vivo using a
number of components of the system as markers (Boisclair et al, 1990). During the
generation of thrombin by activated Factor X, prothrombin is cleaved to produce
activation fragments (PF 1+2) which can be measured in plasma as an indication of
in vivo thrombin generation. Following the activation of thrombin it becomes
irreversibly bound to the proteinase inhibitor antithrombin. Levels of these thrombin-
antithrombin (TAT) complexes therefore reflect thrombin production and inhibition
in vivo. Activation of the fibrinolytic system can be monitored by measurement of
specific fibrin degradation products such as D-dimers, which are released following
lysis of cross-linked fibrin by plasmin. Each of these by-products of coagulation
activation or fibrinolysis have been reported to be elevated in hypercoagulable states
such as disseminated intravascular coagulation and VTE (Bozic et al, 2002;Levi et
al, 2002).
We have measured sP-sel, sE-sel and PF 1+2 in MPD patients and controls and
correlated these with clinical and haematological parameters in the MPD patients.
We have also assessed the relationship of these parameters to plasma microparticle
levels.
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5.2 Materials and Methods
Patient recruitment and data collection were performed as detailed in Chapter 2.
5.2.1 Sample collection and processing
Subjects attended on a single occasion and 15ml of whole blood was obtained by
venepuncture with a 14G needle and collection into citrate vacutainers (Becton
Dickinson). Samples were processed within one hour and PPP was prepared
according to the protocol described in Chapter 3. Samples were aliquoted and frozen
at -80°C until analysis.
5.2.2 Assays
Soluble P-sel (CD62P) and E-sel (CD62E) were measured by enzyme immunoassay
(Quantikine assay, R and D Systems, Minneapolis). PF1+2 were measured by
enzyme immunoassay (F1+F2 microassay, Sysmex).
5.2.3 Statistical analysis
Normally distributed data is reported as mean values and SEM. Between group
comparisons were made by the student's t-test. sP-sel, sE-sel and PF 1+2 results and
some haematological parameters were not normally distributed and values are
therefore reported as median and IQR. Between group comparisons were made
using the non-parametric Mann Whitney U tests. No correction was made for
multiple comparisons. Associations between variables were analysed used
Spearman's rank correlation. Multivariant analysis was by multiple regression
analysis of data log transformed to a normal distribution. P values of <0.05 were
considered to be statistically significant. All calculations and analyses were
performed using Minitab 15 software (Minitab Inc, USA).
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5.3 Results
5.3.1 Normal ranges and control subjects
The results for sP-sel, sE-sel and PF 1+2 in the control subjects are shown in Table
5.1. The normal range quoted by the manufacturers for sP-sel is 18-40ng/ml. The
upper limit for our control group was 91.2ng/ml, with 16/30 controls above 40ng/ml.
Our normal range based on the control subjects was 28.4-66.3ng/ml (mean ± 2sd).
The manufacturer normal range for sE-sel is based on serum samples and a lower
normal range would be expected from citrated plasma, consistent with our results.
We observed a similar range for PF 1+2 in our control samples to that quoted by the
manufacturer (76-293 and 69-229 pmol/L respectively).
5.3.2 sP-selectin, sE-selectin and PF 1+2 by diagnosis
The results for sP-sel, sE-sel and PF 1+2 in the MPD patients are shown in Table 5.1
and Figure 5.1. sP-sel was elevated in all MPD and each of the PV and PT groups
compared to controls (all p<0.001) and was significantly higher in the PV group
compared to the PT group (p=0.020). 71/73 patients had sP-sel levels greater than
40ng/ml and 54/73 patients had sP-sel levels above the upper limit of the normal
range for the control subjects. There was no significant difference in sE-sel levels in
the MPD group compared to controls but sE-sel was higher in the PV patients
compared to PT patients (p=0.037). PF 1+2 were elevated in the MPD patients


























































Table 5.1 sP-sel, sE-sel and PF 1+2 results for patients and controls
Results (median and IQR) for sP-sel, sE-sel and PF 1+2 in (a) patients compared to
control subjects and (b) PT compared to PV patients. Statistically significant results
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5.3.3 Vascular markers, age and gender
A sex specific difference was apparent in PF1+2 results with higher levels being
observed in women than men, 238.0 (152.0, 320.3) v 160.0 (106.0, 233.0) pmol/L,
(p=0.004). There were no significant differences according to gender between sP-sel
(p=0.422) or sE-sel (p=0.331).
The MPD patients were significantly older than the control subjects by 15.2 years
(p<0.001) (Table 4.1, Chapter 4). There were moderate correlations between age
and both sP-sel and PF1+2 (r =0.357, p=0.001 and r =0.413, p<0.001) but not sE-sel
(r= -0.156, p=0.116). As the control group were all under 60 years, we divided the
MPD group into those patients above (n=50) and below (n=27) 60 years. The mean
age (SEM) in the younger MPD group was comparable to the control group 47.7
(1.7) years v 49.4 (1.0) years, (p= 0.397).
Comparing the MPD patients above and below 60 years of age there was no
difference in sE-sel or sP-sel levels (p=0.224 and p=0.742) (Figure 5.2). sP-sel levels
were significantly higher in each age group compared to controls (p<0.001 for both).
PF1+2 were significantly higher in the older patients compared to those below 60
years, 251.0 (3173.0, 357.3) v 167.0 (112.8, 277.3) pmol/L (p=0.040). There was no
significant difference in PF1+2 levels between the younger patients and the control
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5.3.4 Vascular markers and haematological and molecular parameters
There were weak but significant correlations between leucocyte count and both sP-
sel (r =0.279, p=0.005) and sE-sel (r = 0.275, p=0.005). There was a moderate
correlation between the platelet count and sP-sel levels (r =0.474, p<0.001). The
ratio of sP-sel to platelet count was higher in PV patients compared to controls
(p=0.002) or PT patients (p=0.004) but there was no significant difference between
PT patients and controls (p=0.293), (Figure 5.3). There were no statistically
significant differences in sP-sel, sE-sel or PF 1+2 between JAK2 V617F positive and
negative PT patients (Table 5.2).
5.3.5 Vascular markers, cardiovascular disease and thrombosis
Within the MPD patients there was no significant difference between sP-sel, sE-sel
or PF1+2 according to history of CVRF, CVD or other thrombosis (all p>0.1) (Table
5.3 and see Table 4.3, Chapter 4 for breakdown of patient groups).
5.3.6 Vascular markers and treatment
Current treatment was known in 73 patients. 60 patients were on aspirin and a
further three patients were on clopidogrel. There was no significant difference in sP-
sel levels according to aspirin or any antiplatelet therapy (p=0.34 and p=0.11
respectively) (Figure 5.4). There were no significant differences in sP-sel or sE-sel in
patients currently treated with hydroxycarbamide (64/73) or not (p>0.2). PF1+2
were lower in patients not on hydroxycarbamide (p=0.037) but this group were of a








































Figure 5.3 Ratio of plasma sP-sel to whole blood platelet count
Ratio of plasma sP-sel to whole blood platelet count in control subjects, PT and PV





























Table 5.2 sP-sel, sE-sel and PF 1+2 in PT patients according to JAK2 mutation
sP-sel, sE-sel and (PF 1+2) in PT patients with the JAK2 V617F mutation compared









































Table 5.3 sP-sel, sE-sel and PF 1+2 according to vascular history
sP-sel, sE-sel and PF 1+2 (median and IQR) in control subjects, patients with no
history of thrombosis, CVRF or CVD (MPD only), patients with CVRF but no
history of thrombosis or CVD (MPD+CVRF), and patients with a history of
thrombosis (including prior cardiovascular events) (MPD+Thr/CVD). There were no
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5.3.7 Multivariant analysis
For the group as a whole, only the presence or absence of disease was a significant
predictor for sP-sel (p<0.001). Age, platelet count and leucocyte count were not
significant. For the patient group only, specific diagnosis (PV v PT) and platelet
count were both significant predictors of sP-sel (p=0.006 and p=0.023 respectively).
Age was the only significant predictor of PF1+2 (p=0.004 v p=0.807 for disease).
5.3.8 Vascular markers and microparticles
There were moderate but significant correlations between sP-sel and both PMP and
EMP (r =0.50 and r =0.52, p <0.001 for both). There was no correlation between
EMP and sE-sel (r =-0.02, p=0.882) (Figure 5.5). PF1+2 were weakly correlated
with PMP (r =0.298, p=0.002) (Figure 5.5) but not with any other microparticle
subgroup.
We examined the addition of these results to the multivariant analysis for PMP and
EMP. For PMP the presence of disease and platelet count remained the strongest
predictors. sP-sel was predictive of PMP independent of platelet count (both
p<0.001) but not independent of disease (p=0.120). Similarly, disease remained the
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5.4 Discussion
We have found elevated levels of the platelet activation marker sP-sel but not the
soluble endothelial molecule sE-sel in MPD patients compared to controls. The
coagulation activation marker PF1+2 was elevated in the MPD patients as a whole
but this could be attributed to the older age of the patients compared to controls. sP-
sel levels showed a moderate correlation with PMP consistent with their release
following platelet activation and were also independently predictive ofEMP.
Normal ranges
We used commercial immunoassays to measure sP-sel, sE-sel and PF1+2. The sP-
sel levels in our control group were higher than the manufacturer's range which was
based on a similar number of samples. Half of the control samples but almost all of
the patient samples were above the manufacturer upper limit. This may be explained
by different sample preparation, in particular, different protocols for the preparation
of PPP. Our control range (10.8-81.8 ng/ml) was similar to that reported in other
control groups (14-104 ng/ml, n=127) (Robertson et al, 2007). The manufacturer
control range for sE-sel is based on serum samples and as expected we obtained a
lower range in plasma samples. The range of PF1+2 results in the control patients
was similar to that quoted by the manufacturer.
sP-selectin and sE-selectin
We found elevated levels of sP-sel in both PV and PT patients compared to controls,
consistent with previous studies of sP-sel (Robertson et al, 2007;Musolino et al,
2000) and of platelet membrane P-sel measured by flow cytometry (Villmow et al,
2002;Arellano-Rodrigo et al, 2006;Jensen et al, 2000a;Falanga et al, 2005). sP-sel
levels showed a moderate correlation with age but this could not fully account for the
elevated levels in MPD patients which were equivalent in older and younger MPD
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patients and greater in both than in controls. Similar to other groups we noted a
moderate correlation between peripheral blood platelet count and sP-sel levels
(Robertson et al, 2007). On multiple regression analysis, overall only the presence
of disease was significant for sP-sel levels. However within the patient group, the
diagnosis ofPV compared to PT, and platelet count were also significant factors.
To further investigate the effect of platelet count, we determined the ratio of sP-sel to
whole blood platelet count. This remained significantly higher in PV patients
compared to controls but in PT patients the ratio was no different to controls and was
significantly lower than PV patients. In three studies which measured the proportion
of platelets positive for P-sel by flow cytometry, one did not differentiate PT from
PV patients (Jensen et al, 2000a), one found equally elevated P-sel expression in both
compared to controls (Villmow et al, 2002) and one found more P-sel positivity in
the PV patients compared to PT patients (Falanga et al, 2005). In a study of sP-sel in
PT patients, although levels were higher in comparison to healthy controls there was
no difference from controls with secondary thrombocytosis (Musolino et al, 2000).
Our findings, along with those of some of the previous studies (Musolino et al,
2000;Falanga et al, 2005), may suggest that different mechanisms contribute to
elevated sP-sel in PV and PT patients, with the platelet mass being a more significant
influence in PT patients.
Unlike platelet activation markers, results for markers of endothelial activation or
damage in MPD have been less consistent. In separate studies sE-sel, vWF antigen
and sTM have each been reported to be either elevated or no different from controls
(Bellucci et al, 1993;Falanga et al, 2000;Musolino et al, 2000;Robertson et al, 2007).
No clear explanation for these differences has been offered but methodological
factors such as patient group or sample preparation may have some effect. In the
current study we found no difference in sE-sel levels between patients and controls.
We did not observe any difference in sP-sel or sE-sel according to treatment with
either hydroxycarbamide or aspirin in keeping with previous studies (Arellano-
Rodrigo et al, 2006;Falanga et al, 2000;Robertson et al, 2007). There has been a
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lack of consensus in previous studies with regard to the association between P-sel,
sE-sel and thrombotic history (Table 5.4). Both sP-sel and sE-sel levels in our study
were no different between patients with or without a history of cardiovascular risk
factors, cardiovascular disease or other thrombosis. The current study and all others
published to date are limited by relatively small cohorts in this respect.
More recently there has been interest in the relationship of the presence of the JAK2
V617F and thrombosis. Leucocyte count at diagnosis has been found to be an
independent risk factor for thrombosis (Gangat et al, 2007;Landolfi et al, 2007) and
PT patients with the mutation are observed to have higher leucocyte counts at
diagnosis (Campbell et al, 2005;Wolanskyj et al, 2005). An association between
JAK2 V617F and venous thrombosis has been reported in two studies (Campbell et
al, 2005;Kittur et al, 2007) but has not been observed in others (Carobbio et al,
2007;Wolanskyj et al, 2005). Robertson and colleagues reported significantly higher
sP-sel levels in patients with the mutation than wild type but they did not
differentiate PV and PT patients (Robertson et al, 2007). Their JAK2 V617F group
was therefore dominated by PV patients. We observed that PV patients had
significantly higher sP-sel levels than PT patients, despite equivalent platelet counts,
which may explain the association in that study. However, in 49 PT patients of
whom 22 had a previous history of thrombosis, platelet P-sel expression was
correlated with both JAK2 V617F positivity and thrombotic history (Arellano-
Rodrigo et al, 2006).
Coagulation activation
Similarly to endothelial abnormalities, evidence of coagulation activation in MPD
has been variable and even within single studies, measurement of the different
markers, D-dimer, TAT and PF1+2, have produced differing results (Bellucci et al,
1993;Falanga et al, 2000;Robertson et al, 2007). We found elevated levels of PF1+2
in patients compared to healthy controls. It has been suggested that coagulation
activation may be a non-specific finding associated with age and cardiovascular co-
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morbidities (Robertson et al, 2007). In a comparison of MPD patients with age
matched hypertensive controls who are at increased risk of sub-clinical vascular
disease, no significant increase in D-dimer, TAT or PF1+2 was observed (Robertson
et al, 2007). We found no difference in PF1+2 levels between patients with or
without cardiovascular risk factors, overt cardiovascular disease or other thrombosis.
However, PF1+2 did correlate with age and levels were only elevated in the older
MPD patients compared to the younger MPD patients whose levels were not
significantly different to the control group. The lower PF1+2 levels in patients who
were not on hydroxycarbamide are likely to reflect the younger age of the untreated
group.
Relationship of microparticles to established vascular markers
We observed a modest correlation between sP-sel and CD42+ve PMP, a relationship
which has been reported previously in a cohort of patients with peripheral vascular
disease (Tan et al, 2005). In contrast, no association with platelet P-sel was
observed in patients with VTE or sP-sel in patients with atrial fibrillation (Chirinos et
al, 2005;Choudhury et al, 2007). As the mechanisms of PMP formation include
platelet activation and P-sel-PSGL interactions (Hrachovinova et al, 2003), one
might indeed predict an association between sP-sel and PMP. It is also possible that
some of the "soluble" P-sel measured in PPP is in fact PMP bound. However PMP
formation can also be induced by specific receptor binding interactions not involving
P-sel, for example GPlb-vWF (Reininger et al, 2006). Interestingly, in the PT
subgroup the ratio of sP-sel to whole blood platelet count was similar to controls but
the ratio of PMP to platelets was significantly higher than in controls. This would
support the theory that more than one mechanism of PMP formation is involved.
The simultaneous measurement of platelet P-sel, CD42 and P-sel positive PMP and
soluble P-sel in both PPP and microparticle free plasma might provide useful
information in this regard.
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In contrast, we observed no association between EMP, which were elevated in MPD
patients, and sE-sel which was not. One reason for this may be that we identified
EMP by the constitutive antigen CD31, while sE-sel is an endothelial activation
antigen. Although constitutive microparticle release has been observed in vitro,
whether this translates to the in vivo situation is unclear. Alternatively, increased
CD31+ve EMP release following apoptotic stimuli has been observed in vitro and
appeared to correlate with the in vivo situation (Jimenez et al, 2001;Jimenez et al,
2003b). Our results are at variance to previous studies which have reported variable
correlation of EMP with sE-sel and other markers of endothelial activation. In post-
stem cell transplant patients, sE-sel, VCAM-1 and EMP were all elevated (Nomura
et al, 2005) whilst in hypertensive patients, CD31+ve EMP correlated with V-CAM
and VWF but not sI-CAM (Preston et al, 2003).
Differences in the endothelial antigens measured may therefore explain this
discrepancy but as with PMP, an alternative explanation is that the EMP were
induced by different mechanisms to the endothelial adhesion molecules. EMP may
also be a more sensitive or general marker of endothelial activation/damage than
specific adhesion molecules. In patients with Type II DM both VE-cadherin positive
EMP and soluble ICAM levels were elevated compared to controls and were higher
still in patients with underlying CAD. However, only EMP were independently
predictive for the presence ofCAD (Koga et al, 2005).
A moderate correlation between EMP and sP-sel has previously been reported
(Preston et al, 2003) and we also observed such an association. It may suggest either
concomitant activation of platelets and endothelial disturbance, perhaps by a shared
mechanism, or that activated platelets or PMP can induce endothelial cell changes as
has been demonstrated in vitro (Barry et al, 1997;Burger & Wagner, 2003).
The phospholipid properties of microparticle membranes and the presence of TF on a
proportion of monocyte and also endothelial microparticles can contribute to
thrombin generation. We therefore considered whether there was any association
between microparticles and PF 1+2 which are released during the activation of
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prothrombin. Such an association between total and TF bearing microparticles and
PF1+2 as well as TAT and D-dimer have been reported in sickle cell disease (Shet et
al, 2003;Switzer et al, 2006). We observed a weak but statistically significant
correlation for PF1+2 and PMP but none of the other microparticle subtypes.
Flowever this association was confounded by the effect of age on both PF1+2 and
PMP. The prothrombotic properties of microparticles may be more relevant in the
response to local tissue damage than to measures of systemic coagulation activity.
Summary
We have measured established markers of platelet, endothelial and coagulation
activation in MPD compared to microparticles which are thought to provide similar
information on the state of the vasculature. In keeping with previous studies we
observed evidence of platelet activation in MPD with elevated sP-sel levels. sP-sel
correlated moderately with and was a significant predictor of PMP but our results
suggested that platelet activation may not be the sole mechanism of PMP formation
in MPD. Unlike previous studies associating platelet activation with the JAK2
V617F mutation we did not correlate sP-sel with the JAK2 V617F mutation in the
PT patients.
We did not see an increase in sE-sel but did observe elevated EMP which correlated
with sP-sel. This may be due to methodological reasons, in particular disparity
between the markers used, and previous studies measuring endothelial markers in
MPD have also reported variable results. Alternatively our results may indicate non-
activating endothelial damage in MPD perhaps due to the effect of activated platelets
or PMP. EMP may also prove to be a more sensitive marker for endothelial
abnormalities than the measurement of specific adhesion molecules.
PF1+2 levels were only elevated in older patients, suggesting that the systemic
coagulation activation which has been observed in MPD patients may reflect more
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general age related changes. Microparticles did not appear to be independently
associated with this systemic marker of thrombin activity and may be more important
in coagulation at the local level. Specific investigation of the prothrombotic
properties of microparticles in MPD, for example by the measurement of thrombin




































































and bone marrow fibrosis
6.1 Introduction
Bone marrow fibrosis is the prominent finding in PMF which carries the worst
prognosis of the MPD (Reilly, 1997). In PV and PT, fibrosis is rarely marked at the
initial presentation (Bain et al, 2001), but during the course of the disease it may
progress to a histologically higher grade or to overt post-PV or PT myelofibrosis.
Transformation to fibrosis is reported at rates of between 3 and 20% and the risk of
transformation is associated with increasing time from diagnosis (Alvarez-Larran et
al, 2007;Harrison et al, 2005;Marchioli et al, 2005;Passamonti et al, 2004;Tefferi et
al, 2001;Wolanskyj et al, 2006).
Marrow studies in PMF demonstrate a marked increase in neovascularisation of the
stromal tissue together with an increased deposition of ECM components. This is a
reactive phenomenon mediated by cytokines, including TGFp and PDGF (Reilly,
1992). TGFp has a number of profibrotic actions (Miyazono & Takaku, 1989) and
has been shown to be critical in the development of MF in murine models
(Chagraoui et al, 2002). In addition, elevated levels have been observed in vivo in
patients with PMF or fibrosis secondary to other haematological disorders (Shehata
et al, 2004;Rameshwar et al, 1998).
Bone marrow megakaryocytes and platelets are a major source of TGFp and PDGF,
being contained within their a-granules (Fava et al, 1990). Platelet a-granules also
contain BTG and PF4, intraplatelet levels of which are reported to be reduced or
normal in MPD (Lev et al, 2002;Katoh et al, 1988), while plasma and urine levels
are elevated (Lev et al, 2002;Gersuk et al, 1989;Sacchi et al, 1986). These
observations suggest a mechanism whereby defects of a-granule storage or release in
MPD could result in elevated levels of TGFp and PDGF in the plasma and/or bone
marrow.
In order to investigate whether such a generalised abnormality of platelet a-granules
might be responsible for elevated plasma levels of profibrotic cytokines, we have
assessed plasma levels of the a-granule proteins BTG, PF4, TGFp and PDGF, in
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patients with MPD compared to controls. We have also investigated the association
of levels of these proteins with disease related factors including specific diagnosis,
haematological and molecular parameters and their association with the degree of
bone marrow fibrosis. The reproducibility of assessment of bone marrow fibrosis for
use in investigating such an association was also considered.
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6.2 Materials and Methods
6.2.1 Participant recruitment and ethical approval
Investigation of plasma levels of platelet a-granules in MPD was performed using a
different group ofMPD patients and control subjects from those involved in the work
previously discussed.
Patients with a documented diagnosis of MPD (PV, PT or PMF) or
myeloproliferative disorder not otherwise specified (MPD NOS) were recruited from
the haematology out-patient service at the Royal Infirmary of Edinburgh. These
diagnoses were based on the PVSG or BCSH criteria (Appendix 1). Two different
control groups were recruited. Patients with a diagnosis of secondary polycythaemia
or reactive thrombocytosis (based on the above diagnostic guidelines) were recruited
from the haematology out-patient service at the Royal Infirmary of Edinburgh.
Control subjects without haematological disease were recruited from the orthopaedic
pre-assessment clinic.
For all groups, participant information sheets and consent forms (Appendix 2) were
sent out at least one week prior to their pre-arranged clinic appointment and for those
wishing to participate, informed consent was obtained on the day of attendance.
Ethical approval was obtained from the Lothian Local Research Ethics Committee.
6.2.2 Data collection
Clinical history and haematological parameters at diagnosis, molecular data and
follow-up information on haematological and thrombo-haemorrhagic complications
and management were obtained by retrospective review of patient case records.
Vascular events at presentation included those which occurred up to six months prior
to the diagnosis of MPD. Peripheral blood count, renal function and liver function
tests were also performed at the time of sample collection.
165
6.2.3 Sample collection and processing
We aimed to collect duplicate patient samples on two separate occasions. For
practical reasons control samples were obtained on one occasion only. Whole blood
was collected by venepuncture with a 21G needle into 2 x 3.5ml CTAD Vacutainers
(Becton Dickinson) to improve platelet stability. Samples were immediately placed
on ice and were processed within one hour of collection. PPP was obtained by
double centrifugation at 2500g for 20 minutes with removal of the middle third of
plasma. The obtained PPP samples were aliquoted and stored at -80°C until analysis.
6.2.4 Cytokine assays and data analysis
Plasma BTG and PF4 were measured using the Asserachrom enzyme immunoassay
(Diagnostica Stago). The normal ranges provided by the company were, BTG 10-50
IU/ml and PF4 0-10 IU/ml but it is recommended that each laboratory determine its
own normal range. Plasma TGFp and PDGF were measured using the Quantikine
enzyme linked immunoassays (R and D Systems).
Two samples taken on separate occasions were employed to reduce the likelihood of
the results being influenced by in vitro platelet activation during sampling. Where
duplicate results were available those from the episode with the lower BTG level
were selected. Where only one set of results was available, results with a BTG level
within the normal range (based on the control group) were accepted. For single BTG
results outwith the normal range, a BTG:PF4 ratio of greater than 3.0 was used to
determine whether in vitro platelet granule release was likely to have occurred.
Impairment of renal function is known to increase BTG levels and therefore patients
with creatinine greater than twice the upper limit of normal were excluded from
analysis (Kaplan & Owen, 1981).
We encountered a number of problems with the PDGF assay. Initially the standard
Quantikine assay was unavailable from the suppliers due to technical problems with
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its performance and the company therefore supplied an alternative kit (Duoset). All
plasma samples were processed with this assay but in 63/133 (47.3%) the PDGF
level was below zero from the normal curve. When the Quantikine assay became
available we therefore repeated the PDGF measurements on the 77 samples selected
by low BTG results as above. With this assay a result of less than zero was again
returned on 13 samples (16.8%). Comparing Duoset results of less than versus
greater than zero, the corresponding Quantikine results (median (IQR)) were 21.0
(8.0, 51.0) v 120.0 (48.8, 180.8), (p<0.001) (excluding negative values).
This suggested that there was a particular problem with measurement of values at the
lower end range of PDGF, particularly with the Duoset assay. Therefore, we used
the results from the Quantikine assay and, in order to allow inclusion of results below
the level of detection in the statistical analysis, we assigned these a value of 0.5pg/ml
and added 0.5 to all other results.
6.2.5 Assessment of fibrosis
Where performed, bone marrow histopathology reports were obtained from a variety
of sources - patient case notes, the computerised laboratory result system APEX and
archived copies. Due to the non-standardised nature of reporting by a range of
histopathologists over a long time period, reports were interpreted and categorised
according to the scheme in Table 6.1 for purposes of analysis.
Where available, archived bone marrow trephine slides were obtained and were
reassessed independently by the researcher and a pathologist, both blinded to the
patient diagnosis and previous histopathology report. Reticulin fibrosis was graded
0-3 according to the criteria of Bauermeister (Bauermeister, 1971) (Table 1.1).
Grade 4 fibrosis could not be assessed as collagen stains were not available. Grades
0-3 were then categorised A-C in accordance with Table 6.1.
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6.2.6 Statistical analysis
Normally distributed data is reported as mean values and SEM. Between group
comparisons were made by the student's t-test. The results for some haematological
parameters, BTG, PF4, TGFp and PDGF levels were not normally distributed
(Figure 6.1) and are therefore reported as median and interquartile range IQR.
Between-group comparisons were made using the non-parametric Mann Whitney U
tests. No correction was made for multiple comparisons. Correlation analysis of
skewed data was performed using the Spearman's rank method. Multivariate analysis
was performed by multiple regression analysis of log transformed data. P values of
less than 0.05 were considered to be statistically significant. All calculations and
analyses were performed using Minitab 15 software (Minitab Inc, USA).
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Category A no comment on reticulin fibrosis
reticulin fibrosis normal / not increased
occasional fine reticulin fibres/networks
Bauermeister Grade 0/1
Category B mild diffuse increase in reticulin
no coarse fibres noted
Bauermeister Grade 2
Category C coarse reticulin fibres present
collagen fibres present
Bauermeister Grade %
Table 6.1 Categorisation of fibrosis
Categorisation of bone marrow trephine histopathology reports according to degree



































Figure 6.1 Distribution of BTG, PF4, TGFP and PDGF values





We recruited 62 patients with MPD, including 38 PT, 16 PV, 5 PMF and 3 MPD
NOS. We recruited eight controls subjects with secondary polycythaemia (5) or
reactive thrombocytosis (3) (secondary controls). There were 11 non-haematological
control subjects (NH controls).
The mean age of patients and controls at entry to the study was similar, 65.6 (3.1) v
60.4 (1.9) years respectively, (p=0.157). 9/19 controls were male (47.4%) compared
to 25/62 patients (40.3%) (p=0.606, Fisher's exact test).
The time from diagnosis to study entry was known in 57 patients, with a median of
48 (24, 113.5) months.
6.3.2 Clinical history
Cardiovascular co-morbidities were documented in 23 patients and diagnoses
included IHD (8), cerebrovascular disease (11), PVD (5), hypertension (17), Type II
DM (1) and hypercholesterolemia (7). Smoking status was known in 53 patients -
six smokers, nine ex-smokers and 38 non-smokers.
Thrombotic episodes occurring from six months prior to diagnosis, at the time of
diagnosis or during follow-up, were recorded for 29/62 patients (46.6%). Arterial
events occurred in 23 patients (40%) - seven CVA, four TIA, one myocardial
infarction, four microvascular occlusive episodes and three peripheral thromboses.
VTE occurred in eight patients (13.8%) - two intra-abdominal thromboses, three
recurrent VTE, one PE and two DVT. There were two major and nine minor
haemorrhagic episodes.
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Treatment information was available for 60 patients. 43 patients were currently
taking aspirin, in six it had been taken previously but discontinued due to side-effects
and 11 patients had never received aspirin. Cytoreduction with hydroxycarbamide
was currently prescribed in 50 patients and one further patient had had previous
treatment with this agent. One patient was managed with anagrelide and a further
two patients had previously received this. One patient was undergoing treatment with
radiophosphorus and two had done so previously. A program of venesection was
ongoing in 13/16 PV patients and three further patients (1 PV, 1 PMF and 1 PT) had
previously been venesected. None of the patients with PMF had undergone
splenectomy.
6.3.3 Haematological and molecular parameters
Haematological parameters at the time of the sampling are shown in Table 6.2.
Haemoglobin and leucocyte count were similar in the patient and control groups.
The platelet count was higher in MPD patients compared to the control group as a
whole (p=0.001), but there was no significant difference for the control patients with
secondary polycythaemia or thrombocytosis (p=0.423).
There was a wide range in the haematological parameters for the small group of PMF
patients (n=5) but they had a significantly lower haemoglobin than either the control
group or the PV and PT patients (p=0.012, 0.012, 0.018 respectively) and a
significantly lower platelet count compared to the PT patients (p=0.023).
JAK2 V617F mutation status had been established in 59 patients. Of these 13/15 PV
(87%), 16/35 PT (45.7%), 3/5 PMF and 2/3 MPD NOS were positive for the JAK2
V617F mutation.
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Haemoglobin (g/1) Leucocytes (x 106/l) Platelets (xl0y/l)
Mean (SEM) Median (IQR) Median (IQR)
132 7.0 389*
All MPD (62)
(2.7) (5, 9.5) (299, 440)
101 8 85
PMF (5)
(8.9) (4.5, 23) (52, 398)
138 11 356
PV (16)
(3.7) (8, 13.8) (266.5, 447.8)
133 6 397
PT (38)
(3.3) (5, 7.5) (333,461.5)
138 7 269
MPD NOS (3)
(14.1) (5,8) (249, 433)
137 7.0 231
All controls (19)







Table 6.2 Haematological parameters patients and controls
Haematological parameters in MPD patients and control subjects according to
diagnosis - PMF, PV, PT, MPD NOS, NH (non-haematological controls), secondary
(secondary polycythaemia or reactive thrombocytosis). Mean and SEM are shown
for haemoglobin. Median and IQR are shown for leucocyte count and platelets. *
The platelet count is significantly higher in patients than controls (p=0.001).
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6.3.4 Plasma levels of platelet a granule contents
6.3.4.1 Sample selection
One set of results was available for each of the 11 subjects in the NH control group.
All BTG:PF4 ratios were greater than 2.5. From these results we determined an in-
house normal range for BTG of 12-66 IU/ml (mean +/- 2sd), similar to the suggested
normal range of 10-50 IU/ml.
We considered using the BTG:PF4 ratio to select samples less likely to have been
affected by in vitro activation; a cut-off of BTG:PF4 > 2.5 was selected based on
previously published studies. We compared the BTG and TGFP results in pairs of
samples where both ratios were >2.5 (suggesting in vitro activation had not occurred)
and in pairs where one sample had a ratio of <2.5 (suggesting significant in vitro
activation and therefore that higher BTG and TGFP levels might be expected). We
did not find a consistent association between low BTG:PF4 ratios and higher BTG
and TGFP levels. In 13 of the 32 pairs where both BTG:PF4 ratios were >2.5, there
was a two-fold or greater difference in the BTG and TGFp levels (Figure 6.2).
Therefore the BTG:PF4 ratio was not used in the sample selection process.
In the secondary control group, 6/8 had two sets of samples and the set with the
lower BTG value was selected (all BTG:PF4 ratios >2.5). Two subjects had only
one set of samples; in both the BTG was within the normal range and these results
were included in the analysis. One secondary control subject was excluded due to
the development of fulminant hepatic failure. Sample availability and selection for
the MPD patients is shown in Figure 6.3. For 2/62 patients there were no suitable
samples. Two sets of results were available for 50/60 patients and the set with the
lower BTG value were selected. In ten patients only one set of results was available
due either to haemolysed samples or incomplete follow-up. For 2/10 single samples
the BTG was within our normal range and these results were included in the analysis.
The remaining eight single samples where the BTG was elevated were not included
in the analysis despite BTG:PF4 ratios of greater than or equal to 3.0.
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Figure 6.2 Comparison ofBTG and TGF(3 results by BTG:PF4 ratio
Comparison ofBTG and TGFP results in pairs of samples with BTG:PF4 ratios less
than or greater than 2.5.
Figure 6.3 Sample availability and selection of results for further analysis in the
MPD patient cohort.
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6.3.4.2 BTG, PF4, TGFp and PDGF results
The skewed distribution of the BTG, PF4, TGFp and PDGF results is shown in
Figure 6.1. Results for BTG, PF4, TGFp, and PDGF in the patient and control
groups are shown in Tables 6.3 - 6.5 and Figure 6.4(a-d).
There were significant correlations between BTG and PF4 (r =0.638, p<0.001), BTG
and TGFp (r =0.746, p<0.001) and BTG and PDGF (r =0.420, p<0.001) (Spearman's
rank).
6.3.4.3 Plasma levels of platelet a-granule contents by age and gender
There was no significant difference in BTG, PF4, TGFp or PDGF according to
gender. We detected no association between levels of platelet a-granule contents and
age (r =0.145, r =0.138, r =0.105, r =0.064 for BTG, PF4, TGFp and PDGF
respectively, all p>0.2) (Spearman's rank correlation)
6.3.4.4 Plasma levels of platelet a-granule contents by diagnosis
BTG was significantly higher in all MPD patients compared to all controls and in
each of the PMF, PV and PT groups compared to all controls (all p<0.001). BTG
was highest in the PMF patients and was significantly higher in PMF and PV patients
compared to the PT group (p=0.001 and p<0.001 respectively). PF4 was
significantly higher in all MPD patients compared to all controls (p=0.019) but on
analysis of the patient subgroups this remained significant only for the PV patients
(p=0.003). The BTG:PF4 ratio was higher in patients than controls, 4.9 (3.7, 7.0) v
3.7 (2.9, 4.9), (p=0.017). The ratio was highest in PMF patients at 11.4 (10.2, 18.4)
compared to PV patients, 4.9 (4.3, 5.9) or PT patients, 4.8 (3.4, 6.8), (p=0.004 and
0.014 respectively).
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TGFP was higher in all patients compared to all controls (p<0.001) and was highest
in PMF patients (p=0.034 v PV patients and p=0.014 v PT patients). PDGF was not
significantly different between patients and controls. Median PDGF was highest in
the PV patients, which was of borderline statistical significance compared to PT
patients (p=0.048) however there was marked overlap in the ranges. PDGF values of
less than zero were obtained for 2/17 controls, 2/4 PMF, 1/12 PV and 6/30 PT
results. By considering these as "missing values", there remained no significant
difference between patients and controls (p=0.311).
BTG, PF4, TGFp and PDGF were all higher in the secondary controls compared to

































Table 6.3 BTG, PF4, TGFp and PDGF in patients and controls
BTG, PF4, TGFp and PDGF results for all MPD patients compared to all controls.
Median and IQR values are shown and P values for statistically significant































Table 6.4 BTG, PF4, TGFp and PDGF in control groups
BTG, PF4, TGFP and PDGF results for non haematological controls (NH) compared
to controls with secondary polycythaemia or reactive thrombocytosis (secondary
controls). Median and (IQR) values are shown and P values for statistically















































Table 6.5 BTG, PF4, TGF(3 and PDGF in patient groups
Comparison ofBTG, PF4, TGF and PDGF results for patients with PMF, PV and
PT. Median and IQR values are shown and P values for statistically significant










































































Control PMF PV PT
Figure 6.4 (d)
Figure 6.4 BTG, PF4, TGFp and PDGF in patients and controls
Plasma levels of (a) BTG (b) PF4 (c) TGFp and (d) PDGF in control subjects, PMF,
PV and PT patients. Circles denote individual values and * denotes outlier results.
Median values are shown.
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6.3.4.5 Plasma levels of platelet a-granule contents and haematological
parameters
There were no significant associations between haemoglobin or leucocyte count and
BTG, PF4, TGFp and PDGF values. Across the study cohort as a whole there were
modest but significant correlations between platelet count and BTG (r =0.38,
p=0.001), PF4 (r =0.36, p=0.002) and TGFp (r =0.34, p=0.004). There was no
significant correlation between PDGF and platelet count.
The higher BTG, PF4 and TGFp in the patient group may therefore be confounded
by the higher platelet counts in this group (Table 6.2). On multiple regression
analysis the presence or absence of disease was the only significant predictor for
BTG and TGFP (p<0.001 for both) compared to platelet count which was not
significant (p=0.236 and p=0.484 respectively). However platelet count was the only
significant predictor for PF4 (p=0.008 v 0.164 for disease). To further explore the
influence of platelet count we analysed the ratio of plasma BTG, PF4 and TGFp to
whole blood platelet count (Figure 6.5 (a-c)). The ratios of BTG and TGFp to
platelet count, but not PF4 to platelet count, were significantly higher in patients than
controls.
There were also differences in platelet count within the patient group, being highest
in PT patients and lowest in those with PMF (Table 6.2). Multiple regression
analysis of the patient cohort only, revealed that both specific diagnosis and platelet
count were significant predictors of BTG (p<0.001 and p=0.024). Diagnosis was the
strongest predictor of TGFp (p=0.001 v 0.077 for platelet count) while platelet count
remained the most important predictor of PF4 (p=0.005 v 0.096 for diagnosis).
The BTG:platelet ratios were significantly higher in PMF and PV patients compared
to controls (p=0.002 and p=0.013) but in the PT patients were not significantly
different than controls (p=0.834). Similarly, TGFP:platelet ratios were significantly
higher in PMF and PV patients compared to controls (p=0.003 and p=0.029) but
levels in the PT patients were not significantly different than controls (p=0.088).
PF4:platelet ratios were significantly higher in PMF patients than controls (p=0.026)
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but there was no difference between PV and PT patients and controls (p=0.283 and
p=0.635 respectively).
6.3.4.6 Plasma levels of platelet a-granule contents and JAK2 V617F status
Within the PT patient group, JAK2 V617F mutational status was known in 35/38
patients of whom 16 were positive for the mutation. There were no significant
differences between the mutated and wild type groups for BTG, PF4, TGFp or PDGF
(Table 6.6)
6.3.4.7 Plasma levels of platelet a-granule contents and treatment
There were no significant differences in BTG, PF4, TGFp or PDGF levels between















































Figure 6.5 Ratio of plasma BTG, PF4 and TGFP to whole blood platelet count
Ratio of plasma (a) BTG (b) PF4)and (c) TGFP to whole blood platelet count in
control subjects, PMF, PV and PT patients. Circles denote individual values and *































Table 6.6 BTG, PF4, TGFp and PDGF in PT patients by JAK2 mutation status
Comparison ofBTG, PF4, TGFp and PDGF results in PT patients positive or
negative for the JAK2 V617F mutation. Median and (IQR) values are shown. There
























































Table 6.7 BTG, PF4, TGFP and PDGF in MPD patients by treatment
Comparison of BTG, PF4, TGFp and PDGF results in all MPD patients according to
treatment with or without hydroxycarbamide (HC) or aspirin. Median and IQR
values are shown. There were no significant differences according to treatment.
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6.3.5 BTG and TGFP and relation to fibrosis in MPD patients
Bone marrow histopathology reports were available for 52/62 patients. All five
patients with a diagnosis of PMF had Grade 3 or 4 fibrosis, (category C). Three PV
patients were reported to have Grade 3 fibrosis, none of whom have developed
clinical MF. One patient originally diagnosed with PT progressed to clinical MF
around the time of the study. One patient initially presented with a platelet count
>2000x109/L but defaulted from follow-up. He re-presented three months later with
a progressive pancytopenia, splenomegaly and Grade 4 fibrosis, at which time he
participated in the study. Without treatment, his pancytopenia and splenomegaly
have subsequently resolved with a recurrence of thrombocytosis and his most recent
trephine histology showed Grade 2 reticulin.
Platelet count, BTG, PF4, TGFP and PDGF levels according to classification of
fibrosis are shown in Table 6.8. There was no significant difference in platelet count
or any of the plasma a-granule contents between those patients for whom reports
were or were not available. Patients with more severe fibrosis (C) had significantly
higher BTG and TGFP levels compared to the group with milder fibrosis (A/B)
although the ranges were very wide; there was no significant difference in PF4 or
PDGF levels. The mean platelet count was lower in patients with more severe
fibrosis due to the inclusion of thrombocytopenic PMF patients, but the difference

















































Table 6.8 BTG, PF4, TGFp and PDGF and degree ofmarrow fibrosis
Comparison ofBTG, PF4, TGFp and PDGF results in the MPD patients only
according to grading of bone marrow fibrosis described on most recent trephine
biopsy histopathology report. Fibrosis was categorised A-C as described in Table
6.1. A/B represents milder reticulin fibrosis (Bauermeister Grade 0-2) compared to
C, more severe fibrosis (Bauermeister Grade 3-4). Median and IQR values are
shown. BTG and TGFp were significantly higher in patients with more severe
fibrosis. Statistically significant differences are highlighted in bold.
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6.3.6 Assessment of bone marrow fibrosis
Bone marrow histopathology reports were available for 52/62 patients and 5/8
control subjects with secondary polycythaemia or reactive thrombocytosis. Archived
bone marrow trephine slides were available and suitable for evaluation for 33/62
patients and 4/8 secondary controls. Table 6.9 (below) shows the numbers graded in
each of the categories of reticulin fibrosis.
Missing A B C
Histopathology report 13 28 19 10
Researcher 34 20 8 8
Pathologist 33 7 6 24
Table 6.9 Grading of bone marrow trephines for fibrosis
Of the 35 bone marrow trephines where the histopathology report was available and
the trephine slides were evaluated. Concurrence of grading between the report and
either the researcher or the pathologist is tabulated below (Table 6.10).
A B A/B C
Report/Researcher (35) 12/16 4/13 23/29 2/6
Report/Pathologist (36) 4/17 1/13 11/30 5/6
Table 6.10 Concurrence of grading for bone marrow fibrosis
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6.4 Discussion
We observed elevated plasma levels of platelet a-granule proteins in patients with
MPD compared to both healthy controls and those with secondary thrombocytosis or
polycythaemia. This included elevated plasma levels of the profibrotic cytokine
TGFp, which was highest in those patients with more marked bone marrow fibrosis.
In some of the patient groups, differences in the plasma levels of the platelet a-
granule proteins could be attributed to the higher platelet counts. However a disease
effect independent of platelet count was also observed, especially in the PMF and PV
patients. Our results also cast uncertainty on the reliability of using the BTG:PF4
ratio to recognise in vitro platelet activation and reinforce the problems of inter-
observer variability in the assessment of bone marrow histology.
Sampling and use of the BTG:PF4 ratio
We aimed to measure circulating levels of platelet a-granule proteins in treated
MPD. Plasma samples were chosen to try to assess the constitutive release of a-
granule contents in vivo. Other studies have measured serum levels, which may be
more reflective of the intraplatelet content which is released following ex vivo
platelet degranulation. Previously published data has suggested that due to the
different clearance kinetics of BTG and PF4 in vivo, a reduced BTG:PF4 ratio (less
than 2-3) may indicate in vitro activation and conversely that higher ratios would
exclude this (Kaplan & Owen, 1981).
Examination of the 56 duplicate sets of results in the current study revealed
inconsistencies in the relationship of BTG:PF4 ratios to the absolute values. In half
of the pairs where one ratio was less than 2.5, the associated BTG and TGFp results
were both higher, which would be consistent with the theory that a reduced ratio may
indicate in vitro platelet granule release. However in the remainder, the BTG and
TGFp results from both occasions were similar despite differences in the PF4 level
and consequently the BTG:PF4 ratio. Conversely, in 32 of the 56 paired results both
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had a BTG:PF4 ratio greater than 2.5, but in 13 of these there was at least a two-fold
difference in the BTG or TGFp between the samples.
These observations question the usefulness of the BTG:PF4 ratio for determining
whether in vitro activation has occurred in a single sample. In addition the previous
studies of BTG:PF4 ratios did not consider the effect of thrombocytosis specifically
but did suggest that the BTG:PF4 ratio varies inversely with the BTG level. Lower
ratios might therefore be expected in view of the elevated BTG levels seen in the
MPD patients.
The observed discrepancies in the absolute results and the BTG:PF4 ratios between
episodes may reflect a number of factors. The patients and controls were all tested in
a clinic setting which introduces methodological variables known to influence
platelet activation; phlebotomy was performed by a number of different individuals
and it is therefore likely that technique was variable. Individual patient variation due
to external influences such as concomitant illness or drug changes may also have
resulted in true variation in the plasma levels of the proteins.
The use of duplicate samples and selection of those with the lower BTG level was
intended to help exclude those samples in which activation and a-granule release
may have occurred in vitro. This may however have attenuated the observed
differences between patients and controls, if some of the higher values did in fact
reflect biological variation as opposed to in vitro activation.
Assessment of Fibrosis
The bone marrow reports available for the patients span a period of 25 years from
1981 to 2006 and were reported in a non-standardised way by a number of different
histopathologists. Clearly this introduces bias in both the assessment made of the
degree of fibrosis and our interpretation of the report. To try to appreciate the degree
of inter-observer variability in assessment and reporting, the trephines were
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reassessed by the researcher and an independent histopathologist and comparison
was made with the original report.
Initially the reports of the researcher and histopathologists were divided into normal,
intermediate or marked fibrosis (Grades grade A - C) based on the Bauermeister
grading system and the reports were similarly interpreted. Using this system there
was concurrence of all three assessments for only 6/35 reports. Comparing the
reports for the researcher and the histopathologist, a significant degree of inter-
observer variation was apparent even when the trephines were assessed by the same
grading system. There also appeared to be systematic bias towards reporting either a
lower or higher degree of fibrosis and inter-observer variability was most marked at
the intermediate grades of fibrosis. Combining groups A and B, who have no
fibrosis or a non-pathological degree of fibrosis, compared to group C, resulted in
improved concurrence with the original report of 25/35 and 16/36 for the researcher
and histopathologist respectively. Our findings reflect the recognised difficulties in
the use of trephine histology in the diagnosis of MPD, particularly outside the
research setting or specialist centres (Kuter et al, 2007). We did not reassess
megakaryocyte morphology which is used in the WHO criteria to distinguish pre-
fibrotic and early myelofibrosis from PT but which is also recognised to be difficult
to assess reproducibly (Campbell & Green, 2005).
BTG, PF4 and TGFP - clinical and haematological associations
In keeping with previous studies our results show that plasma levels of the platelet a-
granule proteins BTG, PF4 and TGFp are elevated in MPD patients compared to
both healthy controls. Furthermore, levels were elevated compared to patients with
either secondary polycythaemia or thrombocytosis, which has not been previously
reported. Of the MPD patients, those with PMF had the highest BTG, PF4 and
TGFp levels but this was only statistically significant for TGFp compared to PV and
PT patients and for BTG compared to PT patients. The lack of statistical
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significance for some of these comparisons is likely to reflect the wide range in
results and the small number ofPMF patients in the study.
TGFp has been clearly associated with marrow fibrosis in PMF and by extrapolation
is also implicated in myelofibrosis complicating the other MPD (Chagraoui et al,
2002;Dong & Blobe, 2006;Rameshwar et al, 1998;Yanagida et al, 1997). A lesser
degree of reticulin fibrosis may also be present at diagnosis in PV and PT or may
develop during the course of the disease. In the ten patients (five PMF, three PV and
two PT) who were reported to have bone marrow fibrosis equivalent to Grade 3 or
higher, we observed higher BTG and TGFp levels compared to those with fibrosis
equivalent to Grade 2 or less. Flowever many patients within the lower grade fibrosis
group (which may be considered to be within normal limits) had BTG and TGFp
levels above the median level of those with higher grade fibrosis and overall had
significantly higher BTG and TGFp levels compared to controls.
Where available the most recent bone marrow report was used; post-diagnosis bone
marrow assessments were likely to have been performed for a clinical indication
such as suspicion of progression. However, for the majority of patients only a
diagnostic marrow had been performed. It is therefore possible that the degree of
fibrosis at the time of the study, although subclinical might have progressed since
diagnosis thus underestimating the association with BTG and TGFp levels. Repeat
bone marrow examinations would be required to explore this possibility.
As the factors that we have measured are platelet and megakaryocyte derived we
might expect them to be higher in the patient group due to their higher platelet
counts. Consistent with this, moderate but significant correlations were observed
between the whole blood platelet count and BTG, PF4 and TGFp. Multivariate
analysis suggested that the presence or absence of disease was the most important
factor determining BTG and TGFp but that platelet count was more significant for
PF4. In keeping with this, the ratios of BTG and TGFp to platelet count were higher
in patients than controls but PF4 to platelet ratios were similar.
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Platelet counts were also variable between the patient groups, being lowest in PMF
and highest in PT. Multivariate analysis within the patient group only suggested that
both disease type and platelet count were significant determinants of BTG but that
diagnosis was the most important predictor of TGFp and that platelet count remained
the more significant determinant of PF4. Investigation of the factor to platelet ratios
within the patient subgroups showed that BTG and TGFp ratios were elevated in
PMF and PV patients but in PT patients were similar to controls.
Pathophysiology of increased plasma BTG, PF4 and TGFp
The above observations suggest two separate mechanisms whereby levels of platelet
a-granule proteins are elevated in MPD. The first is that the platelet mass itself does,
as would be expected, influence the plasma levels of platelet a-granule proteins and
that this may be particularly relevant in PT patients. Uncontrolled thrombocytosis
might therefore be expected to increase the risk of fibrosis in an individual via the
release of higher quantities of the profibrotic TGFp. This might explain the
increased rates of fibrotic progression seen in follow-up from the PVSG-01 trial in
PV patients treated with phlebotomy alone compared to a cytoreductive agent
(Najean et al, 1994). Against this theory is the apparently increased rate of fibrotic
progression observed in the anagrelide arm of the high risk PT-1 trial despite
equivalent control of the platelet counts (Harrison et al, 2005). We found no
difference in platelet a-granule levels in relation to treatment with hydroxycarbamide
but the majority of patients who were not treated with hydroxycarbamide either did
not have a thrombocytosis (in the case of PV patients), or received an alternative
cytoreductive.
Secondly, our observations suggest that in MPD patients, particularly those with
PMF, there is also a qualitative difference in platelet release ofBTG and TGFp. One
mechanism for this could be that increased platelet activation in MPD patients may
promote platelet degranulation with release of a-granule contents. We observed no
difference in BTG and TGFp levels in relation to treatment with aspirin but increased
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platelet activation has been observed in MPD despite aspirin therapy. Other
postulated mechanisms of a-granule release include neutrophil-platelet interactions
(Schmitt et al, 2000) or intracellular NFkB activation by dysregulated Tpo signalling
as can be caused by the JAK2 V617F mutation (Rameshwar et al, 2000;Khwaja,
2006;Komura et al, 2005). We found no association between BTG and TGFp levels
and the presence or absence of the JAK2 V617F mutation. Neither was there an
association with leucocyte count, however we did not measure PLA which are
reported to be elevated in patients with PT and PV (Falanga et al, 2005;Jensen et al,
2001).
As these postulated mechanisms of increased a-granule protein release are common
to the MPD they do not explain the observation that BTG and TGFp levels were
higher in patients with clinical PMF or higher grade fibrosis than in the other patient
groups (independent of platelet count). This suggests either that these mechanisms
may be more active in some patients, or that additional sources are important, for
example megakaryocytes. Another possibility is that non-platelet or megakaryocyte
sources of TGFp are significant but this would not explain the correlation of TGFp
and BTG.
We also observed that PF4 levels were more dependent on platelet count than disease
status and that the BTG to PF4 ratio was significantly higher in PMF patients. This
might be more in keeping with specific changes in the production and/or release of
TGFP (and BTG) as opposed to non-specifically increased release of all platelet a-
granule proteins. However the more rapid clearance of PF4 from plasma (compared
to TGFP and BTG), resulting in relatively lower levels of this protein, may have
influenced any observed associations.
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PDGF levels
In contrast to the findings of previous studies, PDGF levels were not significantly
different between the patient and control groups (Gersuk et al, 1989;Lev et al, 2002).
No correlation was seen between PDGF levels and those of the other a-granule
proteins, although similar to TGFp and BTG, there was a weak correlation with the
platelet count. Again, this might suggest that the elevated levels of BTG and TGFp
are not the result of a general increase in the release of platelet a-granule proteins.
However any interpretation should be made with caution in view of the high number
of ELISA results falling below zero on the standard curve. The cause of this
problem was unclear but as it did not arise with the other measurements, it suggests a
problem with the assay rather than the samples. It is also possible that the quality of
the frozen samples may have deteriorated due to the delay in analysis of PDGF
because of assay supply problems.
Summary
Our observations of elevated plasma levels of a-granule proteins, including TGFP, in
MPD patients compared to both healthy controls and to patients with reactive
thrombocytosis or secondary polycythaemia, concur with and extend the findings of
previous studies. Furthermore, we observed that the highest levels were in those
patients with greater degrees of bone marrow fibrosis, which supports the pivotal role
of TGFp in fibrosis. The strong correlation of TGFp with BTG confirms that platelet
a-granules are an important source of TGFp in these patients. As expected the
plasma levels of the a-granule proteins correlated with platelet count and this
appeared to be a significant factor contributing to the elevated levels in PT patients.
However in the patients with PMF and PV plasma levels were disproportionately
elevated compared to the platelet count, suggesting a specific mechanism of
increased a-granule release in this group of patients. Elucidation of such a






The main objective of this work was to set up an assay to measure plasma
microparticles and to apply this to a population of patients with MPD in whom we
might expect microparticles to be elevated considering their prothrombotic risk. We
also wished to identify any association of microparticle levels with clinical and
laboratory characteristics and to compare this novel measurement to established
markers of platelet and vascular abnormalities. In addition we investigated the role
of platelets in the fibrotic complications ofMPD.
Microparticle assay
We have established a method for the measurement of plasma microparticles by flow
cytometry. This method includes the quantitation of microparticles in cell free
samples thus permitting more reliable comparisons between samples analysed at
different times. The assay was optimised for the effects of preanalytical variables,
the most important of which was identified as the centrifugation protocol; slower
centrifugation resulted in greater platelet contamination of the samples and increased
numbers of PMP. Previously published studies have used a variety of centrifugation
protocols in their sample preparation and this is therefore one factor limiting the
comparison of results between studies. A more important implication may be the
effect of this preanalytical variable on the investigation of microparticle coagulation
activity; coagulation assays dependent on phospholipid activity may be significantly
influenced by residual platelet phospholipid in the samples. This is likely to be a
particular problem for stored samples that have been freeze-thawed as this process
will increase platelet membrane phospholipid exposure.
When the current assay was applied in practice to the measurement of microparticles
in MPD patients, a number of problems were identified. We frequently encountered
high levels of positivity in the negative isotype controls for the CD31 monoclonal
antibody that was used in the identification PMP and EMP. This had a more
significant effect of the measurement of EMP due to their relatively lower numbers
and so the investigation of the use of other endothelial markers would be helpful.
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The numbers of LMP that we identified in both patients and controls was
proportionately somewhat lower than has been reported in previously published
studies (Daniel et al, 2006;Berckmans et al, 2001). We used a CD45 monoclonal
antibody that identified leucocytes in samples of whole blood however the use of an
in vitro model of LMP generation might be a preferable positive control.
A further issue that we identified with the current method was that the population of
small platelets was continuous with that of microparticles (by forward light scatter
measurement) using a size limit of 1pm for differentiation. Although this is the
widely accepted size limit for microparticle identification there is no clear evidence
for its use (Biro et al, 2004;Dignat-George et al, 2004;Hugel et al, 2004;Jimenez et
al, 2004;Jy et al, 2004;Nomura, 2004;Shet et al, 2004). Concomitant measurement of
Annexin V binding as a measure of membrane PPS in comparison to particle size
may aid differentiation of PMP and small platelets, as PMP would be expected to
have proportionately greater membrane PPS exposure (Sinauridze et al, 2007). We
also recognised a population of events of <lpm that did not stain for the cell specific
antigens used. Annexin V double staining would help to identify whether this
population represent microparticles or are non-significant debris, which can be a
problem at the lower threshold of the detection ability of the flow cytometer.
Interest in the investigation of microparticles has greatly expanded in the last few
years, even since we began this project. Data similar to ours with regard to the
influence of preanalytical variables, especially centrifugation and platelet
contamination, has been presented by a number of other investigators. There has
also been a move away from the measurement of PMP and towards measurement of
EMP and LMP, in particular monocyte microparticles. This may reflect some of the
difficulties that we have described with the reliable discrimination of PMP from
platelets. In addition, the use of functional assays that can assess the
pathophysiological properties of microparticles, has taken prominence. There is now
more emphasis on the identification of microparticles bearing tissue factor and the
measurement of their coagulation potential. The use of flow cytometry with double
staining for cell specific markers and functional molecules, in combination with
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coagulation type assays, may be the most appropriate way to take forward our
investigation of plasma microparticles in disease states. With this knowledge, we
plan further refinement of the assay with regard to the choice of cell specific
antibodies and double staining for tissue factor and annexin V binding. Samples
have also been stored for thrombin generation analysis as a measure ofmicroparticle
coagulation potential. However we will need to determine whether the residual
platelets in these frozen samples will obscure any meaningful data.
Microparticles in myeloproliferative disorders
We were able to recruit a cohort of patients with PT and PV with a demographic
comparable to the overall local group of patients with MPD although the PT patients
included in the study were slightly younger. The clinical and laboratory
characteristics of the study cohort were largely similar to those reported in previously
published studies. However we observed a lower incidence of thrombotic events
both at presentation and during follow-up (Gangat et al, 2006;Gangat et al,
2007;Harrison et al, 2005;Marchioli et al, 2005;Passamonti et al, 2004;Wolanskyj et
al, 2006). This is in line with recent trends towards a greater proportion of
asymptomatic patients being diagnosed with PT or PV after investigation for an
incidental finding of thrombocytosis or raised haematocrit on the ever-increasing
workload of peripheral blood counts (Jensen et al, 2000b).
We observed increased numbers of PMP and EMP in the PV and PT patients
compared to a healthy control group but the influence of a number of potential
confounding factors should be considered. Our control population were significantly
younger than the patient cohort as a whole and within the patient cohort an effect of
age on PMP numbers was evident. Further, the majority of the patient cohort had
either a history of cardiovascular disease or risk factors; circulating microparticles
have been reported to be elevated in vascular disease in a number of previous studies
(Amabile et al, 2005;Bernal-Mizrachi et al, 2003;Koga et al, 2005;Preston et al,
2003;Simak et al, 2006). Comparison of our patient cohort with a control group
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matched for the presence of cardiovascular disease or risk factors would allow
investigation of whether microparticles are elevated in patients with MPD in excess
of these background factors.
It is however important to consider that the incidence of thrombotic complications in
younger patients with MPD, although lower than in older patients, remains greater
than that of an age-matched healthy population (Alvarez-Larran et al, 2007). It is
therefore relevant that in our younger patients without a history of cardiovascular
disease, both PMP and EMP were significantly elevated compared to controls. We
cannot exclude the presence of unrecognised cardiovascular disease in these patients
and certainly the low incidence of hypercholesterolemia and smoking suggests that
these may be under-reported or under-diagnosed in our patient group. Further,
microparticles have been reported to be predictive of sub clinical atherosclerosis in
diabetic patients and this would be another possible explanation. The measurement
of microparticles in a larger number of low risk MPD patients and thorough
cardiovascular investigation may be enlightening in this regard.
Our observations of the relationship between microparticles and the more established
markers of platelet and endothelial dysfunction were mixed. A correlation between
PMP and sP-sel was noted, in keeping with PMP being a marker for platelet
activation. However as sP-sel was measured in PPP prepared in the same way as for
microparticle measurement we cannot exclude that in fact this "soluble" form was in
fact microparticle bound. Concomitant measurement of PMP, microparticle
positivity for P-sel by flow cytometry and measurement of sP-sel in PPP and
microparticle free plasma would be useful to explore this. We did not measure
platelet-leucocyte aggregates (PLA) that are elevated in MPD and other vascular
disorders, but it is probable that some of the leucocyte positivity for platelet antigens
is in fact due to PMP-leucocyte binding. This may merit further investigation, as the
functional potential of such cell-bound microparticles is unknown.
Although altered endothelial dysfunction has been shown in MPD by
plethysmography, previous studies of soluble endothelial markers have reported
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mixed results (Bellucci et al, 1993;Falanga et al, 2000;Musolino et al,
2000;Neunteufl et al, 2001 ;Robertson et al, 2007). Despite the elevation in EMP we
did not observe an elevation in sE-sel or a correlation between EMP and sE-sel. One
reason for this may be that whilst we used antigens constitutively expressed by
endothelial cells to measure EMP, in comparison sE-sel is expressed only on
activated endothelium. Differences in the expression of a variety of endothelial
antigens by EMP in vivo have been reported in patients with acute CVA and in vitro
studies have suggested different EMP antigen profiles depending on the nature of the
microparticle trigger (Jimenez et al, 2003b;Simak et al, 2006). This may suggest
that EMP are released by non-activating stimuli in MPD; again concomitant
measurement of EMP by constitutive and activation antigens would be useful in this
regard. We did however find a correlation between sP-sel and EMP. This may
simply reflect a general prothrombotic state in these patients but an alternative
explanation is that PMP induced by activating stimuli have been shown in vitro to
induce endothelial cell changes which may result in EMP release (Barry et al,
1997;Barry et al, 1998).
Interestingly, microparticle numbers were elevated despite the fact that the majority
of the patient cohort was receiving standard therapy with venesection and/or
cytoreductives. This is in keeping with the observation that although correction of
the elevated haematocrit and thrombocytosis reduces thrombotic risk, it does not
normalise it. Serial measurement of microparticles in new patients commencing
treatment would be useful to examine the effects of cytoreduction on microparticle
levels. The point data collected suggested that our patient group may have been less
aggressively managed compared to current recommendations, however recent studies
have reported no increased risk of thrombosis at comparable haematocrit or platelet
levels (Di Nisio et al, 2007). The observation that PMP have proportionately higher
procoagulant activity compared to platelets implies that despite relatively normal
platelet counts higher circulating levels of microparticles could significantly increase
thrombin generation potential (Sinauridze et al, 2007). It is likely that in the future,
studies in other patient groups with vascular or prothrombotic disorders will address
the effects of treatment modalities on microparticle levels and in view of their
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procoagulant activities microparticles may themselves become a potential therapeutic
target.
The importance of leucocytes in MPD is increasingly recognised, with the
observation of elevated PLA and the association between leucocyte count at
diagnosis and thrombosis - an effect that is abrogated by the reduction of the
leucocyte count by cytoreductive therapy (Carobbio et al, 2007). The absence of a
significant difference in LMP was therefore perhaps surprising and possible
problems with the LMP assay have already been discussed. As with the possibility
of PMP binding to leucocytes, any circulating LMP may become platelet bound, a
possibility that could be investigated by measurement of platelet positivity for
leucocyte antigens or tissue factor.
We did not identify a direct correlation between microparticle numbers and
thrombotic history, similar to many previous studies that have identified vascular
abnormalities in MPD patients and to studies of microparticles in other
prothrombotic disorders. At least in part, this is likely to reflect the small numbers of
thrombotic events in our patient population but also it is also probable that a
combination of factors contribute to the thrombotic risk. There has been much
interest in the role of the JAK2 V617F mutation in thrombosis and an association
with the incidence of venous thrombosis has been reported in two large studies but
not by others (Campbell et al, 2006;Carobbio et al, 2007;Kittur et al,
2007;Wolanskyj et al, 2005). Two recent studies investigating vascular markers in
myeloproliferative patients reported an association of the mutation with markers of
platelet activation (Arellano-Rodrigo et al, 2006;Robertson et al, 2007). In contrast
we did not identify a correlation of sP-sel or microparticles with the JAK2 V617F
mutation status in the PT patients. However one of these studies did not differentiate
PT from PV patients who comprised the majority of patients in the JAK2 positive
group which may have confounded their results.
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Platelets and myelofibrosis
The other direction of our investigation of the role of platelets in the complications of
MPD was in relation to myelofibrosis. The importance of the profibrotic cytokine
TGFp is well established but the mechanism of its elevation in MPD patients is less
clear. As TGFp is contained within the a-granules of both platelets and
megakaryocytes, we investigated whether other a-granule proteins were similarly
elevated and if circulating levels were related to fibrosis. In keeping with previously
published studies we found significantly elevated plasma levels of TGFp in the MPD
patients compared to controls (Rameshwar et al, 1998). We included a control group
of patients with secondary polycythaemia or thrombocytosis, excluding
thrombocytosis per se as the explanation for this difference. Furthermore, we
observed that levels were highest in patients with PMF, however the number of these
patients was small and the range of TGFp levels was wide. Investigation of more of
these patients would be desirable to confirm and validate the results. We also
observed a correlation between severity of marrow fibrosis and TGFp levels in the
PV and PT patients. However the degree of fibrosis was based on the most recent
trephine report, which in the majority of cases was from diagnosis. The strength of
the association may therefore have been underestimated if fibrosis had progressed
since diagnosis. This could also explain the observation of elevated TGFp levels in
the range of the PMF patients in a number of PV and PT patients who had no
increase in fibrosis. Clearly further bone marrow assessment of these patients would
be required to investigate this possibility.
We also observed an increase in the circulating levels of other a-granule proteins,
with BTG and PF4 similarly elevated and BTG strongly correlated with TGFp levels.
This would support a general mechanism of increased release of platelet a-granule
contents as opposed to specific release of TGFp from platelets or another source.
Comparison with PDGF levels would have been useful to support this interpretation
of our results but these were difficult to analyse due to technical difficulties with the
assay. We did not directly investigate the mechanism of increased release of platelet
a-granule proteins but the elevated sP-sel and PMP in our other MPD patient cohort
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would support platelet activation as at least one contributory mechanism. Another
question is the degree to which systemic TGFP levels influence bone marrow
fibrosis, if at all or whether megakaryocyte TGFP is more important. If local
production of TGFP is more important, then the correlation of systemic platelet ex-
granule protein levels with fibrosis may suggest a shared mechanism of increased
release, for example due to defective granule packaging.
Platelets in PV and PT
Although our two MPD patient cohorts were separate, the clinical characteristics of
the PV and PT patients were similar and certainly there was some crossover in the
patients. The results of both studies underline the persistent platelet related
abnormalities in MPD patients despite standard therapy. We did not observe a
difference in the measured platelet parameters (PMP, sP-sel and platelet a-granule
proteins) between the JAK2 positive and negative PT patients consistent with the
absence of a prognostic effect of JAK2 status on clinical course and in particular
thrombotic risk. However, interestingly, in both studies the influence of the
peripheral platelet count on the measured platelet parameters was greater in the PT
patients than the PV patients. This suggests that there may be qualitative differences
in the platelets between PV and PT with perhaps greater platelet activation in the PV
patients. The mechanisms responsible for these platelet abnormalities remain elusive
although, as discussed, leucocytes are increasingly implicated in the vascular
disturbances in MPD and may be important in platelet activation. The observed
similarities in the JAK2 wild-type and mutated PT patients and the differences
between the PT and PV patients support the theory that other as yet undetected
molecular abnormalities are likely to be important in the pathophysiology of these
disorders.
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In summary, our investigation of platelet and vascular abnormalities in MPD we
have combined two areas of growing interest. The discovery of the JAK2 tyrosine
kinase mutation in MPD has renewed enthusiasm for investigation into the
mechanisms responsible for these disorders and their thrombotic and fibrotic
complications. As in previous studies, we have observed a variety of vascular and
platelet abnormalities in MPD patients which are not reversed by our current
therapeutic options of cytoreduction and antiplatelet agents. That differences in
these abnormalities exist between the clinical groups but are not associated with
JAK2 mutation status, confirms the need to identify whether other pathogenic
molecular mechanisms exist. Such mechanisms may be potential therapeutic targets
to reverse not only the cellular overproliferation but also the vascular abnormalities
of MPD. The field of microparticles is also rapidly evolving, with a growing
emphasis on investigation of their functional properties. Further optimisation of our
current assay by minimisation of platelet contamination, identification of
microparticle phenotype by functional molecules in addition to cell specific antigens
and its use in conjunction with a coagulation assay will hopefully produce a useful
addition to our current research tools and will be applicable to the investigation of a
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Appendix A - Guidelines for the diagnosis of Polycythemia
Vera and Primary (Essential) Thrombocythemia
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PVSG parameters for the Diagnosis of Polycythaemia Vera (Murphy et al, 1986)
Categories
A1. Raised red cell mass
Male > 36ml/kg
Female >32ml/kg




Platelet count >400 x 109/l
B2. Leucocytosis >12 x 109/l
No fever or infection
B3. Raised leucocyte alkaline phosphatase >100
No fever or infection
Raised serum B12 (>900pg/ml)
Diagnosis acceptable if following combinations are present: A1 + A2 + A3; A1 +A2 +
any two from category B.
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British Committee for Standards in Haematology (BCSH) Guidelines for the
diagnosis of polycythaemia vera (McMullin et at, 2005)
Major
A1: Raised red cell mass (>25% above mean normal predicted value*) or Hct
>0-60 males; >0-56 females
A2: Absence of cause for secondary erythrocytosis (consider possibility of dual
pathology)
A3: Palpable splenomegaly!
A4: Clonality marker, i.e. acquired abnormal marrow karyotype
Minor
B1: Thrombocytosis (platelet count >400 x 109/l)
B2: Neutrophil leucocytosis (neutrophil count >10 x 109/l in non-smokers;
>12-5 x 109/I in smokers)
B3: Splenomegaly (demonstrated on isotope/ultrasound scanning)!,!
B4: Characteristic BFU-E growth or reduced serum erythropoietin§
A1 + A2 + A3 or A4 establishes PV.
A1 + A2 + any 2B criteria establishes PV.
*RCM - mean normal predicted value: for males =(1486 x S*) - 825 ml; for
females = (106 x age) + (822 x s*) ml (*S, surface area).
!Without evidence of a secondary cause such as portal hypertension.
!Splenomegaly can be calculated from the ultrasound result
§Serum erythropoietin level varies depending on the assay used
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Amendment to the BCSH guideline for diagnosis and investigation of
polycythaemia /erythrocytosis (McMullin et al, 2007)
JAK2-positive polycythaemia vera
A1 High haematocrit (>0.52 in men, >0.48 in women) OR raised red cell mass
(>25% above predicted)*
A2 Mutation in JAK2
Diagnosis requires both criteria to be present
JAK2-negative polycythaemia vera
A1
Raised red cell mass (>25% above predicted) OR haematocrit >0.60 in
men, >0.56 in women.
A2 Absence of mutation in JAK2
A3 No cause of secondary erythrocytosis
A4 Palpable splenomegaly
A5
Presence of an acquired genetic abnormality (excluding BCR-ABL) in the
haematopoietic cells
B1 Thrombocytosis (platelet count >450 x 109/l)
B2 Neutrophil leucocytosis (neutrophil count > 10 x 109/I in non-smokers;
>12.5 x 109/I in smokers)
B3 Radiological evidence of splenomegaly
B4 Endogenous erythroid colonies or low serum erythropoietin
Diagnosis requires A1 + A2 + A3 + either another A or two B criteria
*Dual pathology (co-existent secondary erythrocytosis or relative erythrocytosis)
may rarely be present in patients with a JAK2-positive myeloproliferative
disorder. In this situation, it would be prudent to reduce the haematocrit to the
same target as for polycythaemia vera.
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2001 WHO criteria for polycythemia vera (Michiels et a/, 2006)
A-criteria
1. Elevated red cell mass > 25% above mean normal predicted value, or
hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women, or > 99th percentile of
method-specific reference range for age, sex, altitude of residence
2. No cause of secondary erythrocytosis, including:
a. Absence of familial erythrocytosis
b. No elevation of erythropoietin caused by:
i. Hypoxia (arterial p02 i'92%)
ii. High oxygen affinity hemoglobin
iii. Truncated erythropoietin receptor
iv. Inappropriate erythropoietin production by tumor
3. Splenomegaly
4. Clonal genetic abnormality other than Philadelphia chromosome or BCR-ABL
fusion gene in marrow cells
5. Endogenous erythroid colony formation
B-criteria
1. Thrombocytosis > 400 x 109/L
2. Leukocytosis > 12 x 109/L
3. Bone marrow biopsy showing panmyelosis with prominent erythroid and
megakaryocytic proliferation
4. Low serum erythropoietin levels
Diagnosis requires the presence of the first 2 A-criteria together with either any 1
other A-criterion or 2 B-criteria.
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2008 Proposed revised WHO criteria for polycythemia vera (Tefferi et al, 2007)
Major criteria
1. Hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women or other evidence of
increased red cell volume*
2. Presence of J/\K2617V>F or other functionally similar mutation such as JAK2
exon 12 mutation
Minor criteria
1. Bone marrow biopsy showing hypercellularity for age with trilineage growth
(panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic
proliferation
2. Serum erythropoietin level below the reference range for normal
3. Endogenous erythroid colony formation in vitro
Diagnosis requires the presence of both major criteria and 1 minor criterion or the
presence of the first major criterion together with 2 minor criteria.
*
Hemoglobin or hematocrit greater than 99th percentile of method-specific
reference range for age, sex, altitude of residence or hemoglobin greater than 17
g/dL in men, 15 g/dL in women if associated with a documented and sustained
increase of at least 2 g/dL from an individual's baseline value that can not be
attributed to correction of iron deficiency, or elevated red cell mass greater than 25%
above mean normal predicted value
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PVSG Diagnostic criteria for essential thrombocythaemia (Murphy et al, 1986)
1. Platelet count > 600,000/pl
2. Haemoglobin <13g/dl or normal red cell mass
3. Stainable iron in marrow or failure of iron trial (< 1 g/dl rise in haemoglobin after 1
month of iron therapy
4. No Philadelphia chromosome
5. Collagen fibrosis of marrow
a. Absent: or
b. <1/3 of biopsy area without both splenomegaly and leukoerythroblastic
reacton
6. No known cause for reactive thrombocytosis.
229
2001 World Health Organization criteria for essential thrombocythemia
(Michiels et al, 2006)
Positive criteria
1. Sustained platelet count >600 x 109/L
2. Bone marrow biopsy specimen showing proliferation mainly of the
megakaryocytic lineage with increased numbers of enlarged, mature
megakaryocytes
Criteria of exclusion
1. No evidence of polycythemia vera
a. Normal red cell mass or hemoglobin < 18.5 g/dL in men, 16.5 g/dL in
women
b. Stainable iron in marrow, normal serum ferritin, or normal MCV
c. If the former condition is not met, failure of iron trial to increase red cell
mass or hemoglobin levels to the PV range
2. No evidence of chronic myeloid leukemia: no Philadelphia chromosome and
no BCR-ABL fusion gene
3. No evidence of chronic idiopathic myelofibrosis
a. Collagen fibrosis absent
b. Reticulin fibrosis minimal or absent
4. No evidence of myelodysplastic syndrome
a. No del(5q), t(3;3)(q21;q26), inv(3)(q21q26)
b. No significant granulocytic dysplasia, few, if any, micromegakaryocytes
5. No evidence that thrombocytosis is reactive caused by




2008 Proposed revised WHO criteria for essential thrombocythemia
(Tefferi et al, 2007)
Diagnosis requires meeting all 4 criteria.
1. Sustained platelet count >450 x 109/L*
2. Bone marrow biopsy specimen showing proliferation mainly of the
megakaryocytic lineage with increased numbers of enlarged, mature
megakaryocytes; no significant increase or left-shift of neutrophil granulopoiesis
or erythropoiesis
3. Not meeting WHO criteria for PV, PMF,* CML,^ MDS,11 or other myeloid
neoplasm
4. Demonstration of JAK2QM\J>F or other clonal marker, or in the absence of a
clonal marker, no evidence for reactive thrombocytosis"
*
During the work-up period.
^Requires the failure of iron replacement therapy to increase hemoglobin level to the
PV range in the presence of decreased serum ferritin. Exclusion of PV is based on
hemoglobin and hematocrit levels, and red cell mass measurement is not required.
'Requires the absence of relevant reticulin fibrosis, collagen fibrosis, peripheral
blood leukoerythroblastosis, or markedly hypercellular marrow for age accompanied
by megakaryocyte morphology that is typical for PMF- small to large with an
aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous or irregularly folded
nuclei and dense clustering.
'Requires the absence of BCR-ABL.
11 Requires absence of dyserythropoiesis and dysgranulopoiesis.
11 Causes of reactive thrombocytosis include iron deficiency, splenectomy, surgery,
infection, inflammation, connective tissue disease, metastatic cancer, and
lymphoproliferative disorders. However, the presence of a condition associated with
reactive thrombocytosis does not exclude the possibility of ET if the first three
criteria are met.
231
Appendix B - Patient information sheets
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Patient Information Sheet
Microparticles in Myeloproliferative Disorders.
You are being invited to take part in a research project. Before you decide it is important for
you to understand why the research is being done and what it will involve. Please take time
to read the following information before deciding whether to take part. Talk to others about
the study if you wish.
■ Part 1 tells you the purpose of this study and what will happen to you if you take part.
■ Part 2 gives you more detailed information about the conduct of the study.
Ask us if there is anything that is not clear or if you would like more information. Take time
to decide whether or not you wish to take part.
Part 1
What is the purpose of the study?
Patients with myeloproliferative disorders have either too many red blood cells
(polycythaemia) or too many platelets (primary thrombocythaemia). Platelets are the blood
cells which help to stop bleeding. Patients with either polycythaemia or primary
thrombocythaemia have an increased risk of blood clots. The reasons for this are not
completely understood. Research into other conditions with an increased risk of blood clots
has found high levels of microparticles in patients' blood. Microparticles are small pieces of
the surface of blood cells or the blood vessel lining cells, which can contribute to blood
clotting.
We wish to measure the levels ofmicroparticles in patients with too many red blood cells or
platelets compared to people without blood disorders. We will also look at the role of
microparticles in blood clotting.
Why have I been chosen?
You have been chosen as a patient who is attending the haematology clinic for management
of one of these blood disorders. We hope to look at around 80 patients.
Do I have to take part?
No. It is up to you to decide whether or not to take part. If you do, you will be given this
information sheet to keep and asked to sign a consent form. You are still free to withdraw at
any time and without giving a reason, and your blood samples and the information collected
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would be destroyed. If you decide not to take part, or to withdraw, this will not affect your
care.
What will happen to me if I take part?
We will contact you to arrange for you to attend the clinical research unit, which is in the
hospital, at your next routine clinic appointment. You will have your blood taken as usual
but at the same time 3 extra tubes of blood (about 1 tablespoon) will be taken for the
research tests. Then you will go along to clinic as usual and your clinic blood results will be
sent there. Only one research visit is required. We will also look at your medical notes as
part of the study.
What are the possible disadvantages and risks of taking part?
The risks are the same as those of having your usual blood sample taken, possibly some
discomfort or bruising at the site where the blood is drawn.
What are the possible benefits of taking part?
There are no direct benefits to you but we hope that the information we get might help us to
understand why people with high red blood cells or platelets get blood clotting problems.
What if there is a problem?
Any complaint about the way you have been dealt with during this study will be addressed.
The detailed information on this is given in Part 2.
Will my taking part in this study be kept confidential?
Yes. All the information about your participation in this study will be kept confidential. The
details are included in Part 2.
Contact for further information:
Dr Susan Lynch, Clinical Lecturer
Department ofHaematology, Royal Infirmary Edinburgh. Tel: 0131 242 6814 or 242 6096
This completes Part 1 of the information sheet. If the information in Part 1 has
interested you and you are considering participation, please continue to read the
additional information in Part 2 before making your decision.
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Part 2
What if there is a problem?
If you have a concern about any aspect of this study, you should ask to speak with the
researchers who will do their best to answer your questions (Dr Susan Lynch 0131 242
6814). If you remain unhappy and wish to complain formally, you can do this through the
NHS Complaints Procedure. Details can be obtained from the hospital.
In the event that something does go wrong and you are harmed during the research study
there are no special compensation arrangements. If you are harmed and this is due to
someone's negligence then you may have grounds for a legal action for compensation
against Lothian NHS Trust and Edinburgh University but you may have to pay your legal
costs. The normal National Health Service complaints mechanisms will still be available to
you (if appropriate).
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research will be kept
strictly confidential. The results of your routine clinic blood tests will be stored on the
hospital computer system. All other information obtained from your samples will be stored
securely within the department of haematology under the care of Professor Ludlam.
Reseachers will have access to identifiable data. This may also be looked at by
representatives from regulatory authorites or authorised people from NHS Lothian to check
that the study is being carried out correctly. With your consent, your own GP will be
informed of your participation in the study.
What will happen to any samples I give?
The samples you give will be processed within the Clinical Research Facility and the
Department of Haematology. Study researchers will have access to these samples which will
be identified by a unique study number. The research samples will be stored securely within
the department of haematology for use in this study for up to 5 years. At the end of the
study, or if you decide to withdraw, the samples will be destroyed.
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What will happen to the results of the research study?
When the results of the study are available it is planned to present these at academic
meetings and publish them in medical journals. You will not be identified in any
publication. In addition a short report will be provided for the participants.
Who is organising and funding the research?
The study is organised by NHS Lothian and Edinburgh University and is funded by an award
from the Royal College ofPathologists/Jean Shanks Foundation.
Who has reviewed the study?
This study was given a favourable ethical opinion for conduct in the NHS by the Lothian
Research Ethics Committee 01.
Thank you for taking the time to read this information sheet.
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Patient Information Sheet
Platelet alpha-granule contents in myeloproliferative disorders
You are being invited to take part in a research project. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information before deciding whether
to take part.
Thank you for taking the time to read this
What is the purpose of the study?
Patients with myeloproliferative disorders such as myelofibrosis, primary
thrombocythaemia (high platelets) and polycythaemia (high red blood cells) have
different amounts of fibrosis or scarring in their bone marrow. Previous research has
shown that this might be related to the abnormal release of substances from the bone
marrow cells which produce platelets. These substances are also found in the
platelets in our blood.
We wish to measure the blood levels of these substances to see how they differ
between patients with different blood disorders. We will also look to see whether
they are related to the amount of fibrosis in the bone marrow.
Why have I been chosen?
You have been chosen as a patient attending the Haematology Clinic for
investigation or treatment of high red blood cell or platelet counts, or myelofibrosis.
Do I have to take part?
It is up to you to decided whether or not to take part. If you decide to take part you
will be asked to sign a consent form. If you take part you are still free to withdraw at
any time and without giving a reason and your blood samples would be destroyed. If
you decide not to take part or to withdraw this will not affect your care.
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What will happen to me if I take part?
When you next attend the haematology clinic you will be asked to sign a consent
form, a copy of which is enclosed, and you will be given a copy to keep along with
this leaflet. This also asks for your consent to look at your medical notes as part of
the study. Then you will have your blood taken as usual but at the same time 2 extra
tubes of blood (about 1 tablespoon) will be taken for this research. These extra
samples will be taken on one further occasion, the next time that you attend
haematology clinic. These samples will be stored in the Haematology Department
for use in this study for up to 5 years. At the end of the study, or if you decide to
withdraw, the samples will be destroyed.
Contact for further information:
Dr Susan Lynch, or
Department ofHaematology,
Royal Infirmary Edinburgh.





Appendix C - Flow cytometer instrument settings
Microparticle collection
Detectors / Amps:
Parameter Detector Voltage Amp gain Mode
P1 FSc E00 2.0 Log
P2 SSc 396 1.0 Log
P3 FL1 591 1.0 Log










Parameter Detector Voltage Amp gain Mode
P1 FSc E00 2.0 Log
P2 SSc 396 1.0 Log
P3 FL1 505 1.0 Log







FL2 - 18.1% FL1
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Appendix D - Presentations arising from this thesis
S F Lynch, D Stirling, C A Ludlam. Microparticles (platelet, endothelial and
leucocyte) are elevated in patients with myeloproliferative disorders.
This work was presented as a poster at the 49th American Society of
Haematology Annual Meeting, December 2007
S F Lynch. D Stirling, C A Ludlam. Platelet and endothelial microparticles are
elevated in patients with myeloproliferative disorders.
This work was presented at the British Society for Haemostasis and
Thrombosis Annual Scientific Meeting, September 2007
SF Lynch. D Stirling, CA Ludlam. Effect of preanalytical variables on microparticle
numbers.
This work was presented as a poster at the XXIst Congress of the
International Society on Thrombosis and Haemostasis, July 2007
SF Lynch. P Dawson, D Stirling, CA Ludlam. Platelet derived growth factors and
bone marrow fibrosis in myeloproliferative disorders.
SF Lynch. D Stirling, P Hayes, CA Ludlam. Hyaluronic acid and liver function in
myeloproliferative disorders
This work was presented as a poster at the British Society of Haematology
Annual Scientific Meeting, May 2007
SF Lynch. K Shaw, D Stirling, CA Ludlam Prevalence of the JAK2 tyrosine kinase
mutation in patients with an established diagnosis of myeloproliferative disease and
to aid diagnosis.
This work was presented as a poster at the British Society of Haematology
Annual Scientific Meeting, April 2006
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